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Colon cancer is one of the most commonly diagnosed forms of cancer, responsible for 
approximately 1 in 10 cancer-related deaths worldwide. The molecular mechanisms 
behind the development of colon cancer are heterogeneous but nonetheless important in 
relation to patient treatment and prognosis. Dysregulation of the intestine specific 
transcription factor caudal-related homeobox transcription factor 2 (CDX2) has been 
linked to the development and progression of colon cancer. It plays a critical role in the 
homeostasis of the heathy colon epithelium, however, the role of CDX2 in colon cancer 
development is yet to be determined. Evidence suggests that loss of CDX2 expression 
in colon cancer tumors is linked to poor prognosis, but at the same time CDX2 is 
regarded as a lineage survival oncogene in colon cancer cell lines. This thesis explores 
the role of CDX2 in regulation of gene expression in colon cancer cells and what effect 
CDX2 dysregulation may have on the development and progression of colon cancer.  
 
In paper I, a cellular model to investigate effect of a gene of interest was generated by 
introducing doxycycline inducible CDX2 expression in the LS174T colon cancer cell 
line. Using this model which allows tight control of CDX2 expression, novel target genes 
of CDX2 important in colon homeostasis are identified.  
The role of CDX2 in regulation of expression of the recurrent colon cancer fusion gene, 
VTI1A-TCF7L2, was investigated in paper II. Here we discover that the fusion protein 
is a dominant negative regulator of Wnt signaling and that it is transcriptionally regulated 
by CDX2, possibly resulting in aberrant expression of a dominant negative version of 
TCF7L2.  
The surgical stress response is regarded as a risk factor of the recurrence of colon cancer. 
Paper III investigates the effect of perioperative serum from patients undergoing colon 
cancer surgery on the adhesion abilities of colon cancer cell lines, as well as the effect 




in postoperative serum compared to preoperative serum, and the increased adhesion in 
the postoperative serum is seen to depend on CDX2 expression.  
 
Together, the results in this thesis aim to elucidate the role of CDX2 both in colon 
homeostasis but also in the development and progression of colon cancer. Novel CDX2 
target genes are identified, including the colon cancer fusion protein VTI1A-TCF7L2 
possibly linked to the development of colon cancer. CDX2 is shown to affect the 
adhesion abilities of cultured colon cancer cells, revealing a probable mechanism in 







Koloncancer er en af de hyppigst diagnosticerede former for cancer og ansvarlig for 
omkring hver 10. cancerrelaterede dødsfald. De molekylære mekanismer bag 
udviklingen af koloncancer er heterogene men ikke desto mindre vigtige i forhold til 
patientbehandling og prognose. Udviklingen og progressionen af koloncancer er koblet 
til dysregulering af den intestinale transkriptionsfaktor caudal-related homeobox 
transcription factor 2 (CDX2), der spiller en kritisk rolle i homeostasen af raskt 
kolonvæv. CDX2s rolle i koloncancer udvikling er endnu ikke fuldstændig klarlagt, men 
forskning tyder på, at nedregulering af CDX2-ekspression i koloncancertumorer er 
associeret med dårligere prognose for patienten. Samtidig betragtes CDX2 som værende 
essentiel for overlevelsen af koloncancercellelinjer. Denne afhandling undersøger 
CDX2s rolle i regulering af genekspression i koloncancerceller, samt hvilken effekt 
dysregulering af CDX2 kan have på udviklingen og progressionen af koloncancer. 
 
I artikel I blev en cellulær model til undersøgelse af gener af interesse udviklet ved at 
integrere doxycyclin inducerbar ekspression af CDX2 i koloncancer cellelinjen LS174T. 
Denne model, der tillader fuld kontrol af CDX2 ekspression, kan anvendes til 
identificering af nye CDX2-regulerede gener, der er vigtige for kolon-homeostase. 
Artikel II undersøger CDX2s rolle i reguleringen af ekspressionen af koloncancer 
fusionsgenet, VTI1A-TCF7L2. Vi viser, at fusionsgenet er en dominant negativ regulator 
af Wnt signalering og at fusionsproteinet er transkriptionelt reguleret af CDX2, hvilket 
muligvis resulterer i unormal ekspression af den dominant negative form af TCF7L2.   
Det kirurgiske stressrespons regnes for at være en risikofaktor for tilbagefald af 
koloncancer. I artikel III undersøges effekten af perioperativt serum fra patienter, der 
undergår operation for koloncancer, på adhæsionsevnerne af koloncancercellelinjer, og 
ligeledes effekten af CDX2-ekspression på adhæsionen. Koloncancercellerne viste øget 
adhæsionsevne i postoperativt serum sammenlignet med preoperativt serum, og den 




Sammenholdt forsøger resultaterne i denne afhandling at belyse, hvilken rolle CDX2 
spiller i både kolon-homeostase samt i udvikling og progression af koloncancer. 
Artiklerne identificerer nye CDX2-targetgener samt en potentiel kobling mellem 
koloncancer fusionsproteinet VTI1A-TCF7L2 og udviklingen af koloncancer. Ydermere 
belyser CDX2s påviste effekt på adhæsionensevnerne hos koloncancercellelinjer en 
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In accordance with guidelines for gene nomenclature, gene names are written in italics 
while proteins are in non-italics. Human proteins are written in all capital letters, while 
mouse proteins are written with only the first letter capitalized.  
 
APC Adenomatous polyposis coli  
BMP Bone morphogenetic protein 
Cdk2 Cycline dependent kinase 2   
CDX2 Caudal-related homeobox transcription factor 2 
CIMP CpG island methylator phenotype 
CIN Chromosomal instability  
CKIα Casein kinase Iα 
DFS Disease-free survival 
ECM Extracellular matrix 
EGF Epidermal growth factor 
EMT Epithelial-to-mesenchyme transition 
FZD Frizzled 
GATA GATA binding protein 
GPA33 Glycoprotein A33 
GSK3β Glycogen synthase kinase 3β 
HEPH Hephaestin 
HNF4α Hepatocyte nuclear factor 4 α 
LAMC2 Laminin subunit γ2 
LRP LDL receptor protein 
MAPK Mitogen-activated protein kinase  
MEP1A Meprin 1A 
MET mesenchyme-to-epithelial transition  




MSI Microsatellite instability 
NF-κB Nuclear factor κB 
OS Overall survival 
PFS Progression-free survival 
SSR Surgical stress response 
TCF/LEF T-cell factor/lymphoid-binding factor 
TCF7L2 Transcription factor 7-like 2 
VTI1A Vps-ten-interacting-1a 
Wnt Wingless-type  
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1. Introduction  
 
Colon cancer is the third most commonly diagnosed form of cancer worldwide and is 
accountable for approximately 1 in 10 cancer-related deaths (Bray et al., 2018). It tends 
to be slow growing, typically developing over 10-15 years (Dekker et al., 2019). The 
mortality rate is largely dependent on disease stage at time of diagnosis, but up to 90% 
are diagnosed at advanced stages resulting in significantly worse survival (Mattiuzzi et 
al., 2019). The incidence of colon cancer is 3-fold higher in developed compared to 
developing countries, but with limitations in treatment in developing countries there is 
less variation in mortality rate (Bray et al., 2018).  
To determine patient treatment and prognosis, cancer tumors are currently classified 
according to a wide range of tumor cell characteristic, including degree of invasion, 
grade of differentiation, deregulated molecular pathways, and mutational status, as well 
as lymphocyte density at the tumor center and invasive margin (Angell et al., 2020). 
The molecular mechanisms underlying the development of colon cancer are 
heterogeneous but the pathogenesis is nonetheless clinically important, as it is often 
related to response to treatment and prognosis of the patient (Melo et al., 2013; 
Sadanandam et al., 2013).  
In the last 10 years, dysregulation of the intestine specific transcription factor caudal-
related homeobox transcription factor 2 (CDX2) has been implicated in the development 
and progression of colon cancer (Baba et al., 2009; Graule et al., 2018). It plays a crucial 
role in proper embryonic development as well as homeostasis of the adult intestinal 
epithelium (Gao et al., 2009; Keller et al., 2004; Olsen et al., 2013). CDX2 is specifically 
expressed in the epithelial cells of the adult intestine and it is used as a biomarker to 
determine the origin of the primary tumor when unknown (Bruun et al., 2018). Reduced 
expression of CDX2 in colon cancer tumors has been linked to poor prognosis (Bae et 
al., 2015; Dalerba et al., 2016), and it has been characterized as a tumor suppressor 
(Mallo et al., 1997). However, in other cancers CDX2 is considered to be an oncogene 




(Natoli et al., 2013; Salari et al., 2012). Therefore, the effect of CDX2 on the 
development and progression of colon cancer are yet to be determined. 
 
 
2. Aim of the thesis 
 
The overall aim of this thesis was to investigate the effect of CDX2 expression on the 
transcriptional activity of genes involved in colon homeostasis and to explore its role in 
the development and progression of colon cancer.  
 
Specific aims of the thesis: 
• Determine the gene regulatory activity of CDX2 in colon cancer cells (Paper I) 
• Investigate the role of CDX2 in expression of the recurrent colon cancer gene fusion 
of the TCF7L2 and VTI1A genes (Paper II) 







Colon homeostasis  
 
The epithelium of the colon regenerates rapidly, and homeostasis depends on tight 
control of proliferation, migration, differentiation, and apoptosis. The lumen of the 
colon is lined with a single sheet of columnar epithelial cells shaped into tubular glands 
called crypts of Lieberkühn that extend inwards. Each crypt contains between two and 
three thousand cells and the renewal of the entire colon epithelium stems from these 
crypts (Boman and Fields, 2013). The crypt is divided into three compartments each 
with their own distinct function, seen in figure 1.  
 
Figure 1: Crypt-villus axis – The intestinal crypts are lined with a single sheet of epithelial cells. The 
stem cell niche is located at the bottom of the crypts. Proliferating cells migrate up towards the 
luminal surface though the transient amplifying zone. Proliferation ceases approximately two thirds 
up the crypt and the cells start to differentiate. Modified from (Davidsen et al., 2018).   
The stem cells reside at the base of the crypts in a stem cell niche, and these cells 
replenish not only their own population but also the cells destined for differentiation. 




transient amplifying cells residing in the transient amplifying zone of the crypt. As the 
cells proliferate, they migrate along the vertical crypt-villus axis towards the luminal 
surface. When reaching two thirds up the crypt, the proliferation ceases and the cells 
begin to differentiate (Leedham, 2014). The major types of differentiated cells in the 
colon include absorptive colonocytes, mucous-secreting goblet cells, and hormone-
releasing enteroendocrine cells (Cernat et al., 2014). The differentiated cells reach the 
luminal surface where they reside until undergoing spontaneous apoptosis with 
subsequent shedding into the lumen or phagocytosis, about 5-7 days after generation at 
the bottom of the crypts (Leedham, 2014). 
  
 Stem cell maintenance and proliferation 
The maintenance of homeostasis of the stem cell niche is crucial in retaining normal 
colon function. The composition of the stem cell niche is complex and only partly 
defined but consists of two major components; the extracellular matrix (ECM) 
consisting of a network of fibrous structural proteins that act as a scaffold and maintains 
the structure of the colon, and the cellular niche surrounding the stem cell niche. The 
cellular niche is comprised of pericryptal myofibroblasts, fibroblasts, neuronal cells, 
endothelial cells, pericytes, and smooth muscle cells that tightly line the basal lamina of 
the crypt base (Sailaja et al., 2016; Spit et al., 2018). Together, the ECM and the cellular 
niche provide the crucial signals that regulate intestinal fate. The four main signaling 
components in stem cell niche maintenance are epidermal growth factor (EGF), Notch, 
inhibitors of bone morphogenetic protein (BMP), and wingless-type (Wnt) (Spit et al., 





Figure 2: Signaling components of the stem cell niche and proliferation – Wnt, EGF, Notch, and BMP 
inhibitors are highly expressed at the bottom of the crypts. In the transient amplifying zone Wnt, EGF, 
and Notch remain highly expressed, while the level of BMP inhibitors decreases and levels of BMP 
increase towards the luminal surface. As the cells reach differentiation Wnt, EGF, and Notch levels 
decrease. Modified from (Davidsen et al., 2018). 
Activation of EGF receptors activates AKT and ERK pathways that both activate 
downstream targets involved in regulating cell proliferation and apoptosis. Notch 
signaling requires direct membrane contact between two adjacent cells in the crypt, one 
expressing Notch receptors and one expressing Notch ligands. A cell expressing Notch 
ligands induces Notch signaling in all surrounding cells, which in turn prevents 
activation of its own pathway. Cells with active Notch signaling enter into the secretory 
lineage while cells with inactive Notch become absorptive, thereby securing even 
distribution of secretory and absorptive cells. BMP’s counteract the proliferative signals 
in the intestine and promote cell differentiation. Inhibitors of BMP are present at the 
base of the intestinal crypts, but expression decreases along the crypt-villus axis (Gehart 
and Clevers, 2019). As the canonical Wnt signaling pathway has more impact on stem 
cell maintenance, proliferation and cell fate of intestinal cells than any other pathway, 





The canonical Wnt signaling pathway 
Wnt ligands can activate both canonical and non-canonical Wnt signaling pathways. 
The non-canonical Wnt signaling pathways are involved in cell polarization during 
epithelial development and intracellular Ca2+ influx (Hoppler and Kavanagh, 2007), 
while the canonical Wnt signaling pathway regulates gene expression, and is known to 
be the main driver of proliferation of the stem cells in the intestinal crypts (Ong et al., 
2014). The canonical Wnt signaling pathway will in the following be referred to as the 
Wnt signaling pathway.  
In the absence of Wnt ligands the Wnt signaling pathway is inactive and the 
transcriptional co-activator β-catenin is phosphorylated and subsequently degraded in 
proteasomes. Phosphorylation occurs through a large multi protein degradation complex 
composed of the kinases glycogen synthase kinase 3β (GSK3β) and casein kinase Iα 
(CKIα), as well as the scaffold proteins adenomatous polyposis coli (APC) and AXIN 





Figure 3: The Wnt signaling pathway – In the absence of Wnt ligand intracellular β-catenin will be 
degraded though interaction with the degradation complex, comprised of AXIN, APC, CKIα, and 
GSK3β. Activation of the Wnt signaling pathway occurs when Wnt ligands binds to the FZD and LRP 
receptor complex. Upon binding, the degradation complex cannot be formed leading to the 
accumulation of β-catenin, which subsequently enters the nucleus and activates TCF7L2 by displacing 
Groucho. As R-spondin protects the FZD and LRP from degradation, it presence is required for active 
Wnt signaling.     
The Wnt signaling pathway is activated when secreted Wnt glycoproteins bind to the 
Frizzled protein (FZD) and low-density lipoprotein receptor-related protein (LRP) 
transmembrane receptor complex. The activation of the Wnt pathway is also dependent 
on the presence of R-spondins, secreted and soluble proteins that bind receptors of the 
LGR family, a stem cell marker (Yan et al., 2017). In the absence of R-spondin, the 
FZD and LRP receptors are continuously degraded through ubiquitination (Hao et al., 
2012). Activation of the Wnt signaling pathway leads to association of AXIN with the 
LRP receptor and accumulation of the transcriptional co-activator β-catenin in the 
cytosol. It is subsequently localized to the nucleus where it associates with and activates 




transcription factors, and induces transcription of Wnt target genes. In the colon, the 
main binding partner of β-catenin is the transcription factor 7-like 2 (TCF7L2) 
transcription factor, also known as TCF4 (Gehart and Clevers, 2019). In the absence of 
β-catenin, TCF7L2 forms a complex with the co-repressor Groucho making TCF7L2 
act as a transcriptional repressor. Upon activation, β-catenin displaces Groucho turning 
TCF7L2 into a transcriptional activator (Kriegl et al., 2010; Pinto et al., 2003) that in 
turn activates transcription of downstream target genes such as c-myc and cyclin D1 
(Fevr et al., 2007; Yu et al., 2019).   
Wnt signaling has not only been shown to be important in preserving the stem cell niche, 
but also in maintaining the transient amplifying zone of the crypts (Kuhnert et al., 2004; 
Pinto et al., 2003). The first hint of the crucial role of Wnt signaling was discovered in 
a genetically modified mouse model lacking TCF7L2. These mice die within 24 hours 
after birth and completely lack proliferating compartments in the intestine (Korinek et 
al., 1998). Proliferation in the crypts of adults remains dependent on Wnt signaling as 
conditional deletion of both β-catenin and TCF7L2, as well as overexpression of the 
Wnt inhibitor Dickkopf1, in adult mice both result in a cease in proliferation and loss of 
intestinal crypts (Fevr et al., 2007; Pinto et al., 2003; van Es et al., 2012). TCF7L2 is 
not only believed to be important in the proliferative compartments of the crypts, but 
may play a role as a trigger in the shift from proliferating to differentiating cell. (Kuhnert 
et al., 2004; Mariadason et al., 2001; Pinto et al., 2003). Conditional loss of TCF7L2 in 
the colon of adult mice results in enlarged crypts, suggesting continued proliferation 
and lack of differentiation (Angus-Hill et al., 2011), further underlining the importance 
of the Wnt signaling pathway in intestinal homeostasis.    
 
Differentiation of the colon epithelium 
The transcription factor CDX2 is considered a master regulator of intestinal identity, 
regulating a number of transcription factors important in colon development and 
homeostasis. The CDX2 gene consists of three exons generating a 313 amino acid 




binds to gene enhancer and promoter regions on the DNA and can either activate or 
repress gene expression (Drummond et al., 1997), although results suggest that CDX2 
predominantly acts as a transcriptional activator (Pinto et al., 2017) (Paper I). In 
addition to regulating transcription, CDX2 is known to control the active chromatin 
structure at thousands of sites in the intestine of adult mice, maintaining chromatin 
access and transcription (Verzi et al., 2013). 
The crucial role of CDX2 in differentiation of the colon epithelium has been well 
established. Knockdown of CDX2 in differentiated Caco-2 cells leads to decreased 
expression of genes specific for differentiated colon epithelial cells (Natoli et al., 2013). 
Adult mice with complete knockdown of CDX2 expression develop severe diarrhea and 
rapid wasting with continued proliferation and lack of differentiation of the colon 
epithelium (Hryniuk et al., 2012). Organoids derived from mouse small intestine lacking 
CDX2 expression fail to differentiate but turn into a more gastric like lineage (Simmini 
et al., 2014), emphasizing the vital role CDX2 plays in differentiation of the colon 
epithelium. 
 
Regulation of intestinal homeostasis by CDX2 
Numerus of genes involved in the function and structure of the colon have been shown 
to be transcriptionally regulated by CDX2, see figure 4. One of the key functions of the 
intestine is breakdown and transport of nutrients from the lumen. The iron-transport 
protein hephaestin (HEPH), which transports dietary iron in the intestinal epithelium, 
has been shown to be transcriptionally regulated by CDX2. So has the enzyme Meprin 
1A (MEP1A), a membrane associated protein that hydrolyses various peptide and 
protein substrates (Boyd et al. 2010; Coskun et al. 2012; Hinoi et al. 2005). CDX2 is 
also seen to  regulate the expression of lactase, responsible for the hydrolysis of lactose 





Figure 4: CDX2 and intestinal homeostasis – CDX2 is involved in the transcriptional regulation of many 
genes important in different aspects of normal intestinal homeostasis, including nutrient uptake and 
breakdown, regulation of transcription factors, maintaining the intestinal barrier, cell migration, and 
cell-cell adhesion and tight junctions.  
CDX2 is also a key player in upholding the integrity of the intestinal lining by regulating 
expression of factors important in cell adhesion and tight junctions. It has been linked 
to members of the cadherin family, molecules that mediate cell-cell adhesion (Hinoi et 
al., 2002), as well as transcription of glycoprotein A33 (GPA33) (Pinto et al., 2017) 
(Paper I). The functional role of GPA33 remains to be determined. It is expressed in 
the epithelial cells of the intestine with increased levels at cell-cell junctions (Johnstone 
et al., 2000), and has been implicated in cell-cell adhesion and maintenance of the 
intestinal barrier function (Ackerman et al., 2008; Williams et al., 2015). CDX2 is also 
known to regulate the expression of several claudins, membrane proteins that act as a 




et al., 2002; Satake et al., 2008). Further, CDX2 has been shown to regulate the 
transcription of the ST14 gene that encodes a type II transmembrane serine protease, 
also called matriptase (Danielsen et al., 2018). Matripase is involved in maintaining the 
permeability of tight junctions, possibly by incorporating claudins into intercellular 
junctions (Buzza et al., 2010). Matripase is under strict post-translation control by two 
inhibitors encoded by the SPINT1 and SPINT2 genes. In addition to regulating 
transcription of ST14, CDX2 also regulates the transcription of the inhibitor encoded by 
SPINT1 (Danielsen et al., 2018). 
The laminin subunit γ 2 (LAMC2), an ECM protein important in cell migration, is also 
seen to be transcriptionally regulated by CDX2 (Coskun et al., 2017). As is the 
expression of the ELMO3 gene encoding a scaffold protein that stimulates cell migration 
(Coskun et al., 2010), implicating CDX2 in regulation of cell migration in the colon. A 
number of mucins have also been shown to be transcriptionally regulated by CDX2, 
including MUC5AC, MUC5B, and MUC6 (Pinto et al., 2017) (Paper I). These mucins 
are secreted by goblet cells and provide a selective barrier to protect the gastrointestinal 
tract from acid, enzymes, food, and bacteria, as well as creating lubrication (Krishn et 
al., 2016). 
Besides activating the transcription of functional and structural genes, CDX2 is also 
involved in the transcriptional regulation of other transcription factors important in the 
colon. In differentiated Caco-2 cells, CDX2 is seen to bind to and activate transcription 
of the hepatocyte nuclear factor 4 α (HNF4a) gene (Boyd et al., 2010), encoding a 
transcription factor involved in crypt formation, cell-cell adhesion, and maturation of 
goblet cells (Cattin et al., 2009; Garrison et al., 2006). CDX2 has also been shown to 
bind a novel enhancer region of the Yes-associated protein 1 (YAP1) gene, a co-
transcription factor that regulates many genes important in proliferation, adhesion, 
migration and ECM organization (Larsen et al., 2019).    
Tissue-specific gene expression reflects the coordinated activities of multiple 
transcription factors, some of which are restricted to individual organs and some that 




and either GATA binding protein 4 (GATA4) or HNF4α show different crypt 
consequences. The combination of CDX2 and GATA4 deletion results in impaired crypt 
cell replication, while CDX2 and HNF4α deletion severely compromises cell 
differentiation but does not affect cell replication. Both combinations produced 
significantly greater defects and rapid lethality compared to single mutants (San Roman 
et al., 2015). Thus, CDX2 cooperates with other broadly expressed transcription factors 
to regulate distinct aspects of intestinal homeostasis.       
 
CDX2 and the Wnt signaling pathway 
Evidence suggests that CDX2, in addition to regulating differentiation, also acts as a 
regulator of the Wnt signaling pathway. In human colon cancer cell lines, the effect of 
CDX2 on Wnt signaling has been investigated using the TOP/FOP-Flash reporter 
system (Veeman et al., 2003). In CDX2 knockdown cells, the activity of Wnt signaling 
is increased while overexpressing CDX2 leads to reduced Wnt signaling (Yu et al., 
2019). In several human colon cancer cell lines, CDX2 has been shown to bind directly 
to β-catenin, thereby inhibiting β-catenin from binding to and activating TCF7L2 (Guo 
et al., 2010). In mice, it has also been shown that CDX2 regulates the transcription of 
the protocadherin Mucdhl, which interacts with and inhibits the transcriptional activity 
of β-catenin, showing that CDX2 also indirectly affects β-catenin activity (Hinkel et al., 
2012). In human cancer tissue, expression of CDX2 is seen to be inversely related to β-
catenin expression as well as expression of cyclin D1 and c-myc, both downstream 
target genes of Wnt signaling (Yu et al., 2019) supporting the notion that CDX2 
suppresses Wnt signaling in human colon cancer cells.  
In addition, the expression of APC, AXIN2, and GSK3β, all members of the β-catenin 
degradation complex in the Wnt signaling pathway, have also been associated with 
CDX2. In colon cancer cells, the expression of APC has been shown to be 
transcriptionally regulated by CDX2 (Olsen et al., 2013). However, in CDX2 knockout 
and CDX2 overexpression colon cancer cell lines, no change in APC expression can be 




to be associated with nuclear APC levels, but no association is seen with cytoplasmic 
expression of APC (Tóth et al., 2018). Therefore, the true effect of CDX2 on APC 
expression remains to be determined.  
ChIP-seq data from colon cancer cells show increased CDX2 binding of the AXIN2 
promoter region in differentiating cells compared to proliferating, indicating that CDX2 
might upregulate the expression of AXIN2 during differentiation (Boyd et al., 2010). 
AXIN2 has also been shown to transcriptionally regulated by CDX2 in colon cancer 
cell lines (Olsen et al., 2013). Knockdown of CDX2 in colon cancer cell lines leads to 
a decrease in expression level of AXIN2, while overexpression of CDX2 increases the 
AXIN2 mRNA level (Yu et al., 2019), clearly indicating that CDX2 regulates the 
transcription of AXIN2.  
In colon cancer cells, CDX2 has been shown to bind to the promoter region of GSK3β 
but not activate transcription (Olsen et al., 2013). However, downregulation of CDX2 
by TNF-α in colon cancer cells suppresses GSK3β expression (Coskun et al., 2014). 
Furthermore, knockdown of CDX2 in a colon cancer cell lines leads to a decrease in 
expression level of GSK3β, while overexpression of CDX2 increases the mRNA level 
(Yu et al., 2019). These results indicate that while CDX2 binds to the GSK3β promoter, 
activation of transcription may be dependent on other factors besides CDX2. Despite 
the conflicting evidence regarding the role of CDX2 in the transcription of APC and 
GSK3β, it is clear that CDX2 regulates the transcription of AXIN2 and plays a part in 
regulation of the degradation complex. 
Reducing the level of CDX2 in differentiated colon cancer cells results in an increase 
in transcription of TCF7L2, the main binding partner of β-catenin in the colon. (Boyd 
et al., 2010). Further, CDX2 has been shown to bind and activate transcription of HBP1, 
a transcriptional repressor that has been shown to suppress Wnt signaling by inhibiting 
TCF transcription factors (Boyd et al., 2010). These results indicate that CDX2 





Despite evidence of the inhibitory effect of CDX2 on Wnt signaling through inhibition 
of β-catenin, activation of transcription of members of the degradation complex and 
repression of transcription of TCF7L2, other studies indicate a possible interplay 
between the two. In colon cancer cell lines, a synergistic effect of CDX2 and β-catenin 
can be observed in activation of the transcription of claudin-1 (Bhat et al., 2012). 
Further, CDX2 has been shown to occupy some of the same regulatory regions as 
TCF7L2, resulting in an increase in intestine-specific transcripts compared to TCF7L2 
binding alone (Verzi et al., 2010), suggesting that CDX2 may cooperate with Wnt 
signaling and not only acts as a negative regulator.  
    
 
Colon cancer development 
 
The median age of diagnosis with colon cancer is approximately 70 years (Brenner et 
al., 2014). Age is the single most dominant risk factor of colon cancer development, but 
other identified risk factors include inflammatory bowel disease (Jess et al., 2012), 
smoking (Liang et al., 2009), obesity (Ma et al., 2013), excessive alcohol consumption 
(Fedirko et al., 2011), diabetes (Jiang et al., 2011), high consumption of red and 
processed meats (Chan et al., 2011), and family history of colon cancer (Taylor et al., 
2010). While few under the age of 50 are diagnosed, increasing incidence in young 
adults has been observed, possibly linked to alterations in diet, sedentary lifestyle, and 
rise of obesity (Cai et al., 2019; Loomans-Kropp and Umar, 2019).  
Degree of disease if determined according to TNM classification, describing the extent 
of invasion of the primary tumor (T), involvement of regional lymph nodes (N), and 
metastasis to distant sites (M). The three categories are combined into staging groups  
I-IV, with stage I tumors typically confined to the submucosa or muscular layer of the 
colon and stage IV presenting with distant metastasis (Piñeros et al., 2019), see table 1. 
The 5-year survival of patients with colon cancer is 90% in patients with localized 




15% in patients with distant metastasis (stage IV). Thus, the mortality rate is largely 
dependent on stage of disease at time of diagnosis, and up to 90% of colon cancer 
patients are diagnosed with advanced stage of disease, typically after onset of 
symptoms. Advances in screening methods have slightly reduced the number of 
diagnoses at late stage disease (Mattiuzzi et al., 2019). The primary treatment of colon 
cancer patients is surgical resection of the tumor as well as adjuvant therapy for patients 
with stage III and resectable stage IV disease. Some subsets of patients with stage II 
also benefit from adjuvant therapy, although up to 80% are cured by surgery alone 
(Kannarkatt et al., 2017). The risk of recurrence after curative resection of colon cancer 
is up to 30 % (van der Bij et al., 2009). Colon cancer surgery induces a surgical stress 
response (SSR) that results in reduced anti-tumoral defense as well as an increase in 
inflammatory factors (Neeman and Ben-Eliyahu, 2013), leading to an increased risk of 
postoperative recurrence (Heaney and Buggy, 2012).  
 
Table 1: Overview of colon cancer disease stage – Colon cancer is categorized according to degree of 
invasion of the primary tumor (T), involvement of regional lymph nodes (N), and metastasis to distant 
sites (M). The combination of the three factors confers to disease stage I-IV, with stage I being early stage 
and stage IV regarded as late stage.    
 Disease stage 
Stage I Stage II Stage III Stage IV 





muscle layer or 
through 
peritoneum  
Any degree of 
tumor invasion 
Any degree of tumor 
invasion 
N No metastasis to 
regional lymph 
nodes 
No metastasis to 
regional lymph 
nodes 
Metastasis to at 
least one regional 
lymph node 
Any degree of 
metastasis to regional 
lymph nodes 











While well-defined inherited forms account for approximately 2-5% of colon cancer 
cases, the majority are sporadic. For sporadic colon cancer to develop multiple genetic 
events are required, and genomic and epigenomic instability is recognized as a hallmark 
feature of colon oncogenesis (Hanahan and Weinberg, 2011). Several distinct pathways 
of genomic and epigenomic instability in colon cancer have been described, including 
chromosomal instability (CIN), microsatellite instability (MSI), and CpG island 
methylator phenotype (CIMP) (Pino and Chung, 2010). CIN is observed in 70-85% of 
all sporadic cancers and is characterized by duplication or deletion of either whole 
chromosomes or parts of chromosomes. MSI tumors are characterized by a defect in the 
DNA mismatch repair (MMR) system leading to instability in stretches of DNA 
microsatellites. The CIMP pathway exhibits gene silencing due to hypermethylation of 
CpG islands. As the definitions of these three pathways are not mutually exclusive, a 
tumour can exhibit features of multiple pathways (Grady and Markowitz, 2016).    
The majority of colon cancers are adenocarcinomas that stem from adenomatous 
precursor lesions. Over time these lesions grow in size and degree of dysplasia, 
eventually developing into tumors (Grady and Markowitz, 2016). In sporadic colon 
cancers that follow the adenoma-carcinoma pathway, inactivation of the APC gene is 
regarded as the early and perhaps initiating event in the multistep process of cancer 
formation. This loss of action mutation is followed by mutations of essential oncogenes 
and tumor suppressors (Fearon, 2011). While the majority of colon cancers follow the 
so-called adenoma-carcinoma pathway, 15-30% arise from early neoplastic serrated 
lesions histologically characterized by saw-tooth morphology of the epithelial glands in 
the precursor lesions as well as poor prognosis (Melo et al., 2013; Sakamoto et al., 
2017).       
 
The role of CDX2 in cancer development  
In early studies, loss of CDX2 expression has been implicated as a common event in 
tumorigenesis labelling CDX2 a tumor suppressor (Mallo et al., 1997). Mice embryos 




heterozygote mice are viable but multiple adenomatous polyps can be observed in the 
colon between week 12 and 28 (Chawengsaksophak et al., 1997). Mosaic deletion of 
Cdx2 in the colon of adult mice results in gastric-like lesions that do not spontaneously 
evolve into cancer (Balbinot et al., 2018), however, when paired with mice with mutant 
Apc a significant increase in tumor formation can be observed (Balbinot et al., 2018; 
Hryniuk et al., 2014). By tracking the Cdx2 depleted cells it has been shown that the 
tumors do not originate from the Cdx2 depleted cells but rather from Cdx2 intact cells 
(Balbinot et al., 2018), thereby indicating that the Cdx2 depleted cells do not become 
tumorigenic, but rather stimulate tumorigenesis in adjacent Cdx2 intact Apc mutated 
cells.  
Despite the evidence of its tumor suppressor function, there is also evidence that CDX2 
may have oncogenic properties. In leukemia and gastrointestinal cancers of the stomach 
and esophagus CDX2 is considered to be an oncogene (Barros et al., 2012; Rawat et al., 
2012; Tamagawa et al., 2012), and studies also indicate oncogenic properties in colon 
cancer. CDX2 has been shown to be essential for the viability of a number of colon 
cancer cell lines (Natoli et al., 2013; Salari et al., 2012), and in human colorectal cancers 
that exhibit chromosomal instability the CDX2 locus has been shown to be amplified 
(Subtil et al., 2007), indicating that CDX2 plays a role in colon cancer cell survival. 
Knockdown of CDX2 in colon cancer cells promotes cell proliferation in vitro and 
accelerates tumor formation in vivo, while the overexpression of CDX2 suppresses cell 
proliferation and viability, suggesting that CDX2 inhibits proliferation in colon cancer 
cells (Yu et al., 2019). 
Tumors with a strong reduction of CDX2 primarily belong to the serrated subtype, 
typically associated with MSI and CIMP, and poor prognosis (Balbinot et al., 2018; 
Melo et al., 2013). A synergistic oncogenic effect has been observed between loss of 
CDX2 expression and mutations in the BRAF oncogene in serrated tumors, possibly 
driving the development and progression of colon cancer. In adult mice the 
simultaneous inactivation of the Cdx2 gene and mutation of Braf dramatically decreased 




serrated histological features and altered gene expression (Sakamoto et al., 2017; Tong 
et al., 2017). Correlation between loss of CDX2 expression and BRAF mutation has also 
been observed in human serrated cancers (Landau et al., 2014; Neumann et al., 2018; 
Olsen et al., 2014; Sakamoto et al., 2017), and a study has implicated BRAF in the 
regulation of CDX2 (Herr et al., 2015), further underlining an interaction between 
CDX2 and BRAF in early colon cancer development.  
CDX2 has been seen to regulate the transcription of several genes that then dysregulated 
become tumorigenic. The ST14 gene, encoding matripase, as well as one of its two 
inhibitors, are both regulated by CDX2 (Danielsen et al., 2018). Matripase has been 
shown to be dysregulated in a number of cancer types, including cancer of the breast, 
ovary, uterus, prostate, skin, cervix, and colon (reviwed by Tanabe and List 2017). 
However, mRNA levels of matripase have also been described to be downregulated in 
colon cancers, but this downregulation was followed by a downregulation of mRNA of 
the inhibitors, resulting in the same ratio of matripase to inhibitor (Vogel et al., 2006).  
The ratio between matripase and its two inhibitors is seen to be increased in cancers, 
suggesting that this balance is vital in avoiding cancerous development (Parr et al., 
2012). As CDX2 regulates both matripase and one of its inhibitors, the dysregulation of 
CDX2 may be critical in the matripase to inhibitor ratio balance.  
Further, CDX2 is shown to bind to enhancer regions of the YAP1 gene, encoding the 
co-transcription factor YAP1 (Larsen et al., 2019). It is known to be a key regulator of 
proliferation, adhesion, migration and ECM organization, has also been linked to cancer 
progression (Liang et al., 2014; Steinhardt et al., 2008; Tschaharganeh et al., 2013). 
Nuclear localization and overexpression of YAP1 has been associated with poor 
prognosis in colon cancer, as well as other types of cancer (Xia et al., 2018; Zygulska 
et al., 2017).  
Alterations in mucin expression, organization, and glycosylation has shown to be 
associated with colon cancer (Krishn et al., 2016), as well as various other cancers, 
including breast, ovarian, gallbladder, pancreatic, lung, gastric, and prostate cancer 




including MUC5AC (Pinto et al., 2017) (Paper I), which is not expressed in healthy 
colon epithelium. However, its expression has been observed to be upregulated in early 
stage colon cancers but decrease as dysplasia increases. Patients with MUC5CA-
negative colon cancers have worse overall survival and more aggressive disease (Imai 
et al., 2013; Wang et al., 2017). The dysregulation of CDX2 expression in colon cancers 
may be linked to the aberrant expression of mucins, possibly driving colon cancer 
development.   
The expression of the tight junction protein claudin-1 is regulated through an interplay 
between CDX2 and Wnt signaling (Bhat et al., 2012), and increased expression of 
claudin-1 has been reported in colon cancer (Dhawan et al., 2005; Kinugasa et al., 2010).  
Mice with mutated Apc and claudin-1 expression have significant increase in colon 
tumor growth (Pope et al., 2014), and colon cancer cells overexpressing claudin-1 
injected into nude mice form tumors at a significantly faster rate compared to injecting 
with control colon cancer cells (Dhawan et al., 2005). In rectal cancer, however, 
decreased expression of claudin-1 in cancer tissue has been associated with recurrence 
and poor prognosis (Yoshida et al., 2011), and perhaps the dysregulation of claudin-1 
by CDX2, whether it be up- or down-regulated, may be instrumental in cancer 
development.       
A recurrent fusion between the v-SNARE encoded by Vps-ten-interacting-1a (VTI1A) 
and the TCF7L2 gene has been observed in approximately 3% of primary colon cancer 
tumors (Bass et al., 2011). Gene translocations and deletions are well known to be 
associated with cancer development, and the first fusion gene was discovered in chronic 
myelogenous leukemia (Parker and Zhang, 2013). Other recurrent fusion genes have 
been observed in other types of cancer, including prostate and lung (Soda et al., 2007; 
Yu et al., 2010). The fusion between the VTI1A and TCF7L2 genes has been shown to 
result in a dominant negative form of the TCF7L2 protein, transcriptionally activated 
by CDX2 (Davidsen et al., 2018) (Paper II), indicating that not only does the function 




The true role of CDX2 as either a tumor suppressor or an oncogene remains to be 
determined, but the dysregulation of CDX2, whether it be up or down regulated, seems 
to play a vital part in the development of colon cancer.   
 
Regulation of CDX2 expression 
The expression of CDX2 is regulated, in part, by CDX2 itself in an auto regulatory loop 
where it activates transcription from its own promoter (Barros et al., 2011; Boyd et al., 
2010), as seen in figure 5. A combination of different factors have also been shown to 
regulate the intestine specific expression of CDX2, including TCF7L2, HNF4α, 
GATA6, and nuclear factor κB (NF-κB) (Benahmed et al., 2008; Boyd et al., 2009; Kim 
et al., 2002). Further, methylation at two distinct promoter regions of the CDX2 gene 
correlates with diffuse, partial, or absent CDX2 expression in colon cancer cell lines 
(Graule et al., 2018).  
CDX2 protein can be detected all along the crypt-villus axis but its activity is regulated 
by post-translational phosphorylation of different sites. Phosphorylation at serine 60 via 
the mitogen-activated protein kinase (MAPK) pathway is observed in the proliferating 
compartment of the intestinal crypt, resulting in decreased transactivation capacity 
(Rings et al., 2001). Interestingly, when CDX2 is phosphorylated by the MAPK family 
member p38 the transactivation capacity increases (Houde et al., 2001). When 
phosphorylated by cycline-dependent kinase 2 (Cdk2), CDX2 is marked for rapid 
degradation by the ubiquitin/proteasome pathway (Boulanger et al., 2005; Gross et al., 





Figure 5: Regulation of CDX2 expression – The GATA6, TCF7L2, HNF4α and NF-κB transcription factors 
regulate the transcription of CDX2. Methylation of the promoter region of CDX2 results in inhibition 
of transcription. The activity of CDX2 is regulated by phosphorylation. When phosphorylated through 
the MAPK and by Cdk2, activity of CDX2 is repressed, while phosphorylation by p38 activates CDX2.  
 
CDX2 as a prognostic marker 
 
As CDX2 expression is retained in most colon cancers it is commonly used as a tissue 
biomarker to determine the origin of primary tumor. However, a subgroup of patients 
present with tumors with loss or reduction of CDX2 expression (Baba et al., 2009; Hinoi 
et al., 2001). The CDX2 gene is rarely mutated (Xia et al., 2009) but epigenetic changes, 
such as hypermethylation of  the CDX2 promoter, are believed to lead to transcriptional 
downregulation or loss of expression of CDX2 (Dawson et al., 2014; Graule et al., 
2018). Loss of CDX2 expression is seen as a signature for undifferentiated colon cancer 
cells and poorly differentiated cancers are seen to be more aggressive with a higher risk 
of recurrence (Merlos-Suárez et al., 2011). Therefore, the possible prognostic feature of 
CDX2 status has been thoroughly investigated but despite the substantial amount of 




The majority of studies investigating CDX2 as a prognostic marker determine an 
association with loss of CDX2 with either worse overall survival (OS), progression-free 
survival (PFS), and/or disease-free survival (DFS). Some, however, find no independent 
prognostic value in loss of CDX2 expression, or find that prognostic value is limited to 
certain cancer stages or molecular and phenotypical subtypes, as reviewed in table 2. 
Table 2: CDX2 as a prognostic marker – Overview of literature that investigates the applicability of CDX2 
status as a prognostic marker for prognosis in colon cancer patients. The table shows surname of fist 
author, year of publication, stage of disease, and whether an association between loss of CDX2 expression 
and prognosis was observed.      
First author Year Stage Loss of CDX2 expression 
Asgari-
Karchekani et al.  
2019 I-IV No impact 
Bae et al.  2014 III 
IV 
Associated with lower PFS. 
Associated with lower PFS and OS. 
Bonetti et al.  2017 I-III Associate with lower OS and DFS in tumors with 
poorly differentiated clusters of cells.  
Bruun et al.  2018 IV Associated with lower 5-year DFS 
Cecchini et al.  2019 II No impact 
Dalerba et al.  2016 II & III Associated with lower 5-year DFS. 
Dawson et al.   2014 I-IV No impact 
Graule et al.  2018 I-IV Associated with lower 5-year DFS 
Hansen et al.  2018 II Associated with lower 7-year DFS 
Ma et al.  2019 II & III Associated with lower DFS in MMR deficient 
tumors 
Neumann et al.  2018 I-IV Associated with lower OS 
Nishiuchi et al.  2019 II & III Associated with lower 5-year OS and DFS 
Olsen et al.  2016 I-IV No impact on risk of recurrence. 
Pilati et al.  2017 II & III Associated with lower OS and DFS 
Ryan et al.  2018 I-IV No impact in MMR deficient tumors 




Slik et al.  2019 II Associated with lower 5-year DFS in MSI 
tumors 
Xu et al. 2019 I-IV Associated with lower OS and DFS 
Zhang et al.  2017 IV Associated with lower OS and PFS in metastatic 
colon cancers 
DFS: disease-free survival. MMR: mismatch repair. MSI: microsatellite instability. OS: overall survival 
PFS: progression-free survival.  
 
The difference in the prognostic value of CDX2 on survival may be attributed to 
multiple factors, including the method used to determine CDX2 status and well as the 
cut-off value for a negative CDX2 status. Assessing CDX2 status from whole-slide 
immunohistochemistry is often difficult, as there may be areas with CDX2 loss despite 
most of the tumor being positive (Cecchini et al., 2019). The disease stage of the patients 
included also varies. Some studies include patients with stage I to stage IV disease, 
while others investigate patients within one stage or even within one distinct molecular 
subgroup. The number of patients and time to follow-up also varies, and when taking 
all these factors into account, the discrepancy of the results may not be surprising. 
While CDX2 is regarded as an independent prognostic factor in some studies, others 
speculate that other molecular features of the tumor should also be taken into account. 
Mutation of the BRAF oncogene have been associated with loss of CDX2 expression 
(Dawson et al., 2014; Neumann et al., 2018; Slik et al., 2019), and CDX2 loss has 
displayed strong prognostic value in patients with BRAF mutated tumors (Bruun et al., 
2018).  
Tumors with MMR deficiency have been associated with loss of CDX2 expression 
(Graule et al., 2018; Olsen et al., 2016), and the prognostic impact of CDX2 is also seen 
to be dependent on whether the tumor is MMR deficient or proficient. On one hand, in 
patients with MMR deficient tumors loss of CDX2 has been shown to have no impact 
on survival (Ryan et al., 2018), but loss of CDX2 expression also been observed to result 
in worse disease-free survival (Ma et al., 2019). MMR deficient tumors are often 




with loss of CDX2 expression become a more aggressive subtype of colon cancer. Pilati 
et al. also shows that the prognostic abilities of CDX2 depends on the molecular subtype 
of the cancer, and that it can only predict prognosis in some colon cancer subtypes (Pilati 
et al., 2017). 
In addition to molecular subtypes, CDX2 status may also be paired with other features 
to more precisely determine prognosis. Loss of CDX2 expression has been seen to have 
improved prognostic value in combination with tumor stage (Xu et al., 2019), Muc2 
expression (Cecchini et al., 2019), SATB2 expression (Ma et al., 2019), and number of 
poorly differentiated clusters of cancer cells within the tumor (Bonetti et al., 2017). To 
summarize, the applicability of CDX2 as a prognostic marker remains controversial, 
despite a majority of studies finding association between loss of CDX2 expression and 
poor prognosis.  
 
CDX2 expression and metastasis 
The molecular mechanism behind the possible prognostic abilities of CDX2 remains to 
be elucidated, however several steps in cancer progression and metastasis have been 
linked to CDX2. Tumor budding cells frequently show reduced CDX2 expression, 
despite the tumor being CDX2 positive (Graule et al., 2018; Hansen et al., 2018), 
associating downregulation of CDX2 with the metastatic process.   
Alternation in the adhesion abilities of cancer cells is believed to be a critical element 
in cancer cell metastasis (Läubli and Borsig, 2019). In order to disengage from the 
primary tumor, cancer cells downregulate cell-cell adhesion through modification of the 
cadherin-catenin complex (Aamodt et al., 2010), as well as downregulate expression of 
claudins, reducing the integrity of tight junctions (Tabariès and Siegel, 2017). As 
previously mentioned, CDX2 has been shown to regulate the expression of both 
cadherins and claudins (Bhat et al., 2012; Hinoi et al., 2002; Sakaguchi et al., 2002; 
Satake et al., 2008). Furthermore, loss of CDX2 expression has been shown to affect 
adhesion abilities of colon cancer cells (Davidsen et al., 2020) (Paper III), implicating 




cells attach to metastatic sites the expression of selectins, integrins, and members of the 
immunoglobulin superfamily are upregulated (Gallicchio et al., 2008; Robertson et al., 
2009; Tremblay et al., 2008). CDX2 has been shown to mediate E-selectin ligand 
expression in colon cancer cells (Sakuma et al., 2012), thereby also involving CDX2 in 
cancer cell attachment at distant sites of metastasis.   
 
Figure 6: Proposed model of CDX2 expression in metastasizing cancer – For cancer cells to 
metastasize, the cells must first disengage from the primary tumor. The cells downregulate CDX2 
expression leading to EMT and enter circulation. When attaching at distant sites, CDX2 expression is 
upregulated leading to increased adhesion and MET, resulting in establishment of distant metastasis.  
Loss of intestinal identity though the downregulation of CDX2 has been suggested as a 
precursor to epithelial to mesenchymal transition (EMT) in metastatic colon cancer 
cells, as seen in figure 6. As the circulating cancer cells establish metastasis, CDX2 




transition (MET) (Brabletz et al., 2004; Zhang et al., 2015). When overexpressing 
CDX2 in colon cancer cell lines, a decrease in mobility and dissemination of cancer 
cells has been observed (Gross et al., 2008; Zheng et al., 2011), further implicating 
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Investigating the true function of essential genes can be challenging. The aim of this 
study was to develop a method where inducible transcriptional elements could be 
integrated into cultured cells, enabling tight control of gene expression with the use of 
doxycycline. To demonstrate the possibility of using this method to investigate gene 
function, the LS174T human colon cancer cell line was genetically engineered as a bi-
allelic CDX2 knockout containing doxycycline inducible CDX2 expression.  
This paper demonstrates that the PrIITE systems allows for induction of expression of 
the gene of interest, while at the same time enabling control over protein levels of the 
gene of interest. This approach revealed novel downstream effector genes of CDX2, 
indicating the extensive role of CDX2 in gene expression regulation. Further, normal 
expression of downstream effector genes was highly dependent on the level of CDX2 
protein expressed. The method developed in this study can be used to study the functions 
of other essential genes in a dose-dependent manner.   
 
This paper is a result of collaboration between multiple institutions. My contribution as 
co-author was determining the transcriptional regulation of promoter reporter constructs 
by CDX2. Results are presented in figure 6 and supplementary figure 3.  
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ABSTRACT
Tetracycline-based inducible systems provide pow-
erful methods for functional studies where gene ex-
pression can be controlled. However, the lack of tight
control of the inducible system, leading to leakiness
and adverse effects caused by undesirable tetracy-
cline dosage requirements, has proven to be a lim-
itation. Here, we report that the combined use of
genome editing tools and last generation Tet-On sys-
tems can resolve these issues. Our principle is based
on precise integration of inducible transcriptional el-
ements (coined PrIITE) targeted to: (i) exons of an en-
dogenous gene of interest (GOI) and (ii) a safe harbor
locus. Using PrIITE cells harboring a GFP reporter or
CDX2 transcription factor, we demonstrate discrete
inducibility of gene expression with complete abro-
gation of leakiness. CDX2 PrIITE cells generated by
this approach uncovered novel CDX2 downstream ef-
fector genes. Our results provide a strategy for char-
acterization of dose-dependent effector functions of
essential genes that require absence of endogenous
gene expression.
INTRODUCTION
Historically, analysis of the molecular genetic mechanisms
underlying cell fate and animal phenotypes has been studied
by abrogating gene function in cellular and animal model
systems. Initially this has been accomplished by random
mutagenesis (1–3), homologous recombination (4) and re-
cently by the use of precise genome editing technologies that
allow for target inactivation of any GOI in cells, tissues and
animal models (5–7). However, the fact that the genetic le-
sions induced are static render these approaches inadequate
in situations where swift reversal of gene function is desired
or in cases where the GOI plays an essential function for
cellular survival. Thus, alternative approaches have to be
employed in these situations. One commonly used alterna-
tive is based on gene ‘knock down’ by RNAi/shRNA (8).
Although the successful application of these technologies
in cell lines is well documented, knock down strategies are
hampered by lack of quantitative and absolute inactivation
of gene function, which makes this approach problematic
in situations where downstream gene functional studies re-
quire complete gene inactivation. In these situations, the use
of inducible gene expression systems has shown to be a pow-
erfulmethodology that allows for: (i) control of gene expres-
sion levels of potentially toxic gene products that could have
adverse side effects on cell growth and survival when ex-
pressed constitutively, (ii) temporal and spatially controlled
activation of genes and proteins and (iii) analysis of cellu-
lar gene dose/response effects. Various inducible gene ex-
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pression systems have been described in the literature based
on cre-lox P system (9), myxovirus resistance 1 promoter
(10), estrogen receptor (11), optogenetics (12), ecdysone-
induciblity (13) or tetracyclin (Tet)-Off/On systems (14–
17). The latter systems are probably the most commonly
used inducible systems for which a plurality of reagents have
been developed, published and are commercially available
(18). However, one disadvantage of Tet-inducible systems
and the majority of the aforementioned inducible systems,
is their well described ‘leakiness’ (19–23). Furthermore, in-
ducible expression in both transient and stable expressing
cells have indicated that cells respond differently to induc-
tion, which has been attributed to heterogeneity in chromo-
somal integration of the inducible gene elements in individ-
ual cells leading to non-homogenous induction responses
(21). Importantly, well known side effects of tetracycline
(and its derivatives) on cell fitness, in particular after long
term treatment, caution for its use in biomedical research
when used at traditional concentrations >100 ng/ml (24–
26).
Thus, there is a yet unmet need in the field to improve
the tightness of the available inducible systems.We reasoned
that the observed ‘leakiness’ with the most commonly used
‘Tet-On’ system (17,27) is due to the uncontrolled random-
ness of integration of the genetic elements encoding both
the ectopically expressed transactivator and the inducible
GOI, leading to muddled inducible gene expression with
pleiotropic downstream effects dependent on the activation
conditions used. Therefore, we hypothesize that by inte-
grating a defined number of transactivator and inducible
transcriptional elements at defined cellular genomic loci we
can (i) circumvent the ‘leakiness’ issue and (ii) lower the
Dox concentration needed for induction below the levels
causing cellular stress. Thus, by taking advantage of pre-
cise genome editing and last generation Tet-On platforms
(18,27), the objectives of this study were to establish a flex-
ible ‘non-leaky’, minimal Dox concentration requiring iso-
genic knockout-rescue system. We built our cellular model
system on the colorectal cell line LS174T and by mono- or
bi-allelic targeting of constitutively expressing transactiva-
tor (Tet3G) elements (TET3G) to one locus and inducible
GFP-reporter elements to another safe harbor locus we
demonstrate minimal Dox requirement, no leakiness and
reversibility of the system. We next demonstrate the util-
ity of the isogenic PrIITE system by mono- or bi-allelic in-
tegration of inducible CDX2 transcription factor elements
into PrIITE cells and re-confirm the reversibility and lack
of leakiness of the system. We also for the first time demon-
strate, that Tet-On leakiness is related to the cellular copy
number of integrated transactivator elements and not the
number of integrated inducible elements of the inducible
system.
Finally we confirm the complete absence in leakiness of
the system by RNA-seq and in combination with ChIP-seq
identify several novel genes directly transcriptionally con-
trolled by CDX2 (Figure 1). The selection of CDX2 as our
target gene was based on its relevance as a key regulator
of intestinal differentiation, with many downstream targets
that can be assessed as read-outs (28).
MATERIALS AND METHODS
ZFN gene targeting plasmids and plasmid donor construction
CDX2 and AAVS1 CompoZr ZFN plasmids for human
CDX2 and AAVS1 were obtained from Sigma targeting
exon 1 of CDX2 (AACTTCGTCAGCCCCccgcagTACCC
GGACTACGGCGGTT) and intron one of the PPP1R12C
gene at theAAVS1 hotspotAAV integration site (ACCCCA
CAGTGGggccacTAGGGACAGGAT), respectively. ZFN
binding sites are shown in upper case and linker cut site
in lower case lettering. ZFNs were tagged with 2A peptide
fused GFP or Crimson as described recently (29). Fluores-
cent protein tagging allows for FACS enrichment and im-
proves efficiency in obtaining correctly targeted clones.
Donor construct was designed based on the previ-
ously described approach by Maresca et al. (30) with the
only modification that inverted ZFN binding sites were
positioned flanking the entire donor insert. A synthetic
ObLiGaRe CDX2 donor vector frame work possess-
ing inverted CDX2 ZFN binding sites (AACCGCCG
TAGTCCGGGTAccgcagGGGGCTGACGAAGTT)
flanking a XhoI/EcoRV linker was generated (EPB64,
Genewiz, USA, Addgene ID#90017). A CMV-Tet3G-
SV40UTR TET3G transactivator encoding fragment
(pTet3G, Clontech/Takara, USA) was XhoI/HindIII
excised (HindIII overhang bluntended) and inserted into
XhoI/XbaI (overhangs bluntended) site of EPB64-donor
vector generating pCDX2-pCMV-TET3G-ObLiGaRe
donor vector.
Various inducible gene expressionObLiGaRe donor con-
structs targeted to the AAVS1 safe harbor locus were
generated based on available AAVS1 safe harbor Com-
pZr ZFN binding element information (Sigma-Aldrich,
USA). A AAVS1 ObLiGaRe donor vector framework was
generated (EPB58, Genewiz, USA, Addgene ID#90016)
and designated pObLiGaRe-AAVS1, possessing the re-
spective inverted ZFN binding elements (5′-atcctgtcccta
ggccacccactgtgggt-3′) flanking an EcoRV multiple cloning
site linker (see Supplementary Figure S11 for vector de-
sign). A full-length codon optimized CDX2 (CDX2opt)
construct was generated (EPB40, GeneArt/ThermoFisher,
USA and SalI/BamHI insert cloned into SalI/BamHI
sites of pTRE3G (Clontech/Takara, USA) generating
pTRE3G-CDX2opt.
A BamHI fragment encoding a Golgi targeted EYFP
fusion protein, T2EYFP (31) was blunt end cloned into
the EcoRV site of pTRE3G generating pTRE3G-T2EYFP.
T2EYFP encodes theN-terminalGolgi targeting and reten-
tion sequence fused to EYFP. The XbaI/XhoI Tet respon-
sive expression fragments from both pTRE3G-CDX2opt
and pTRE3G-T2EYFP were excised and blunt end cloned
into the EcoRV site of pObLiGaRe-AAVS1 (EPB58) gener-
ating pAAVS1-TRE3G-CDX2opt and pAAVS1-TRE3G-
T2EYFP. For pAAVS1-TRE3G-T2EYFP, the donor insert
was excised with PacI/PmeI and inserted into PacI/PmeI
site of a modified AAVS1 targeting vector (EPB71,
Genewiz, USA, Addgene ID#90018) where PacI/PmeI
cloning sites are flanked by insulator sequences and the in-
verted AAVS1 ZFN binding sites. See Supplementary Fig-
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Figure 1. Overview of the established isogenic knockout-rescue model system based on precise integration of inducible elements (PrIITE) in LS174T.
(A) pCDX2-pCMV-TET3G-ObLiGaRe donor vector (pCMV-Tet3G) was targeted to CDX2 exon1 by ZFN mediated targeted integration followed by
pTRE3G-inducible Gene Of Interest (GOI) ObLiGaRe donor vector (pTRE3G-indGOI) targeting to the safe harbor AAVS1 locus. (B) Schematic illus-
tration of the isogenic inducible CDX2 LS174T cell model system based on the mono- (upper panel) or bi- (lower panel) allelic precise genome targeting of
CDX2 inducible elements, CDX2−/−1XindCDX2 and CDX2−/−2XindCDX2 respectively. (C) Illustration of the experimental workflow including deep
transcriptomic analysis (RNA-seq) of wild type LS174T and isogenic indCDX2-PrIITE cells exposed to variable concentrations of doxycycline inducer
and CDX2 target validation by genome-wide CDX2 ChIP-seq (ChIP-seq) analysis.
ure S11 for vector constructs used and generated. All plas-
mids were Sanger sequencing verified.
Cell culture and transfection
LS174T (ATCC-CL-188) human intestinal cell line was
maintained in Ham’s nutrient mixture F12/Dulbecco’s
modified Eagle’s medium (1:1) supplemented with 10% fetal
bovine serum and 1% glutamine. Different target ‘knock in’
strategies were undertaken, including use of 800 bp homol-
ogy arms flanking the donor integration cassette D (data
not shown). Successful LS174T targeted KI was only ob-
tained when the ObLiGaRe strategy for improved target
specific ‘knock in’ integration of donor constructs was em-
ployed (30). In brief, the ObLiGaRe strategy is based on use
of existing ZFNbinding elements that in an ‘inverted’ orien-
tation flank the donor DNA construct. By co-nucleofection
of ZFN’s and donor DNA, double stranded breaks at both
the specific chromosomal target site and flanking the donor
plasmid will occur allowing cellular repair pathway medi-
ated target specific integration of the linearized donor at the
desired target site.
For stable pCDX2-pCMV-TET3G-ObLiGaRe integra-
tion the first exon of the CDX2 gene was targeted through
CDX2 CompoZr ZFNs driven integration (Sigma-Aldrich,
USA) (AACTTCGTCAGCCCCccgcagTACCCGGAC-
TACGGCGGTT, left and right ZFN binding sites capital-
ized and linker cloning site in lower case). 1 × 106 LS174T
cells were transfected by nucleofection, simultaneously
with the GFP/E2 Crimson tagged CDX2 ZFN plasmids (2
g each) and the pCDX2-CMV-TET3G-donor vector (5
g). Nucleofector solution T (Lonza, CH)/Nucleofector
program T-020 were used for the electroporation procedure
in an Amaxa Cell Line Nucleofector device (Lonza, CH).
Cells were then cultured for 6 h at 37◦C to stabilize, and
then moved on to a 30◦C cold shock. Two days after
transfection, cells expressing both GFP and E2 Crimson
were sorted out in a FACS ARIA III (BD BioSciences,
USA) as previously described (29). The cell bulk was plated
out to grow in collagen-coated plates and two rounds of
cloning were then employed.
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Single cell clones were screened by junction PCR using a
primer flanking the 5′ CDX2 target locus and a reverse ori-
ented primer localized within the integrated pCMV-TET3G
cassette (Supplementary Figure S1A and B). Based on
IDAA assay (32), one of them (5B5) showed the presence
of wt allele, representing heterozygozity for pCMV-TET3G
integration at the CDX2 locus (clone named LSCDX2+/−),
while the other two clones (3D6 and 5E2) were found to
possess successfully integrated pCMV-TET3G transactiva-
tor at both alleles representing homozygozity for pCMV-
TET3G (clones named LSCDX2-/−#1 and LSCDX2-/−#2 re-
spectively).
1 × 106 cells from a CDX2 KO clone containing mono
or bi-allelic pCMV-TET3G transactivator inserted into the
two CDX2 alleles were then transfected by nucleofection
with GFP/E2 Crimson tagged AAVS1 ZFN plasmids (2 g
each) and 5 g pAAVS1-TRE3G-CDX2opt or pAAVS1-
TRE3G-T2EYFP.
Clone characterization by polymerase chain reaction (PCR)
and IDAA
In order to identify correct integration of pCDX2-CMV-
TET3G, a region comprising a part of CDX2 exon 1 up-
stream the ZFNs cutting site and left 800 bp homology arm
and a part of the CMV promoter was amplified using Ex-
pand Long Template PCR System (Roche Applied Science,
GE) (5′-CMV-TET3G junction PCR). Similarly, the identi-
fication of correctly integrated pAAVS1-TRE3G-CDX2opt
or pAAVS1-TRE3G-T2EYFP fragments intoAAVS1 locus
was performed by amplification of a region comprising a
part of AAVS1 upstream the ZFNs cutting site and a part
of the TRE promoter (5′-TRE3G-CDX2opt or TRE3G-
T2EYFP junction PCR). PCR reaction mixture consisted
of 100 ngDNA, 2.5 l buffer 1, 3.0 l 1.25mMdNTPsmix,
0.25 l each primer at a concentration of 25 M, 0.1 l en-
zyme mix and water to a final volume of 25 l. All junction
PCR primers were obtained from TAG Copenhagen A/S,
Denmark and are listed in Supplementary Table SIV. Am-
plification was done using the following touch down proto-
col. After preheating for 5 min at 95◦C, 12 cycles were per-
formed starting with denaturation for 45 s at 95◦C, anneal-
ing for 15 s at 74◦Cwith a decrease in annealing temperature
of –1◦C/cycle, and 2 min at 72◦C, followed by an additional
25 cycles of 45 s at 95◦C, 15 s at 64◦C and 2 min at 72◦C,
followed by a final extension of 3 min at 72◦C. PCR prod-
ucts were run in a 1.2% agarose gel, bands were gel purified
and sequence confirmed by Sanger sequencing.
FACS-enriched stable clones (29) were screened by junc-
tion PCR using primers flanking the junction between the
CDX2 orAAVS1 genes and the integrated cassette (Supple-
mentary Figures S1 and S2).
Presence of unmodified CDX2 or AAVS1 target (WT
allele presence test) was performed using the recently de-
scribed IDAA method (32) and protocol guidelines (33).
In brief, due to size of the donor constructs used (>2 kb,
respectively) the respective CDX2 or AAVS1 ZFN target
sites can only be successfully amplified if integration has
not occurred at the respective target loci. PCR was per-
formed using 100 ng DNA in 25 l using AmpliTaq Gold
(ABI/Life Technologies) for CDX2 locus or TEMPase Hot
Start DNA Polymerase (Ampliqon A/S, DK) for AAVS1
locus using the recently described IDAA/tri-primer ampli-
fication conditions comprising primers flanking the respec-
tive target site in combination with a universal 6-FAM 5′-
labeled primer (FamF), specific for a 5′-overhang attached
to the forward primer. IDAA primers used were purchased
from TAG Copenhagen A/S and are listed in Supplemen-
tary Table SIV. Fluorescently labeled amplicons were then
analyzed by capillary electrophoresis based fragment analy-
sis using an ABI3030 instrument (Applied Biosystems/Life
Technologies, USA). Raw data obtained was analyzed us-
ing Peak Scanner Software V1.0 (Applied Biosystems/Life
Technologies, USA).
Induction with Dox
The Tet-On3G system was induced with Dox (Sigma-
Aldrich, USA) in a range between 0.004 and 4 g/ml
for CDX2 knock-in (KI) clones and 0.001–5 g/ml for
T2EYFP KI clones. Dox was added to the medium every
24 h for one or 2 days, and medium was exchanged every 48
h after Dox removal. Controls where Dox was not added to
the medium were used (0 g/ml of Dox).
Western blot of cell lysates
Whole-cell extracts were obtained by resuspension of cell
pellets in RIPA buffer (50 mM Tris–HCl pH 7.4, 150 mM
NaCl, 2 mM EDTA, 1% NP-40, 0.1% sodium dodecyl sul-
phate) in the presence of complete protease inhibitors cock-
tail (Roche Applied Science, GE). Quantification of total
protein was determined by bicinchoninic acid protein assay
(Thermo Scientific™ Pierce, USA). 15 g of protein extracts
were then analyzed by standard SDS-PAGE, transferred to
a nitrocellulose membrane (GE Healthcare Life Sciences,
USA) and blotted on at 4◦C with mouse monoclonal pri-
mary antibodies CDX2-88 1:500 (Biogenex, USA), anti-
TetR 1:1000 (Clontech/Takara, USA), anti-MUC2, undi-
luted hybridoma supernatant and anti-actin 1:8000 (Santa
Cruz Biotechnology, USA) in 5% BSA in PBS. Mem-
branes designed forMUC2 blotting were previously treated
with neuraminidase from Clostridium perfringens type VI
(Sigma-Aldrich, USA) diluted in PBS to a final concentra-
tion of 0.2 U/ml, for 1 h at 37◦C. Peroxidase-conjugated
secondary antibodies (goat polyclonal anti-mouse-HRP
1:2000 for CDX2, TetR and MUC2 and goat polyclonal
anti-rabbit-HRP 1:2000 for actin (Santa Cruz Biotechnol-
ogy, USA) were used and developed with the ECL detection
kit (Bio-Rad Laboratories, USA).
RNA extraction
Total RNA was extracted using RNeasy kit (Qiagen, GE)
as recommended by the manufacturer.
Transcriptomics (RNA-Seq)
Polyadenylated RNA was isolated from total RNA using
standard protocols (Dynabeads mRNA Direct Micro Kit,
Ambion/Life Technologies, USA) starting with 5 g total
RNA. Library preparation forNGS using Ion Torrent tech-
nology (Life Technologies, USA) was carried out according
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to the manufacturers recommendations (Ion Total RNA-
Seq Kit v2, Ion torrent/Life Technologies, USA), and se-
quenced using an Ion Proton system (Life Technologies,
USA). Quality control, quantification of RNA and libraries
was carried out using using Agilent RNA 6000 Nano Kit
or Agilent High Sensitivity DNA kit and Agilent Bioana-
lyzer (Agilent Technologies, USA). Sequencing reads were
mapped to hg19 and bioinformatics analysis was conducted
using CLCs Genomic Workbench (CLC bio/Qiagen, DK),
STARBowtie2 followed by Cufflinks for expression anal-
yses. In brief, ∼50 ng polyA RNA was fragmented down
to 100–300 base fragments using RNaseIII for 1–3 min fol-
lowed by adapter ligation, amplification for 9–14 cycles and
barcoding using Ion Express RNA-Seq Barcode kit (Ion
Torrent/Life Technologies, USA). The final library frag-
ment size and concentration was determined by Agilent
Bioanalyzer analysis followed by template preparation us-
ing Ion PI Template OT2 200 Kit v3 (Life Technologies,
USA) and Ion One Touch System followed by NGS on an
Ion Proton system using Ion PI™ Chip Kit v2. In general,
two transcriptome libraries were barcoded and analyzed on
one Ion PI v2 chip. Sequencing depth for the RNA-Seq
data sets ranged from 34.5 to 44.6 mill reads/sample with
95.4–97.7%mappable reads to the hg19 reference data base.
Mean read length for transcriptome RNA-Seq data ranged
from 116 to 136 bp.
Genome-wide analysis of CDX2-binding sites by ChIP-seq.
LS174T cells grown for five days in a 30 × 30 cm cul-
ture dish were cross-linking and sonicated as described pre-
viously to generate fragments of ∼0.2 to 1.2 kb. Here-
after, the ChIP-protocol was performed as previously re-
ported (34). Briefly, immunoprecipitation was done in
four replicates and performed overnight at 4◦C using spe-
cific antibodies to human CDX2 (CDX2-88, Biogenex,
USA) and the influenza hemagglutinin (HA) epitope (rab-
bit polyclonal -HA; Santa Cruz Biotechnology Inc, Hei-
delberg, Germany), used as a negative control. Immuno-
complexes were recovered with 50 l protein A/G beads
(Invitrogen/ThermoFisher Scientific, USA). Verification of
the enrichment in the CDX2-immunoprecipitated DNA
samples was done by qPCR analyzing the DNA level from
known CDX2-targets in the CDX2-immunoprecipitated
samples and comparison it to level in the negative control
(HA-immunoprecipitated DNA).
In order to increase the depth of the analysis, the ChIP
library established was deep sequenced using Ion Proton in-
strumentation generating an approximate≈54million reads
depth. Library preparation for NGS was carried out with
the Ion Xpress Plus gDNA Fragment Library Kit accord-
ing to User Bulletin 4473623: Ion Chipseq Library Prepa-
ration on the Ion Proton System (Life Technologies, USA),
starting with 10 ng DNA. Quality control of the libraries
was carried out using using Experion DNA 1K analysis
kit and the Experion System (Bio-Rad Laboratories, USA).
In brief, 10 ng DNA was end-repaired and ligated to bar-
code adaptors from the Ion Xpress Barcode Adapters 1–
16 Kit (Life Technologies, USA), followed by nick repair
and amplification for 18 cycles. The amplified libraries were
subjected to two rounds of bead capture with the Agen-
court AMPure XP Kit (Beckman Coulter, USA) to size-
select fragments ∼160–340 bp in length. The final library
concentration was determined by Qubit analysis (Ther-
moFisher Scientific, USA). The barcoded ChIP- and IP
control-DNA-libraries were handled similarly to the RNA-
Seq library and analyzed on a single Ion PI™ Chip v2. For
the ChIP- and IP control-DNA-libraries a total of 54.5 mill
reads (21.8 and 32.7 mill respectively) were obtained and
98.5% were mappable to the reference hg19 data base with
a mean read length of 130 bp. The detection of CDX2 ChIP
seq peaks and the location of the closest genewas performed
using CisGenome version 2 (35).
Immunodetection by fluorescence-activated cell-scanning
(FACS) analysis
Cells were trypsinized at different time-points after induc-
tion with Dox or after Dox removal and washed twice
with PBS. After being centrifuged at 1200 rpm for 7 min,
CDX2 KI cells were fixed in 4% PFA for 20 min., washed
in PBS and permeabilized in cold methanol for 15 min. Af-
ter washing with PBS, samples were incubated with the pri-
mary antibody (CDX2-88 clone, BioGenex, 1:500.) for 1
h at 37◦C. Cells were then stained with FITC-conjugated
AfinityPure immunoglobulin antimouse IgG (Jackson Im-
munoResearch Laboratories, USA) diluted 1:100 in 0.05%
BSA in PBS and then subjected to FACS in a FACS ARIA
III (BD BioSciences, USA). T2EYFP KI cells were imme-
diately scanned by FACS after cell trypsinization.
Immunocytochemistry
Cell slides were fixed in cold acetone for 15 min. For TetR
anti-TetR cells were incubated overnight at 4◦C with the
primary antibodies (9G9 clone, Clontech/Takara, USA).
Negative controls were performed by omission of primary
antibodies. After washing, a rabbit anti-mouse Ig FITC-
labeled secondary antibody (Dako A/S, DK) diluted 1:100
in PBS with 5% BSA was added for 45 min, protected from
light. DAPI was used as a nuclear counterstain and slides
weremounted in Vectashieldmountingmedia (Vector Labs,
USA).
For EYFP visualization on the induced T2EYFP KI
clones, trypsinized cells were fixed in cold acetone for 10
min, DAPI was added and slides mounted. Samples were
examined under a Zeiss fluorescence microscope equipped
with DAPI and FITC interference filters. Images were ac-
quired using a Zeiss Axioskop 2 and an AxioCam MR3
camera and Zeiss Application Suit software.
Real time in vivo video material
For the time lapse video, 1 × 106 CDX2−/−2XindT2EYFP
cells were seeded in a well of a six-well plate and 0.5 g/ml
of Dox were added after 24 h. Time lapse images started to
be acquired under dark field immediately after Dox addi-
tion and every 20 min during 24 h using a Leica DMI 6000
timelapse microscope equipped with FITC interference fil-
ter and with CO2 supply.
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RESULTS
Precise integration of inducible transcriptional elements (PrI-
ITE)
CDX2 knock-out by targeted integration of Tet3G transac-
tivator elements. In order to eliminate the adverse cellular
effects seen from prolonged exposure to Dox (25,26), we de-
signed a strategy combining stable and controlled TeT-On
transactivator/TeT3G expression with disruption of a tar-
get gene. First we established a Tet3G expressing LS174T
cell line, in which the TET3G elements were targeted to
CDX2 exon1 CDS, thereby abrogating the endogenous gene
function. Targeting CDX2, a master differentiation tran-
scription factor (36), allowed us to determine the efficacy
of the system in an unprecedented CDX2 knock out cell
system (Figure 1). Multiple attempts at homologous re-
combination driven donor integration at the CDX2 exon
1 locus based on CDX2 ZFNs and a TET3G donor tem-
plate flanked by 700bp homology arms did not give rise
to any correctly targeted clones, likely due to low homolo-
gous repair capacity of LS174T cells used in this study (data
not shown). pCDX2-pCMV-TET3G-ObLiGaRe donor vec-
tor (Figure 1A and Supplementary Figure S1A) was co-
transfected together with CDX2 CompoZr ZFN plasmids
into LS174T cells, whereby pCMV-TET3G transactiva-
tor donor vector was specifically integrated into exon1 of
CDX2, as illustrated in Figure 1A and Supplementary Fig-
ure S1A and B, by ObLiGaRe driven recombination (see
Material and Methods section for details). Three clones
(5E2, 3D6 and 5B5) were shown to include correct inte-
gration of the pCMV-TET3G construct and constitutively
express the Tet3G transactivator (Supplementary Figure
S1C), one clone, 5B5, was mono allelically targeted (des-
ignated LSCDX2+/−) and CDX2 protein expression main-
tained at levels similar to the parental LS174T wt cell line
and in the bi-allelic targeted CDX2 knock-out (KO) clones,
3D6 (LSCDX2−/−#1) and, 5E2 (LSCDX2−/−#2), CDX2 ex-
pression was completely abrogated (Supplementary Figure
S1C and D). Constitutive Tet3G expression and abrogation
of CDX2 was maintained after prolonged cell passaging
and after freeze/thawing lack of CDX2 was correlated with
significantly decreased protein levels of a well-know CDX2
target gene, MUC2 (37) (Supplementary Figure S1C and
D). Lastly, we tested the functionality of the mono and bi–
allelically targeted CDX2 KO cells by cellular transfection
with known CDX2 enhancer reporter constructs and could
show dose dependent decreased expression of aHNF4A re-
porter and >10-fold reduced expression of a HEPH1 re-
porter (38) in the CDX2 KO cells (Supplementary Figure
S3).
We thus show, thatCDX2KO by ZFN-mediated site spe-
cific pCMV-TET3G integration in LS174T cells was effec-
tively accomplished and that stable Tet3G expression was
maintained over time.
Safe harbor targeted integration of inducible T2EYFP ele-
ments. Having shown that both LSCDX2-/−#1 and #2 dis-
play similar transactivator expression levels, an inducible
T2EYFP model system was established in LSCDX2−/−#1.
The inducible pTRE3G-T2EYFP-ObLiGaRe donor vec-
tor was targeted to the safe harbor AAVS1 locus by
co-transfection with AAVS1 CompoZr ZFN’s into the
LSCDX2−/−#1 cells as illustrated in Figure 2A. Multiple
correctly targeted indT2EYFP clones were obtained and
two of these selected for further detailed analysis, one
mono-allelic T2EYFP targeted clone 7E9 (hence forward
referred to as CDX2−/−1XindT2EYFP) and another bi-
allelic targeted clone 5G8 (henceforward referred to as
CDX2−/−2XindT2EYFP), Supplementary Figure S2. Both
clones maintained constitutive Tet3G expression and ab-
sence of CDX2 (Figure 2B).
LS174T indT2EYFP PrIITE cells display no leakiness and
Dox induction is fast and reversible.. We first aimed to de-
termine the leakiness of the inducible T2EYFP reporter in
the CDX2−/−1xindT2EYFP and CDX2−/−2xindT2EYFP
clones by FACS and immunofluorescence, which showed
undetectable fluorescence in uninduced PrIITE cells (Fig-
ure 2C, D and E). Upon induction, immunofluorescence
displayed the expected peri-nuclear reactivity, consistent
with the correct sub-cellular localization of T2EYFP fusion
protein in the Golgi apparatus (39) (Figure 2E).
We next determined the induction dynamics over time
by in vivo live imaging, demonstrating that the induc-
tion dynamics is very rapid. T2EYFP expression is de-
tectable within 4 h post induction and all cells display
full expression of the reporter after 8–10 h (Supplemen-
tary video material). Importantly, the induction dynam-
ics is fully synchronized and all cells simultaneously be-
come positive for the T2EYFP reporter. To elucidate how
Dox dosage might influence on the dynamics of the sys-
tem, induction was performed using variable Dox concen-
trations ranging from 0 to 5 g/ml. As shown in Figure
2C, modest induction was observed with dox concentra-
tions<5 ng/ml, whereas significant induction requiredDox
concentration >10 ng/ml. Interestingly, these results sug-
gest, that the induction potential is related to the number
of inducible elements integrated into the system. For in-
stance, using a 10 ng/ml Dox dosage rendered >90% of
the CDX2−/−2XindT2EYFP cells EYFP reporter positive,
whereas <50% CDX2−/−1xindT2EYFP cells were found
positive for this dosage.
Next, the reversibility of the PrIITE cell systemwas quan-
tified by FACS analysis of the EYFP expressing cell popu-
lation after Dox removal from the media (Figure 2D). As
observed, induction was fully reversible and after 10 days
post Dox removal, all cells in the population returned to
non-expressing levels. However, the dynamics in reversibil-
ity was found to be dependent on both number of inducible
elements integrated and the Dox dosage used. Clearly re-
versal to non-expressing levels was achieved rapidly and
within 5 days for CDX2−/−1XindT2EYFP and slower for
CDX2−/−2xindT2EYFP using the lower 50 ng/ml induc-
tion dosage.
We thus demonstrate that the PrIITE cell system displays
no leakiness, is fully reversible, and that the induction dy-
namics occurs fast and in a synchronized manner and re-
quire below cellular stress inducing Dox concentrations.
LS174T indCDX2 PrIITE cells show no leakiness and ec-
topic CDX2 expression is tightly controlled requiring min-
imal Dox induction levels. The role of CDX2 in intesti-
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Figure 2. Overview of the proof of principle system using inducible T2EYFP reporter in isogenic LS174T-PrIITE cells. (A) First pCMV-Tet3G was tar-
geted to CDX2 exon1 of LS174T cells generating mono- or bi-allelic CDX2 KO cells, CDX2+/− and CDX2−/− respectively. Next, cells were re-targeted
with pTRE3G-T2EYFP ObLiGaRe-donor vector (pTRE3G-T2EYFP) directed to the safe harbor AAVS1 locus generating CDX2−/−1XindT2EYFP and
CDX2−/−2XindT2EYFP cells. (B) Western blot analysis of LS174wt, CDX2−/−, CDX2−/−1XindT2EYFP and CDX2−/−2XindT2EYFP cells show ab-
sence of CDX2 and stable TeT3G expression. (C) FACS based determination of percentage indT2EYFP positive cells after induction with different Dox
concentrations. The graph shows that induction is dose and copy number dependent in CDX2−/−1XindT2EYFP and CDX2−/−2XindT2EYFP PrIITE
cells. Approximate 100% T2EYFP positive cells was achieved using >0.005 g/ml Dox concentration for CDX2−/−2XindT2EYFP. Maximum 70% posi-
tivity was achieved regardless of the higher Dox induction concentrations used for CDX2−/−1XindT2EYFP cells. Importantly, CDX2−/−2XindT2EYFP
cells show complete absence in T2EYFP fluorescence in uninduced cells thus, no leakiness of T2EYFP LS-PrIITE cells was detectable. Critical dox concen-
tration above which adverse cellular stress (24–26) is caused is indicated by a dotted gray line. (D) Reversibility of induction as determined by FACS analysis
of fixed cells 1, 5 or 10 days post 48 h induction with variable Dox induction concentrations. Notably, reversibility was copy number and dox dependent
and full reversibility within 10 days was only achieved for CDX2−/−1XindT2EYFP PrIITE cells using the lower 0.05 g/ml Dox concentration. (E) Sub
cellular localization of inducible T2EYFP as determined by fluorescence of fixed trypsinized indCDX2 PrIITE cells with or without dox induction. Arrow
heads indicate expected Golgi localization of T2EYFP.
nal gene regulation is well known. However, to the best
of our knowledge no studies so far described the effect of
complete ablation of CDX2 from the cellular genome. In
a single study CDX2 has been suggested as a lineage sur-
vival oncogene when amplified in colorectal cancer (40).
In order to distinguish endogenous from ectopically ex-
pressed CDX2 transcripts the inducible CDX2 open read-
ing frame was codon optimized (hereafter referred to as in-
dCDX2). pTRE3G-indCDX2-ObLiGaRe donor vector was
targeted to the AAVS1 safe harbor site of LSCDX2-/−#1
cells generating clones 7D9 (CDX2−/−1XindCDX2) and
6D6 (CDX2−/−2XindCDX2) possessing one or two in-
ducible codon optimized CDX2 copies respectively (Fig-
ure 1B and Supplementary Figure S4). Constitutive
Tet3G expression was maintained in targeted cells and
CDX2−/−2XindCDX2 or CDX2−/−1XindCDX2 cell in-
duction dynamics over 24 h were similar (Figure 3A and
B). To test the reversibility of the CDX2 PrIITE sys-
tem built, we induced with a range of Dox concentra-
tions (0–4 g/ml) for 48 h followed by removal of Dox
from the medium. As expected, no expression of indCDX2
was revealed in non-induced cells followed by fast dose
dependent Dox induction dynamics (Figure 3C). Impor-
tantly, for the lowest concentration of Dox used (0.004
g/ml), the induction dynamics for the CDX2−/− 1Xind-
CDX2 clone was slower than for CDX2−/−2XindCDX2
(Figure 3C). Of notice, the indCDX2 protein levels,
reached for CDX2−/−1XindCDX2 with 4 ng/ml Dox dose,
were similar to the endogenous CDX2 levels detected
in LS174Twt cells (Supplementary Figure S4E) while for
CDX2−/−2XindCDX2 induction reached 120× higher lev-
els relative to LS174Twt levels (Supplementary Figure S4E).
In contrast to the dynamics in reversibility for indT2EYFP
KI clones (Figure 2), reversibility of indCDX2 induction
appeared faster and required very modest Dox induction
dosages in the sub cell stress inducing nanogram/ml range.
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Figure 3. Induction dynamics of isogenic inducible CDX2 LS174T PrIITE cells. (A) Anti-TeT3G transactivator immunofluorescence in
CDX2−/−2XindCDX2 cells and not in LS174T wt cells. (B) 24 h induction kinetics of indCDX2 using different Dox concentrations. >60% of
CDX2−/−1XindCDX2 and CDX2−/−2Xind CDX2 cells become indCDX2 positive after 24 h 0.004 g/ml Dox induction. Use of higher Dox con-
centrations higher percentage of cells become CDX2 positive after 24 h Dox treatment. (C) Dynamics in reversibility of the PrIITE system using different
Dox induction concentrations. CDX2−/−2Xind CDX2 (left panel) and CDX2−/−1Xind CDX2 (right panel) cells were induced 48 h with the Dox con-
centrations indicated above the panels. Hereafter Dox was removed and post induction indCDX2 protein levels were determined by Western blot analysis
1, 3, 5 or 8 days post Dox removal. Maximum indCDX2 induction levels were achieved using 0.004 g/ml Dox concentration for CDX2−/−2XindCDX2
whereas 0.040 g/ml Dox was required for CDX2−/−1Xind CDX2.
Based on western blot analysis indCDX2 protein was un-
detectable within 3 days post Dox removal for both mono-
and bi-allelic clones (Figure 3C).
Validating the tightness in inducibility of the PrIITE by
deep transcriptome analysis. To confirm the tightness of
the PrIITE system and in order to determine the CDX2
downstream target genes, LS174Twt, uninduced and in-
duced CDX2−/−2XindCDX2 or CDX2−/−1XindCDX2
cells were RNA-seq transcriptome profiled (Figure 4A, and
Supplementary Figure S5). To ensure that the isogenic PrI-
ITE cells generated were representative of the mosaic mod-
erately well differentiated LS174Twt cell population (41), all
comparative analysis here and in the following sections in-
cluded LS174Twt cells. Approximately 10 000 genes with
RPKM >1 were shown to be expressed in the wt cells
and the expression profiles for the mucin genes MUC2
and MUC5AC correspond to the profiles previously re-
ported for LS174Twt cells with high expression for the for-
mer and low expression for the latter (42,43) (Figure 5B).
CDX2 target genes were defined by the following crite-
ria; genes with RPKM >1 in wt cells where RPKM values
in uninduced PrIITE cells (CDX2−/−) were reduced >4×
(4×↓) and increased >2× (2×↑) after re-induction rela-
tively to the uninduced RPKM values. In depth analysis
of the RNASeq reads that mapped to the human exon1
CDX2 gene locus, including the region across the CDX2
ZFNs cutting site, confirmed the presence of out of frame
transcripts possessing deletions in CDX2−/−2XindCDX2
exon1, while the heterozygous CDX2−/−1XindCDX2 clone
expressed intact endogenous CDX2 transcripts present at
≈40% of the LS174Twt transcript levels (Supplementary
Figure S5A). Analysis of the unmapped RNA-seq reads
confirmed the presence of the Tet3G transactivator tran-
scripts in CDX2−/− cells (Supplementary Figure S5B) and
importantly, no indCDX2 transcript was detected in the
uninduced state of the CDX2−/−2XindCDX2 clone (Sup-
plementary Figure S5B), thus confirming the biochemical
and immunofluorescence results obtained previously.
Taken together, by biochemical analysis, immunofluores-
cence and deep transcriptome analysis, we have shown that
the PrIITE system allows for absolute control of inducible
and reversible gene expression of CDX2 and it’s down-
stream target genes.
Validating the transcriptome identified CDX2 target genes by
genome-wideChIP-seq analysis. Reasoning that theRNA-
seq identified CDX2 target genes could be direct or indirect
targets of CDX2, we wanted to validate the RNA-seq data
set by genome wide chromatin immunoprecipitation se-
quence analysis (ChIP-seq).We thus used ChIP-seq to iden-
tify trueCDX2binding elements in the vicinity of theRNA-
seq identified CDX2 target genes. ChIP was performed on
LS174Twt cells using a well-known anti-CDX2monoclonal
antibody essentially using a previously reported procedure
(38). A LS174T non-immunoprecipitated library was deep
sequenced in parallel and used as ChIP-seq background
control. An additional requirement was added to the RNA-
seq criteria for positive scoring of primary CDX2 target
genes, in that a ChIP-seq peak (CDX2 binding element)
were to be present within or 1 kb up or downstream of
the target gene. The combined RNA- and ChIP-seq cri-
terion identified 31 direct CDX2 target genes (Figure 4B
and Supplementary Table SI). Among these genes several
known CDX2 regulated targets were found, such as TFF3,
MUC2 and CDX2 itself, but several novel targets were also
found, including MUC5B, MUC5AC, MUC6, GPA33 and
LDLR (Figure 5). Furthermore, in vitro promotor analysis
confirmed the CDX2 dependent regulation of the enhancer
identified in the novel CDX2 target gene GPA33 (44) (Fig-
ure 6) and thus, substantiated both our RNA- and ChIP-
seq findings. Interestingly, a significant intergenic CDX2
binding element was identified in the 300 Mb 11p15 re-
gion containing the mucin genes MUC6, MUC2, MUC5B
and MUC5AC (Supplementary Figure S6A). Clearly our
transcriptome results reveal a significant concerted down-
regulation of this gene cluster and suggest CDX2 as a ‘lo-
cus control gene’ (Figure 5B). As expected, the non CDX2
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Figure 4. Deep RNA-seq and genome wide ChIP-seq analysis of LS174Twt and induced or uninduced CDX2−/−2XindCDX2 PrIITE cells. (A) Of the
20 327 human genes included in the analysis around 9965 were found to be expressed with RPKM >1, the majority hereof (7346) were low expressed
genes with 1 < RPKM < 10 (A), followed by medium expressed genes (1847) with 10 < RPKM < 50 (B) and highly expressed genes (772) with 50 <
RPKM (C). In uninduced CDX2−/−2XindCDX2 (−Dox) PrIITE cells (lacking CDX2), 712 genes expressed in LS174Twt were 4-fold down regulated
and after indCDX2 re-induction (+Dox) 349 of these genes were 2-fold upregulated and thus suggested to be CDX2 downstream target genes. (B) In
order to determine to what degree the genes identified represent direct CDX2 target genes, we included a LS174T ChIP-seq data set and seeked for the
presence of potential CDX2 regulatory elements in the vicinity of the RNA-seq suggested CDX2 target genes. Inclusion of this criteria (numbers shown
in parenthesis) in addition to the RNA-seq criterion defined above resulted in a dramatic decrease in potential direct CDX2 targets going from 349 to 31
genes. The expanded view at right depicts the number of targets identified using the RNA-seq or RNA-seq+ChIP-seq criteria. In the latter case the targets
indicated below the stippled line are listed in Supplementary Table SI.
regulated mucin genes MUC1 and MUC7 did not possess
any CDX2 binding elements and did not respond to CDX2
changes (Figure 5B and Supplementary Figure S6B). Previ-
ously, we have identified CDX2 as a regulator of glycosyl-
transferase encoded ST6GALNAC1 expression (45). How-
ever, in this study, no CDX2 binding elements were iden-
tified in the ST6GALNAC1 locus (Supplementary Figure
S6B), which suggests that CDX2 regulates the expression
of this gene by an indirect effect.
The results also show that several known CDX2 tar-
gets such as FUT2 (46), B3GALT5 (47), ALP1 (48) and SI
(28) in LSCDX2 PrIITE cells were unaffected by CDX2
changes (Figure 5B and Supplementary Figure S7) and no-
tably, in the latter three cases these genes were shown not to
be expressed in LS174Twt cells. Of notice, the only glyco-
genes (49) otherwise affected by CDX2 were FUT3 and
GALNT1 which in the latter case responded inversely to
CDX2 changes (Figure 5B).
In order to assess to what degree the global reversibil-
ity in gene expression for LSCDX2 PrIITE cells was re-
tained, RPKM values from LS174Twt and LSCDX2 PrI-
ITE cells exposed to different Dox concentrations ranging
from 0 to 40 ng/ml were plotted and the regression line for
each data calculated (Figure 7 and Supplementary Figure
S8). The results show that global reversibility of CDX2 con-
trolled gene expression was profound, and in many cases
full reversibility was observed when the lowest 4 ng/ml
Dox concentration was used with CDX2−/−2XindCDX2
cells. Clearly, the combined RNA-seq and ChIPseq filter-
ing strategy employed improved the specificity in defining
true CDX2 regulated genes in our data set (Figure 7C). We
speculate, that the observed highest normalization levels of
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Figure 5. CDX2 regulated target genes. (A) Based on the includedRNA-seq andChIPseq criteria (see Figure 4 and Supplementary Table SI) top 10 primary
targets downstream of CDX2 with most abundant transcripts (highest RPKM values) were ranked. Well known CDX2 target genes were identified such
as TFF3 andMUC2, but novel targets were also identified including GPA33 and LDLR. (B) Careful analysis of 208 glycogenes (49) controlling the cellular
glycophenotype and 23 mucin genes revealed that MUC5B, MUC6 and MUC5AC were controlled by CDX2, whereas MUC1 and MUC7 did show no
correlation with CDX2 expression. No CDX2 correlation with FUT2 and B3GALT5 could be demonstrated, which is in contrast with previous reports.
On the other hand, ST6GALNACI and -VI were shown to correlate with CDX2 expression although no CDX2 binding element could be identified within
the vicinity of the CDS of these genes. Interestingly, an inverse correlation was observed for GALNT1 regulation similar to SOX2 (see Supplementary
Figure S7), with upregulation in the absence of CDX2 expression. Interestingly, the novel CDX2 target GPA33 gene product has been shown to be post
translationally modified by the GALNT1 encoded enzyme. Genes with ChIP-seq identified CDX2 binding elements in the gene locus vicinity are indicated
by an *.
re-induced CDX2 for 4 ng/ml Dox may be due to the role
of CDX2 as a molecular rheostat potentially controlling: (i)
self-renewal as indicated in Figure 5 and/or (ii) regulated
expression of downstream target genes within discrete and
narrow CDX2 expression limits (50). Lastly, in order to de-
termine if the genetic manipulations had changed the dif-
ferentiation state and stemness of CDX2 PrIITE cells gen-
erated, we determined the expression profile of 24 marker
genes before and after genetic manipulation and/or CDX2
re-induction (Supplementary Figure S7). In all cases (ex-
cept forMUC6), the gene expression profiles of genetically
manipulated cells relative to LS174Twt was retained and
displayed a distinct intestinal expression pattern. Interest-
ingly, the stemness related gene, SOX2, is not expressed in
the wt cells, but strongly expressed upon CDX2 KO and
clearly decreased upon reinduction. This may suggest that
also stemness regulation is CDX2 dependent. The CDX2
targets identified in our data-set is to some extent in agree-
mentwith previous findings in a related cellular background
(38) (SupplementaryTable SI). Of note, the karyotype of the
LS174T cells used in our study was determined and found
to be in complete agreement with the originally near normal
published karyotype (41) (Supplementary Figure S9).
DISCUSSION
Gene regulatory mechanisms are complex and profit from
the development of systems in which gene and protein ex-
pression is tightly controlled. Tet-regulated expression sys-
tems have been widely used for inducible protein expression
inmammalian cells. However, current optimized Tet-on sys-
tems are still hampered by residual levels of gene expres-
sion in the uninduced state in both transiently and stably
transfected cells (18,21,22). We hereby demonstrate that the
PrIITE system resolves all issues related to leakiness and
importantly requires use of tetracycline dosages below cell
stress inducing concentrations (24). We first prove the PrI-
ITE concept using a Golgi targeted EYFP model reporter
(31). With this tightly controlled inducible reporter system
at hand, we were able to demonstrate, to the best of our
knowledge for the first time, that leakiness relates to in-
creased expression of the TET3G transactivator element
and not increased presence of the inducible GOI, in this
case the T2EYFP reporter, Supplementary Figure S10. We
furthermore show that stable random integrated pCMV-
TET3G transactivator elements causes leaky expression in
a substantial sub-population of the cells and we speculate
that this sub-population of cells enable uncontrolled Dox
induction levels beyond what is achievable in the tightly
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Figure 6. Identification and validation of the novel CDX2 target gene,GPA33. (A) Panel shows chromosome 1 coverage of CDX2ChIPseq reads (CDX2IP)
and control (input), calculated in 300 bp sliding windows as RPM (reads per million). For each window, input RPM was subtracted from CDX2IP RPM
and normalized values were saved as a bedgraph file for visualization in the UCSC Genome Browser. Major CDX2 binding sites (peaks) are shown with
indication of the GPA33 locus framed in red box. (B) Expanded display of the GPA33 locus, showing detailed identification of CDX2 ChIPSeq peaks
(ChIPseq/RPM) in both LS174T CDX2IP and control input samples. Major GPA33 CDX2 binding element is indicated by red triangle (CDX2 peak).
RNA-seq panel displays the density of individual reads in CDX2−/−2XindCDX2 with or without Dox induction (4 or 0 ng respectively) and LS174Twt
cells. RefSeq gene panel displays the genomic organization of neighboring genes in the GPA33 locus. (C) In vitro promoter analysis of the 0.6 kb CDX2
enhancer element identified in the GPA33 intron. pGL4-GPA33 and pGL4-GPA33enhancer represent the reporter plasmid without or with the enhancer
element included. Reporter expression is clearly dependent on both GPA33 CDX2 enhancer and CDX2 presence.
controlled PrIITE cells generated, Supplementary Figure
S10B. We next exemplify the potential of the system by
clarifying the role of CDX2 in intestinal cells as a con-
sequence of controlled CDX2 expression. This model sys-
tem shows that CDX2 predominantly acts as a transcrip-
tional activator and only a limited number of genes seemed
to be repressed by CDX2 presence, SOX2 being an exam-
ple hereof (Supplementary Table SII). We had anticipated
that CDX2 targeting in LS174T cells could become prob-
lematic due to its proposed essential cellular function and
pre-designed our targeting strategy for dealing with essen-
tial genes. This was accomplished by incorporating a ‘land-
ing pad’ in the EPB71 AAVS1 donor integration vector, just
downstream of the inducible gene of interest (Supplemen-
tary Figure S11). The ‘landing pad’ encodes the Safe Har-
bor #1 (SH1) sequence derived from the CHO genome, that
has successfully been utilized by us (51) and others (52) for
ZFNmediated target integration inCHO cells and thus rep-
resents a unique site when integrated in human cells devoid
of this sequence. This allows for subsequent donor target in-
tegration into the SH1 site. Establishment of a PrIITE cell
model for an essential gene can thus be accomplished, by
targeting of both the TET3G transactivator and inducible
pTRE3G codon optimizedGOI transcriptional elements to
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Figure 7. Global Dox induction reversibility of the PrIITE cells relative to LS174Twt cells. In order to include enough data points in the analysis, filtering
criteria included all genes with RPKM >1, that were 2× reduced in CDX2−/− KO cells and had a CDX2 binding element/peak in the gene locus. RNA-
seq data (RPKM) from wildtype LS174T was plotted against RPKM values from uninduced CDX2−/−2XindCDX2 cells without CDX2 expression (blue
dotted line, 2XindCDX 0 ng DOX) and under different conditions of CDX2/Dox induction (ng/ml) (green dotted line, 2XindCDX2 4 ng DOX; purple
dotted line, 1XindCDX2 4 ng DOX, red dotted line, 2XindCDX2 40 ng DOX). The regression line for each data set is plotted. The dark blue solid line
represents the expression levels in LS174Twt cells. (A) Global display of RNA-seq RPKM values for the samples analysed. RPKMs for the known CDX2
target genesMUC2 and TFF3 and the novel target gene,GPA33, are indicated by grey dotted vertical lines. Box with gray dotted line is area shown in panel
B. Representative examples of genes displaying full reversibility are indicated with arrow heads. (B) Zoom from dotted box from panel A with indication of
RPKM values for the novel CDX2 target gene, LDLR. Representative genes for which complete reversibility was observed are indicated by arrow heads.
(C) Global display of RNA-seq RPKMs for genes fulfilling the RPKM >1 and 2× reduction filtering criteria but without fulfilling the criteria of a CDX2
binding element/peak in the gene locus. Note the unordered dispersed display of RPKMs relative to the LS174Twt regression line, suggesting that a large
proportion of the CDX2 target genes only based on RNA-seq data are not direct targets of CDX2.
theAAVS1 locus, ex. byAAVS1 targeting of the former gene
followed by SH1 targeting of the later gene. Hereafter, pre-
cise target inactivation of the endogenous gene of interest in
the presence of Dox would ensure continued expression of
the inducible codon optimized version of the essential GOI.
In this project, we did not take advantage of this option,
since in the LS174T cellular model CDX2 has not proven
to act as a lineage-survival oncogene in contrast to what is
observed in other cell line models (40).
Our results also show that LS174T cells have a poor ca-
pacity to integrate homology arm flanked donor templates,
which is likely attributed to the lacking HR capacity of
these and other cell lines used (53–55). In general, precise
donor integration remains a challenge in the field and in
spite of the fact that CRISPR efficiently induces double
stranded breaks, CRISPR mediated donor integration im-
portantly comes at the expense of: (i) 3–20-fold higher indel
formation rates at the non-targeted allele (56,57) and (ii)
significant off-target/random integration frequencies (58).
These concerns were evident in a recent in vivo study based
on CRISPR target integration of inducible TRE3G pro-
moter elements, where ‘leaky’ expression in 33% of clones
analyzed was identified (59). In light of these CRISPR re-
lated issues, the ObLiGaRe targeting strategy by Marcello
Maresca et al. remains to be an efficient and reliable tar-
get integration strategy formost cells (60–63), includingHR
compromised cells such as CHO cells (64,65) and colorec-
tal cancer lines as described in this study and by Marcello
Maresca et al.
A whole set of novel genes, including GPA33 (44), LDLR
(66), MUC6, MUC5B and MUC5AC were identified as
CDX2 targets. To our knowledge, this has not previously
been demonstrated and suggests CDX2 as a locus control
gene of the 11p15 mucin gene cluster (67–69) that includes
MUC2, MUC6, MUC5B and MUC5AC. In this respect,
a recent study of 295 gastric adenocarcinomas has shown
that GPA33, MUC6 and MUC2 were among the 10 most
abundant differentially regulated genes in 295 analyzed mi-
crosatellite instable (MSI) colorectal adenocarcinomas (70).
Although CDX2 profiling was not evident in this study it
is stimulating to assume that MSI has impacted on CDX2
expression in the tumors studied. Furthermore, GPA33 is
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expressed in cancer of the gastrointestinal tract, namely in
over 95% of human colon cancers and has thus been sug-
gested as an attractive novel colorectal carcinoma therapeu-
tic target (71,72). Of particular notice, GPA33 gene product
has been shown to be post translationally modified by the
GALNT1 encoded GalNAc-transferase 1 enzyme (73,74),
that we here show is inversely influenced by CDX2 (Fig-
ure 5B). Our finding that LDLR is a major direct CDX2
target gene is surprising since LDLR has been primarily
found to be regulated by sterol regulated element-binding
proteins (SREBPs) (75,76). We speculate that CDX2 plays
novel roles in the co-regulated appearance of these novel
gene targets.
In summary, we hereby describe a novel approach for
generating an inducible ‘non leaky’ isogenic knockout-
rescue system. The principle is based on precise genome in-
tegration of defined copies of third generation Tet-On ele-
ments, which enables for an ‘all or none’ context for study-
ing themechanism by which a given gene works in a cell.We
exemplify the utility of the system by establishing a colonic
CDX2 PrIITE cell system that uncovered novel molecular
interactions governed by CDX2.
MATERIALS & CORRESPONDENCE
All reagents and cell lines used in the study are available
upon request for research purposes under a material trans-
fer agreement, except for TRE3G and TET3G contain-
ing plasmids, due to restrictions over distribution of plas-
mids containing the TRE3G promoter or TET3G ORF.
The RNA-seq and ChIP-seq data shown has been uploaded
at the NIH GEO server: http://www.ncbi.nlm.nih.gov/geo/
and is accessible using the following accession number
GSE97273. Plasmids described are available from Addgene
(https://www.addgene.org/). All correspondence should be
addressed to Eric P. Bennett.
NOTE ADDED IN PROOF
Extended experiments conducted during proofs of this
manuscript revealed that the GPA33 promoter described
in Figure 6 possess bi-directional transcriptional activity,
likely mediated through presence of multiple LINEs con-
tained within the 1KBp GPA33 promoter analyzed. LINEs
have been shown tomediate bi-directional expression (Trin-
klein, N.D., Aldred, S.F., Hartman, S.J., Schroeder, D.I.,
Otillar, R.P. and Myers, R.M. (2004) An abundance of
bidirectional promoters in the human genome. Genome
Res.14:62–66; Core, L.J.,Waterfall, J.J. and Core, J.T. (2008)
Nascent RNA sequencing reveals widespread pausing and
divergent initiation at human promoters. Science, 322:1845–
1848) potentially affecting 4% of all human genes (Speek,
M. (2001) Antisense promoter of human L1 retrotranspo-
son drives transcription of adjacent cellular genes. Mol.
Cell. Biol. 2001, 1973–1985; Criscione, S.W., Theodosakis,
N., Micevic, G., Cornish, T.C., Burns, K.H., Neretti, N.,
and Rodić, N. (2016) Genome-wide characterization of hu-
manL1 antisense promoter-driven transcripts. BMC Ge-
nomics, 17:463).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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Supplementary Table I.  CDX2 as an activator* 
4x in KO, 2x Dox (0.004 g/ml), CDX2 ChIP-seq peak in locus 
CDX2 targets previously identified in CaCo2 cells
Supplementary TableII.  CDX2 as a repressor* 
Genes not expressed in LS174Twt, 4x  in KO, 2x +DOX (0.004 g/ml), CDX2 ChIP seq peak in locus
Supplementary Table III. CDX2 as an activator* 
*Low expressed genes 0<RPKM<1, 4x , 2x +Dox induction (0,004 g/ml), CDX2 ChIP-seq peak in locus




CF: GGG CTC TCT GCT TGT CAC CTA CCA GG 
CR: CAC GCC CAT TGA TGT ACT GCC 
AAVS1 locus: 
AF1: GCC CTC TAA CGC TGC CGT CTC 
AR2: TAT AGG CGC CCA CCG TAC ACG CC 
AF2: CACACCTCCCCCTGAACCTGA 
AR2: CGT AAG CAA ACC TTA GAG GTT CTG G 
IDAA analysis 
CDX2 locus : 
CDX2S: AGC TGA CCG GCA GCA AAA TTG GAC GTG AGC ATG TAC CCT AGC TC 
CDX2AS: CTG CGC GCT GTC CAA GTT CGC TG 
AAVS1 locus:  
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The VTI1A-TCF4 colon cancer fusion protein is a 
dominant negative regulator of Wnt signaling and is 
transcriptionally regulated by intestinal 
homeodomain factor CDX2 
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A recurrent fusion of the VTI1A and TCF7L2 genes has been identified in approximately 
3 % of colorectal cancer patients. This study investigates the characteristics of the 
resulting fusion protein, VTI1A-TCF7L2 (in the paper referred to as VTI1A-TCF4), as 
well as the transcriptional regulation of the protein. As wild-type TCF7L2 is crucial in 
stem cell niche maintenance and proliferation in the intestinal crypts, the fusion protein 
with truncated TCF7L2 may play an undesirable role in colon cancer development.  
This study demonstrates that the VTI1A-TCF7L2 fusion protein is most likely a 
dominant negative regulator of Wnt signaling, and results indicate that CDX2 may 
activate transcription of the fusion protein, resulting in the dominant negative regulator 
being expressed throughout the entire axis of the crypt. The results of this study may 
help to uncover one possible pathway in colon cancer development, as well as highlight 
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Katja Dahlgaard1, Eric Paul Bennett5, Jesper Thorvald Troelsen1*
1 Department of Science and Environment, Roskilde University, Roskilde, Denmark, 2 Department of
Surgery, Zealand University Hospital, Roskilde, Denmark, 3 Department of Clinical Immunology, Naestved
Hospital, Naestved, Denmark, 4 Department of Gastroenterology, Herlev Hospital, Herlev, Denmark,




Sequencing of primary colorectal tumors has identified a gene fusion in approximately 3% of
colorectal cancer patients of the VTI1A and TCF7L2 genes, encoding a VTI1A-TCF4 fusion
protein containing a truncated TCF4. As dysregulation of theWnt signaling pathway is asso-
ciated with colorectal cancer development and progression, the functional properties and
transcriptional regulation of the VTI1A-TCF4 fusion protein may also play a role in these pro-
cesses. Functional characteristics of the VTI1A-TCF4 fusion protein in Wnt signaling were
analyzed in NCI-H508 and LS174T colon cancer cell lines. The NCI-H508 cell line, contain-
ing the VTI1A-TCF7L2 fusion gene, showed no active Wnt signaling, and overexpression
of the VTI1A-TCF4 fusion protein in LS174T cells along with aWnt signaling luciferase
reporter plasmid showed inhibition of activity. The transcriptional regulation of the VTI1A-
TCF4 fusion gene was investigated in LS174T cells where the activity of the VTI1A promoter
was compared to that of the TCF7L2 promoter, and the transcription factor CDX2 was ana-
lyzed for gene regulatory activity of the VTI1A promoter through luciferase reporter gene
assay using colon cancer cell lines as a model. Transfection of LS174T cells showed that
the VTI1A promoter is highly active compared to the TCF7L2 promoter, and that CDX2 acti-
vates transcription of VTI1A. These results suggest that the VTI1A-TCF4 fusion protein is a
dominant negative regulator of the Wnt signaling pathway, and that transcription of VTI1A is
activated by CDX2.
Introduction
Colorectal cancer is one of the most commonly diagnosed types of cancer in the western world
and a leading cause of cancer-related death. The mechanisms behind the development of
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sporadic colorectal cancer are, despite considerable research, not fully understood [1,2]. Yet,
disruptions of the canonical Wnt signaling pathway are known to play a major role in cancer
initiation as well as progression and it is estimated that 80–90% of all colorectal cancer tumors
harbor mutant Adenomatous Polyposis Coli (APC), an essential scaffold protein in the Wnt
signaling pathway [1,3,4].
The central signal transducer in the canonical Wnt signaling pathway is β-catenin. In the
absence of Wnt glycoprotein ligands, β-catenin is phosphorylated and subsequently degraded
in proteasomes. The interaction between the GSK3 and CK1α kinases and β-catenin is facili-
tated by the scaffold proteins APC and axin, and combined, the kinases and the scaffold pro-
teins form the degradation complex [5]. Upon binding of secreted Wnt glycoprotein to
transmembrane co-receptors, the canonical Wnt signaling pathway is activated which leads to
accumulation of intracellular β-catenin. β-catenin then enters the nucleus where it associates
with members of the T-cell factor/Lymphoid enhancer-binding factor (TCF/LEF) family of
transcription factors and activates transcription of Wnt target genes by displacing the Groucho
co-repressor bound to TCF/LEF proteins. If APC or other members of the degradation com-
plex have loss-of-function mutations, β-catenin will not be degraded, resulting in a constitu-
tively active Wnt signaling pathway [1,5,6]. The main binding partner of β-catenin in the
colon is TCF4, and studies have shown that TCF4 plays an important part in maintaining the
proliferative cells in the colonic crypts, and that natural downregulation of TCF4 expression in
colonic epithelial cells migrating up the crypt may induce differentiation [6–8].
Dysregulation of members of the TCF/LEF family of transcription factors has been
observed in both colon cancer cell lines, and colon cancer tumors [1,9], and there is indication
that the TCF/LEF family of transcription factors work in distinct and opposing roles to main-
tain the equilibrium between epithelial cell proliferation and terminal differentiation in nor-
mal colonic epithelium. LEF1 is specifically expressed in early stages of B-cell differentiation
but has also been shown to be expressed in colon cancer tumors [3,10,11]. TCF1 expression
is largely restricted to T-lymphocytes in adult tissue but expression has also been detected in
colorectal cancer cell lines [12]. In adult mice with a dominant mutated APC gene, conditional
knockout of TCF4 significantly enhances colon tumor formation, indicating that TCF4 is a
tumor suppressor [3]. However, the expression of TCF4 in colon tumors has been shown to
correlate to lower survival, indicating oncogenic properties of TCF4 [1]. Thus, the role of
TCF4 in colon cancer is not yet fully understood and it may function as both a tumor suppres-
sor and an oncogene [1,3]. With disruptions in the Wnt signaling pathway found in the major-
ity of colon cancer tumors it is nonetheless to be expected that dysregulation of TCF4 has a
part to play in colon cancer initiation and/or progression.
Through genomic sequencing, Bass et al. (2011) has identified a recurrent fusion of the
Vps-ten-interacting-1a (VTI1A) and the T-cell factor 7-like 2 (TCF7L2) genes in 3% of primary
colorectal adenocarcinomas. The fusion fuses the first three exons of the VTI1A gene with the
fourth exon of the neighboring gene, TCF7L2, thereby omitting the first three exons of the
TCF7L2 gene. The VTI1A gene encodes a v-SNARE protein that mediates vesicle transport
from late endosomes to the trans-Golgi network, and the TCF7L2 gene encodes the TCF4
transcription factor. The fusion of the VTI1A and TCF7L2 genes results in a fusion protein,
VTI1A-TCF4, in which the N-terminal β-catenin binding domain of TCF4 is lacking, while it
still contains the DNA binding domain and the transcription repression domain [13].
Nome et al. (2014) has also detected the VTI1A-TCF7L2 fusion transcript in colorectal can-
cer tissue samples showing that the genomic rearrangement is functional. They have further
shown that 42% of colorectal cancers express the fusion transcript and have detected seven dif-
ferent splice variants of the transcript. The fusion transcripts were also detected in 28% of nor-
mal colonic mucosal samples and 5 normal tissue samples from different anatomical sites of
VTI1A-TCF4 colon cancer fusion protein
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the body. The fact that fusions involving TCF7L2 are highly detectable in colorectal cancers,
normal colonic tissue and other normal tissue types, may indicate that these fusions are neither
specific to cancer nor to the colon or rectum [14]. However, the similar fusion transcripts
observed in individual cancer cell lines induced by genomic rearrangements may still have
oncogenic potential. In this study we investigate the transcript generated by the deletion in the
NCI-H508 colon cancer cell line, a cell line harboring the gene fusion [13].
The VTI1A promoter most likely regulates the transcription of the VTI1A-TCF4 fusion
protein. ChIP-seq data indicates that the VTI1A promoter contains binding sites for caudal
type homeobox 2 (CDX2) [15,16], which is expressed in differentiating cells of the colonic
crypts [17,18], and not in the proliferating cells, where TCF4 is expressed [8]. This means that
the VTI1A-TCF4 fusion protein may be expressed throughout the entire colonic crypt and not
only at the base where expression of TCF4 is normally seen. Further, research indicates that
dysregulation of CDX2 in the colon plays a role in the development and progression of colo-
rectal cancer [19–21].
The VTI1A-TCF4 fusion protein has been shown to play a critical role in anchorage-inde-
pendent growth of the colon cancer cell line NCI-H508, indicating that the VTI1A-TCF4 pro-
tein has functional properties [13]. Other members of the TCF/LEF family of transcription
factors naturally occur as truncated isoforms with no β-catenin binding domains, creating pro-
teins with dominant negative properties [22]. The functional properties of the VTI1A-TCF4
fusion protein have not yet been investigated, but research suggests that it might also exhibit
dominant negative properties as it also lacks the β-catenin binding domains [23,24]. The aim
of this study was to determine the functional properties of the VTI1A-TCF4 fusion protein
and to investigate the level of transcriptional activity from the VTI1A-TCF7L2 fusion gene in
colon cancer cells compared to that of wildtype TCF4. Additionally, it aims to explore the role
of CDX2 in regulation of transcription of the VTI1A-TCF7L2 fusion gene.
Materials andmethods
Cloning of VTI1A and TCF7L2 promoter-reporter constructs
The VTI1A promoter region (735 bp, from position -765 to -30, NM_145206) was amplified
from human genomic DNA using the VTI1A-735 primer set and cloned with the In-Fusion
HD cloning system (Clontech, #639649) into theHindIII site of the modified firefly luciferase
reporter pGL4.10 vector, resulting in the pGL4.10-VTI1A-735 construct. Plasmids for deletion
analysis were created using the same reverse primer but different forward primers. The pro-
moter region for TCF7L2 (1405 bp, from position -1545 to -140, NM_030756) was amplified
from human genomic DNA using the TCF7L2-1405 primer set and cloned into the pGL4.10
vector using the Xho1 andHindIII sites, resulting in the pGL4.10-TCF7L2-1405 construct.
The plasmids were sequence verified (Beckman Coulter Genomics). Primer sequences can be
found in S1 Table.
Cloning of VTI1A-TCF4 expression plasmid
NCI-H508 cells were seeded at 500.000 cells per well in a 6-well plate and incubated at 37˚C
and 5% CO2 for 48 hours. The cells were harvested and total RNA was purified with Total
RNA Kit I (Omega Bio-tek, #R5834-02). RNA to cDNA synthesis was performed using First
Strand cDNA Synthesis kit (Thermo Scientific, #K1612) according to manufactures protocol.
The cDNA was amplified with VTI1A-TCF4 sequence specific primers and gel-purified
VTI1A-TCF7L2 sequence was cloned into NheI digested pLVX-CherryPicker2 vector (Clon-
tech, #632581) using the In-Fusion cloning system (Clontech, #639649) resulting in the
VTI1A-TCF4 fusion protein expression plasmid. The plasmid was sequence verified
VTI1A-TCF4 colon cancer fusion protein
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(Beckman Coulter Genomics). Primer sequences can be found in S1 Table. Protein expres-
sion from the VTI1A-TCF4 expression plasmid was verified by Western Blot, see S1 Fig.
LS174T cells were seeded at 600.000 cells per well in a 6-well plate with or without 1.2 μg
VTI1A-TCF4 expression plasmid, according to transfection protocol below, and incubated
at 37˚C and 5% CO2 for 48 hours. The cells were then lysed in ice cold 1XLDS buffer in
RIPA buffer. Each sample was heated to 82˚C for 3 minutes and separated on 4–12% BisTris
SDS PAGE with 1XMOPS SDS running buffer. Proteins were transferred to PVDF mem-
brane 0.45 μm (Invitrolon), and the membrane was incubated with TCF4/TCF7L2 (C48H11)
Rabbit mAb (Cell Signaling) 1:1000 overnight at 4˚C and subsequently incubated for 2 hours
with Pierce 332260 Goat Anti-Rabbit IgG, HRP-linked Antibody 1:5000 followed by detec-
tion by Pierce’s Dura detection reagent.
Cell culture
LS174T, NCI-H508, and Caco-2 cell lines were used in this study. LS174T and Caco-2 cells
were grown in DMEM 4.5 g/L Glucose with UltraGlutamine (Lonza, #BE12-604F-U1) con-
taining 10% heat-inactivated Fetal Bovine Serum and 100 U/ml penicillin and streptomycin.
The NCI-H508 cells were cultured in RMPI 1640 medium with L-Glutamine (Lonza, #BE12-
702F) added 10% Fetal Bovine Serum and 100 U/ml penicillin and streptomycin. All cells were
grown at 37˚C and 5% CO2 in T75 flasks and passaged twice a week. An LS174T cell line with
both CDX2 alleles genetically knocked out, obtained from Pinto et al. (2017), was also used.
These cells were cultured as the wild type LS174T cell line.
Transfection
For transfections, LS174T cells and NCI-H508 cells were seeded at 100.000 cells per well in
24-well plates. Caco-2 cells were seeded at 50.000 cells per well. Cell transfections were done
using 2 μMPolyethyleneimine (Alfa Aesar #43896). Four replicas were made and each trans-
fection was carried out at least twice. The luciferase reporter plasmid pGL4.10-VTI1A was
used for the transfections, and the pCMV-lacZ plasmid was used to determine transfection
efficiency control. The TOPFlash and FOPFlash reporter system was used to determine Wnt
signaling [25]. For co-transfections, plasmids expressing CDX2, or the VTI1A-TCF7L2 fusion
protein were added the transfection. To normalize to a total amount of 0.3 μg DNA per well
pBluescript SK+ plasmid was added. 48 hours after transfection the cells were harvested, and
the luciferase and β-galactosidase activities were analyzed using the Dual Light assay kit (Invi-
trogen, #T1004) on a GloMax 96 Microplate Luminometer with dual injectors (Promega). The
activity for both luciferase and β-galactosidase were measured for 5 seconds, and each lucifer-
ase activity was normalized to β-galactosidase activity. The activity is stated in relative fluores-
cence units (RFU).
Chromatin immunoprecipitation
Confluent LS174T cells were cross-linked by formaldehyde treatment and then sonicated.
Immunoprecipitation with CDX2 and HA was done as described in Coskun et al. 2012 [26].
Verification of immunoprecipitation enrichment was performed with quantitative PCR
(qPCR) using a Stratagene MX3005P (Agilent Technologies) cycler with Quantitect SYBR
Green PCRMastermix (Qiagen, #204141) according to manufactures protocol. The primer set
CDX2 ChIP was used and can be found in S1 Table. Quantification of the ChIP-DNA was
done using the delta-delta method described by Livak and Schmittgen, 2001 [27].
VTI1A-TCF4 colon cancer fusion protein
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Statistical methods
Values are presented as means with standard deviations, and groups were compared using
two-sided Student’s t-test. P-values lower than 0.05 were considered significant.  indicates
p<0.05,  indicates p<0.01,  indicates p<0.001,  indicates p<0.0001.
Results
The VTI1A-TCF4 fusion protein has dominant negative properties
The level of Wnt signaling in LS174T, NCI-H508, and Caco-2 cell lines was investigated using
the TOPFlash/FOPFlash reporter system [25]. The TOPFlash reporter plasmid contains seven
TCF binding sites upstream a luciferase reporter gene that will be transcribed during active
Wnt signaling. The FOPFlash reporter plasmid works as a negative control and contains
mutated TCF binding sites upstream a luciferase reporter gene and can therefore not be acti-
vated by binding of TCF4 during Wnt signaling [25]. Results showed that the transcriptional
activity of the TOPFlash reporter plasmid in LS174T cells was more than 500-fold higher com-
pared to the activity of the FOPFlash reporter plasmid (p<0.0001, Fig 1b). A ~150-fold higher
TOPFlash transcriptional activity was seen in Caco-2 cells compared to FOPFlash activity
(p<0.0001). Both cell lines have loss-of-function mutations in regulators of the Wnt signaling
pathway. The LS174T cell line has mutated β-catenin, making CK1α unable to bind [28], and
the Caco-2 cell line is APC mutated [29]. These mutations result in constitutively active Wnt
signaling, supporting the high level of TOPFlash activation. When transfecting NCI-H508
cells, that carry the VTI1A-TCF7L2gene fusion (Fig 1a) [13], with the TOPFlash reporter plas-
mid, the luciferase activity was not observed to be significantly higher than that of the FOP-
Flash reporter plasmid (Fig 1b). These results suggest that either the NCI-H508 cell line does
not have active Wnt signaling, or the VTI1A-TCF4 fusion protein in the NCI-H508 cells is not
able to activate transcription from the TCF binding sites.
To determine whether the absence of TOPFlash activation in NCI-H508 cell was a result
of the properties of the VTI1A-TCF4 fusion protein, LS174T cells were co-transfected with a
plasmid expressing the VTI1A-TCF4 fusion protein and the TOPFlash plasmid. A 3-fold
decrease in luciferase activity was observed when co-transfecting with VTI1A-TCF4 fusion
protein expression plasmid (p<0.0001, Fig 1c). This shows that the presence of the VTI1A-
TCF4 fusion protein in the LS174T cells, which has two functional TCF7L2 alleles, has the
ability to significantly reduce the strong Wnt signaling in LS174T cells, and indicates that the
VTI1A-TCF4 fusion protein has dominant negative properties.
The VTI1A promoter is highly active compared to the TCF7L2 promoter in
LS174T cells
In order to investigate promoter activity of VTI1A and TCF7L2, reporter plasmid constructs
containing the VTI1A promoter (pGL4.10-VTI1A-735) and the TCF7L2 promoter (pGL4.10-
TCF7L2-1405) were generated. These two constructs (Fig 2a) were transfected into the
LS174T cell line. The luciferase activity of pGL4.10-VTI1A-735 was significantly higher,
~170-fold, compared with the activity of the pGL4.10 empty vector (p<0.0001) showing that
the promoter is transcriptionally active in LS174T cells (Fig 2b). The activity of pGL4.10-
TCF7L2-1405 was likewise significantly higher than pGL4.10 with a>40-fold increase in lucif-
erase activity (p<0.0001). The luciferase activity of the construct containing the VTI1A pro-
moter, pGL4.10-VTI1A-735, was significantly higher (p<0.0001) than the TCF7L2 promoter
construct. This shows that the promoter region for the VTI1A-TCF7L2 fusion gene, encoding
the VTI1A-TCF4 fusion protein, is much more transcriptionally active than the promoter for
VTI1A-TCF4 colon cancer fusion protein
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TCF7L2 in the LS174T cell line. This will most likely result in altered expression of VTI1A-
TCF4 compared to TCF7L2 in vivo.
The transcriptional activity of the VTI1A promoter is regulated by CDX2
in cultured LS174T cells
Genome-wide CDX2 ChIP-seq data from LS174T cells [30], shows a CDX2 ChIP-seq peak in
the VTI1A promoter region, and the JASPAR CORE database identifies two potential CDX2
binding sites within this peak [31]. To investigate the relevance of CDX2’s role in the transcrip-
tional regulation of the VTI1A promoter region, a CDX2 expression plasmid and the pGL4.10-
VTI1A-735 reporter plasmid were co-transfected into LS174T cells. Overexpression of CDX2
results in a 2-fold increase (p<0.0001) in transcriptional activity of pGL4.10-VTI1A-735 (Fig
3a). These results indicate that CDX2 has an up-regulatory effect on the transcriptional activity
of the VTI1A promoter. Further indication of CDX2 regulation on the transcriptional activity
of the VTI1A promoter was established in a LS174T CDX2 knockout cell line from Pinto et al.
Fig 1. Wnt signaling in colon cancer cell lines. aWildtype TCF4 contains a β-catenin binding domain, a transcription repression domain, a DNA
binding domain, and a nuclear localization signal. With the fusion with VTI1A the resulting fusion protein, VTI1A-TCF4, contains the first three exons
of VTI1A and lacks the β-catenin binding domain of TCF4. The rest of the TCF4 domains are still present. b The cells lines LS174T, Caco-2 and
NCI-H508 were transfected with the TOPFlash and FOPFlash reporter plasmids, and luciferase activity was measured. Activity is stated in mean values
relative to FOPFlash activity for each cell line and corrected with β-galactosidase activity. Error bars indicate SD,  indicates p<0.0001, n = 4 c The
LS174T cell line, showing highWnt activity, was transfected with the TOPFlash and co-transfected with a plasmid expressing the VTI1A-TCF4 fusion
protein. Activity is stated in mean values relative to TOPFlash activity and corrected with β-galactosidase activity. Error bars indicate SD,  indicates
p<0.0001, n = 8.
https://doi.org/10.1371/journal.pone.0200215.g001
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(2017). When transfecting the cells with the pGL4.10-VTI1A-735 reporter plasmid, the lucifer-
ase activity in the CDX2 knockout cells decreased by 50% compared to the activity of the plas-
mid in the LS174T wildtype cells (Fig 3b).
To further elaborate on CDX2’s role in the transcriptional regulation of the VTI1A pro-
moter region, and thereby the expressional regulation of the VTI1A-TCF4 fusion protein,
Fig 2. Transcriptional activity of the VTI1A and TCF7L2 promoters. a The pGL4.10-VTI1A-735 and
pGL4.10-TCF7L2-1405 plasmids were created by inserting the promoter regions of VTI1A and TCF7L2, respectively,
upstream the luciferase gene in the pGL4.10 plasmid. b LS174T cells were transfected with either the pGL4.10-VTI1A-
375 or the pGL4.10-TCF7L2-1405 reporter plasmids. Activity is stated in mean values relative to pGL4.10 activity and
corrected with β-galactosidase activity. Error bars indicate SD,  indicates p<0.0001, n = 8.
https://doi.org/10.1371/journal.pone.0200215.g002
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CDX2 ChIP assay on LS174T cells was performed, where chromatin-protein complexes were
immunoprecipitated with CDX2-specific antibody or HA antibody, used as a negative control.
The region investigated was determined from the CDX2 peak in the ChIP-seq data from Pinto
et al. 2017, and can be seen on Fig 4a. The amount of CDX2 immunoprecipitated DNA was
measured by qPCR using VTI1A promoter-specific primers flanking the potential binding
region. The DNA was fragmented to a size of 300–400 bp in the ChIP assay. Thus, sequences
flanking the CDX2 binding sites will also be precipitated. A good primer set for amplification
of sequences nearby the ChIP-seq peak was chosen. Results show a significant enrichment of
CDX2 ChIP DNA compared to the negative HA antibody control (p<0.01, Fig 4b). These
results indicate that the CDX2 ChIP-seq peak in the VTI1A promoter contains CDX2 binding
sites.
The validity of the identified CDX2 binding site as well as the two potential binding sites
found using the JASPAR CORE database [31] was investigated through a deletion analysis
using different lengths of the VTI1A promoter region cloned into the pGL4.10 plasmid (Fig
4c). The results of the deletion analysis show a 1.4-fold higher luciferase activity of the
pGL4.10-VTI1A-532 plasmid compared to the activity of the pGL4.10-VTI1A-735 plasmid
(Fig 4c). This increase in activity might be a result of inhibitory regions in the pGL4.10-
VTI1A-735 plasmid. The luciferase activity of the pGL4.10-VTI1A-356 plasmid is 3.5-fold
lower compared to the activity of the pGL4.10-VTI1A-532 plasmid, possibly an effect of this
Fig 3. Transcriptional activity of CDX2. a LS174T cells were transfected with the pGL4.10-VTI1A plasmid-735 and co-transfected with a CDX2 expression
plasmid. Activity is stated in mean values relative to pGL4.10 activity and corrected with β-galactosidase activity. Error bars indicate SD,  indicates
p<0.0001, n = 4. b The LS174T wild type cell line and a LS174T CDX2 knockout cell line was transfected with the pGL4.10-VTI1A plasmid. Activity is stated
in mean values relative to pGL4.10 activity and corrected with β-galactosidase activity. Error bars indicate SD,  indicates p<0.0001, n = 4.
https://doi.org/10.1371/journal.pone.0200215.g003
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plasmid not containing the CDX2 regulatory region found previously. When comparing the
luciferase activity of the pGL4.10-VTI1A-356 with that of the pGL4.10-VTI1A-181 plasmid a
5.7-fold decrease in activity and an almost complete abrogation of luciferase activity can be
seen, indicating that fragment of VTI1A promoter omitted in the pGL4.10-VTI1A-181 plasmid
is essential for the regulatory effect of CDX2 on the promoter. Furthermore, the CDX2 binding
sites identified by the JASPER database are located in this fragment of the promoter region.
Discussion
Some members of the TCF/LEF family of transcription factors naturally occur as N-terminally
truncated isoforms lacking the β-catenin binding site [22]. The nuclear localization signal, the
DNA binding domain, and the transcription repression domain are still present in the trun-
cated forms. This means that truncated isoforms of TCF/LEF are able to localize to the nucleus,
bind to DNA binding sites, and recruit the Groucho co-repressor to the transcription repres-
sion domain. As the β-catenin binding site is not present in these truncated variants of TCF/
LEF, β-catenin is unable to displace Groucho, resulting in repression of transcription [9,32].
Studies by Goncalves et al. and Van der Wetering et al. shows that constructs of truncated
TCF4, that lack the N-terminal containing the β-catenin binding site, functions as dominant
negative regulators of endogenous β-catenin/TCF complexes [23,24]. Our results show that
the VTI1A-TCF4 fusion protein, which also lacks the N-terminal domain with β-catenin
Fig 4. CDX2 regulation of VTI1A transcriptional activity. a LS174T CDX2 ChIP-seq data was used to identify a CDX2 peak in the VTI1A promoter
region [30], and the JASPAR CORE database identifies two potential binding sites within this region [31]. b qPCR was performed on CDX2
immunoprecipitated DNA from LS174T cells with primers amplifying the 100 bp region seen in fig 4A. Error bars indicates SD,  indicates p<0.01,
n = 4 c Plasmids for deletion analysis with different lengths of the VTI1A promoter inserted in the pGl4.10 plasmid. The two possible CDX2 binding
sites are marked. The deletion analysis was carried out in LS174T cells and the luciferase activity is stated in mean values relative to the
pGL4.10-VTI1A-735 plasmid and is corrected with β-galactosidase activity. Error bars indicate SD,  indicates p<0.05,  indicates p<0.001, 
indicates p<0.0001, n = 4.
https://doi.org/10.1371/journal.pone.0200215.g004
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binding domain, while it contains the nuclear localization signal, the DNA binding domain,
and the transcription repression domain (Fig 1a), has dominant negative effects onWNT
signaling.
Bass et al. (2011) did not investigate the regulatory properties of the VTI1A-TCF4 fusion
protein, however they propose that it does not act as a full dominant negative protein as engi-
neered dominant-negative TCF4 alleles have been shown to strongly inhibit proliferation of
colorectal carcinoma cell lines [24]. Furthermore, Bass et al. (2011) demonstrated that the
VTI1A-TCF4 protein has a critical role in anchorage-independent growth of VTI1A-TCF4
fusion protein positive NCI-H508 cells, which would not have been expected if the VTI1A-
TCF4 fusion protein is fully dominant negative [13]. In the study by Van der Wetering et al.
(2002), doxycycline inducible plasmids expressing N-terminally truncated TCF4 were trans-
fected into LS174T cells, and upon doxycycline induction the activity of TOPFlash was
completely abrogated and the proliferation of the cells was inhibited [24]. However, when
expressing the VTI1A-TCF4 fusion protein in LS174T cells, a complete abrogation of TOP-
Flash activity was not seen. This indicates that the fusion protein might exhibit different
functional effects than that of a constructed truncated TCF4 protein and might therefore still
allow for cell proliferation. Furthermore, the VTI1A-TCF4 fusion protein contains domains
encoded by the VTI1A gene, which might add other functionalities to the VTI1A-TCF4 fusion
protein.
Our results show that the VTI1A promoter region is significantly more active in LS174T
cells than the promoter region for TCF7L2. This could mean increased expression of the
VTI1A-TCF4 fusion protein in the proliferating cells of colonic crypts, where TCF4 is nor-
mally present [8]. The VTI1A promoter region was also shown to be regulated by CDX2 which
is highly expressed in the upper two-thirds of the crypts [17,33]. Our results suggest that the
VTI1A-TCF4 fusion protein will be expressed in the upper two-thirds of the crypts as well as
at the base of the crypts. Studies have shown that TCF4 plays an important part in maintaining
the proliferative cells in the colonic crypts, and that natural down-regulation of TCF4 expres-
sion as cells move up the colonic crypts may trigger colonic epithelial cell differentiation [6–8].
Tcf7l knockout mice die within 24 hours after birth and show no proliferating crypt stem cell
compartments, supporting the idea that TCF4 plays an essential role in maintaining the prolif-
erative compartment in the crypt [34].
The main binding partner of β-catenin in the colon is TCF4, but colon tumors isolated
from APCmutated mice have an increased expression of LEF1 and TCF1 [3]. During active
Wnt signaling, β-catenin will accumulate in the cell nucleus and with no binding site in
the VTI1A-TCF4 fusion protein, β-catenin might bind and activate other members of the
TCF/LEF family of transcription factors, such as TCF1 and LEF1. As the TCF/LEF family
of transcription factors are indicated to work in distinct and opposing ways to regulate
and maintain the equilibrium in cell proliferation and differentiation [1,9], a shift in this
balance may contribute to the development or progression of colorectal cancer. A proposed
model for the expression pattern of transcription factors in the mutated crypts can be seen
in Fig 5.
In conclusion, we have determined that the VTI1A-TCF4 fusion protein transcribed from
VTI1A-TCF7L2 gene fusion has dominant negative properties and the transcription of this
protein is activated by CDX2 in cultures LS174T cells. The role of the VTI1A-TCF4 fusion pro-
tein in colorectal cancer still needs to be investigated. However, as dysregulation of the Wnt
signaling pathway plays an important role in the development of colorectal cancer the shift
from wild type TCF4, that can function as a transcriptional activator, to the dominant negative
VTI1A-TCF4 in mutated colonic cells will most likely have an effect on colon homeostasis and
may perhaps contribute to the development of colorectal cancer.
VTI1A-TCF4 colon cancer fusion protein
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Supporting information
S1 Fig. Protein expression of VTI1A-TCF4. LS174T cells were transfected with the VTI1A-
TCF4 expression plasmid and after 48 hours protein was extracted and used for Western Blot.
The blot was incubated with TCF4 antibody. In cells transfected with the VTI1A-TCF4 expres-
sion plasmid a clear band can be seen at approx. 43 kDa, corresponding to the length of the
VTI1A-TCF4 fusion protein. In the cells not transfected with the VTI1A-TCF4 expression
plasmid, this band cannot be seen. For both samples the wild type TCF4 protein is seen at
approx. 75 and 55 kDa.
(PDF)
S1 Table. Primers. List of primers used in the study.
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S1 Fig. Protein expression of VTI1A-TCF4. LS174T cells were transfected with the 
VTI1ATCF4 expression plasmid and after 48 hours protein was extracted and used for 
Western Blot. The blot was incubated with TCF4 antibody. In cells transfected with the 
VTI1A-TCF4 expression plasmid a clear band can be seen at approx. 43 kDa, 
corresponding to the length of the VTI1A-TCF4 fusion protein. In the cells not transfected 
with the VTI1A-TCF4 expression plasmid, this band cannot be seen. For both samples the 


















CDX2 expression and perioperative patient serum 
affects the adhesion properties of cultured colon 
cancer cells 
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Surgery of patients with colon cancer induces a stress response that may be related to a 
higher risk of disease recurrence. In this study, we used a real-time, cell-based method 
to examine the effects of patient serum from before and 24 hours after colon cancer 
surgery on the adhesion abilities of cultured colon cancer cells. We also investigated the 
role of CDX2 on the adhesion abilities of colon cancer cells both pre- and 
postoperatively.    
This study demonstrates a significant increase in adhesion abilities of cells in 
postoperative serum compared to preoperative serum, and further, that this increased 
adhesion postoperatively was dependent on CDX2 expression. These results may aid in 
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Abstract
Background: Colon cancer is one of the most commonly diagnosed types of cancer with surgical resection of the
tumor being the primary choice of treatment. However, the surgical stress response induced during treatment may
be related to a higher risk of recurrence. The aim of this study was to examine the effect of surgery on adhesion of
cultured colon cancer cells with or without expression of the tumour suppressor CDX2.
Method: We enrolled 30 patients undergoing elective, curatively intended laparoscopic surgery for colon cancer in
this study. Blood samples were drawn 1 day prior to surgery and 24 h after surgery. The samples of pre- and
postoperative serum was applied to wild type colon cancer LS174T cells and CDX2 inducible LS174T cells and
adhesion was measured with Real-Time Cell-Analysis iCELLigence using electrical impedance as a readout to
monitor changes in the cellular adhesion.
Results: Adhesion abilities of wild type LS174T cells seeded in postoperative serum was significantly increased
compared to cells seeded in preoperative serum. When seeding the CDX2 inducible LS174T cells without CDX2
expression in pre- and postoperative serum, no significant difference in adhesion was found. However, when
inducing CDX2 expression in these cells, the adhesion abilities in pre- and postoperative serum resembled those of
the LS174T wild type cell line.
Conclusions: We found that the adhesion of colon cancer cells was significantly increased in postoperative versus
preoperative serum, and that CDX2 expression affected the adhesive ability of cancer cells. The results of this study
may help to elucidate the pro-metastatic mechanisms in the perioperative phase and the role of CDX2 in colon
cancer metastasis.
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Background
Colon cancer is the third most commonly diagnosed
cancer and the second most leading cause of cancer-
related death, accounting for approximately 1 in 10 can-
cer cases and deaths [1]. Surgical resection of the
tumour is the primary choice of treatment but, despite
medical and surgical advances, the risk of recurrence in
colonic cancer is up to 30% after curative resection [2].
Manipulation of the tumour during surgery results in an
increase in the number of circulating tumour cells [3],
and the operation can lead to a surgical stress response
(SSR) resulting in reduced anti-tumoral defence [4], as
well as an increase in factors favouring an oncogenic en-
vironment [5]. Excessive stimulation of cytokine produc-
tion during the SSR is associated with the risk of
postoperative metastasis [6], and pro-inflammatory cyto-
kines, such as IL-1 and TNF-α have been shown to
stimulate adhesion in circulating cancer cells [2].
Alternations in cell adhesion is believed to be critical
in cancer metastasis [5]. For tumour cells to disengage
from the primary tumour, adhesion is downregulated
through modification of the cadherin-catenin complex
[7, 8]. Further, the integrity of tight junctions that main-
tain cell polarity in normal epithelia is diminished by
downregulation of claudins [9]. Attachment of meta-
static cancer cells to distant tissues is mediated through
expression of selectins [10], integrins [11] and members
of the immunoglobulin superfamily [12]. Surgical trauma
provokes an inflammatory reaction which results in re-
lease of cytokines that are shown to increase adhesion of
colon carcinoma cells to metastatic sites [13, 14]. This
effect of cytokines on the cell adhesion molecules
expressed on cancer cells may contribute to the develop-
ment of metastasis [15].
The transcription factor Caudal type Homeobox 2
(CDX2) is crucial for the homeostasis of the colonic epi-
thelium [16], and has been shown to be at tumour sup-
pressor [17–20]. Lack of CDX2 expression in colon
cancer cells is associated with aggressive clinical behav-
iour and can be used as an adverse prognostic biomarker
[21–25]. CDX2 has been reported to be downregulated
in colon cancer cells in the invasive front of the tumour
[16, 26]. The downregulation of CDX2, and thereby loss
of intestinal identity, has been suggested to be a precur-
sor for metastatic colon cancer to perform epithelial-to-
mesenchyme transition (EMT) [16, 26, 27]. As the circu-
lating colon cancer cells establish metastasis they
undergo mesenchyme-to-epithelia transition (MET) and
CDX2 expression is re-established, allowing for it to be
used as a marker to determine the primary tumours
colonic origin [26]. Overexpression of CDX2 in colon
cancer cell lines has shown decreased mobility and
dissemination of cancer cells, further implicating fluc-
tuation of CDX2 expression in the metastatic process
[28]. Alterations in CDX2 expression is based on
mechanisms such as inflammation and epigenetic
regulation, rather than mutations [21, 29].
Through a cell-based assay, measuring cancer cell ad-
hesion in a colon cancer cell culture treated with serum
obtained from patients before and after colon cancer
surgery, we aimed to examine whether laparoscopic
colon cancer surgery affects the adhesion of cancer cells




From January to July 2016, consecutive patients under-
going elective, curatively intended laparoscopic surgery
for colon cancer, stage I-III according to Union for
International Cancer Control (UICC), at Zealand Uni-
versity Hospital were enrolled in this study. Patients re-
ceiving neoadjuvant radio- or chemotherapy, with
known immune defects, or previous cancer history, were
excluded. All eligible patients received information re-
garding purpose and methods of the study and were in-
cluded after giving oral and written consent. The study
was conducted in accordance with the Declaration of
Helsinki, and the protocol was approved by The Danish
National Committee on Health Research Ethics, Region
Zealand (file no: 2008-58-0020) and approved by the Da-
nish Data Protection agency (protocol: SJ567).
Setting
During the perioperative period, patients followed the
standard of care for colon cancer in a setting of En-
hanced Recovery After Surgery (ERAS), which has been
described in detail for the department elsewhere [30].
There were no restrictions on pain management, and all
patients were encouraged to take their regular medica-
tion after surgery. The choice of anesthetics was deter-
mined at a pre-anesthesia interview, and patients
received universal anesthesia with either Total Intraven-
ous Anesthesia or volatile inhalational. For induction of
anesthesia, propofol 2–3mg/kg and remifentanil or
sufentanil were administered. Hereafter, all patients re-
ceived a single intravenous dose of 240 mg gentamycin
and 1 g metronidazole. Patients assigned to Total Intra-
venous Anesthesia received a continuous infusion of
propofol supplemented remifentanil 0.5 μg/kg/min. Pa-
tients assigned to volatile inhalation received sevoflurane
to a minimum alveolar concentration of 0.7–1.2 and
remifentanil or repeated boli of sufentanil. Prior to extu-
bation, ondansetrone 4 mg, sufentanil 0.4–0.6 μg/kg, and
1 g of paracetamol was given. Ropivacaine, 20 mL, was
administered locally in the wounds.
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Data collection and processing
Demographic data was collected through the electronic
patient charts including age, gender, smoking status,
body mass index (BMI), American Society of
Anesthesiologist (ASA) scores, and Charlson Comorbid-
ity Index. The UICC stage was based on pre-operative
CT scans and histology results. Blood samples were
taken the day prior to surgery, and approximately 24 h
after surgery. Samples were collected in serum separ-
ation gel-tubes and left undisturbed at room temperature
for 30min to allow clotting. Hereafter, samples were cen-
trifuged at 2330 g at 4o C for 10min to remove the clot.
The resulting supernatant was immediately transferred
into Eppendorf tubes and kept at -80 °C until analysis.
Cell culture
The wild type human colon cancer cell lines Caco-2,
DLD-1, SW480, LoVo, LS174T and a CDX2 inducible
LS174T cell line were used in this study. The CDX2 in-
ducible LS174T cell line is genetically modified and are
CDX2 knockout but contain inducible elements that en-
able activation of CDX2 expression by addition of doxy-
cycline to the growth media [31]. LS174T cell lines were
obtained from Assoc. Prof. Eric Paul Bennett. All cell
lines were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) with Ultraglutamine with 4.5 g/L Glu-
cose (Lonza, Basel, Switzerland) supplemented with 10%
Fetal Bovine Serum (HyClone by Fisher Scientific, Wal-
tham, MA, USA) and Penicillin (100 units/mL) Strepto-
mycin (100 μg/mL) (Gibco by Life Technologies, Carlsbad,
CA, USA) The cell cultures were incubated at 37 °C in 5%
CO2 and passaged every 3–4 days. The LS174T cells with
inducible CDX2 were cultured in media with or without
4 ng/ml doxycycline to induce CDX2 expression.
Adhesion measurement
Real-Time Cell-Analysis (RTCA) iCELLigence (ACEA
Biosciences, San Diego, CA, USA) was used to measure
cell adhesion. The RTCA iCELLigence instrument uses
electrical impedance as a readout to monitor changes in
the cellular phenotype. The cell culture plates used in
the instrument have electrodes placed at the bottom of
each well, and cells attaching to the electrodes will lead
to an increase in electrical impedance. The relative
change in the electrical impedance is recorded as a di-
mensionless value termed Cell Index. The RTCA iCEL-
Ligence was set up using E-Plate L8 PET (ACEA
Biosciences, San Diego, CA, USA) and cells in DMEM
containing either 7% pre- or postoperative serum were
added to each well in quadruplicates. For the LS174T
cell line, 2*104 cells were seeded in each well. For the
Caco-2 cell line, 5*103 cells were seeded in each well,
while for the DLD-1, SW480, and LoVo, 1*104 cells were
seeded in each well. For LS174T cell with inducible
CDX2, 2*104 cells with or without 4 ng/ml doxycycline
induced CDX2 expression were seeded in replicates in
the E-plate L8 PET. The impedance was measured every
5 min and the difference in Cell Index at 60 min between
cells seeded in preoperative and postoperative serum
was calculated.
Western blot
Cells for protein extraction were seeded in 6-well plates
at 5*105 cells/well. After 24 h media was changed and
LS174T cells with inducible CDX2 were added media
with or without doxycycline. Cells were lysed after 72 h
of doxycycline treatment by rising with cold PBS and in-
cubated 5 min with 150 μl/well 1x RIPA lysis buffer (1x
PBS, 300 mM NaCl, 1% Tergitol NP-40, 0.1% SDS, 0.5%
7-Deoxycholic acid sodium salt, 0.5 μM EDTA pH 8.0)
with freshly added 1mM DTT and 2 μl/ml protease in-
hibitor mix p8340 (Sigma-Aldrich, St. Louis, MO, USA).
Lysate was centrifuged for 15 min at 12.000 g and 4 °C.
Supernatant was stored at − 20 °C. Protein concentration
was determined by Bradford analysis (Bio-Rad, Hercules,
CA, USA).
For the analysis, 10 μg protein was mixed 1:4 (v/v)
with Bolt loading buffer and 1:10 (v/v) with Bolt sample
reducing agent (Thermo Fisher Scientific, Waltham,
MA, USA). Samples were incubated at 95 °C for 5 min
and loaded on a Bolt 4–12% Bis-Tris Plus gel (Thermo
Fisher Scientific, Waltham, MA, USA) PageRuler pre-
stained protein ladder was used as marker (Thermo
Fisher Scientific, Waltham, MA, USA). SDS-PAGE was
performed in 1X Bolt MOPS running buffer (Thermo
Fisher Scientific, Waltham, MA, USA) for 30 min at 25
V, then 60 min at 120 V. The gel was transferred by wet-
electrotransfer to PVDF membrane for 60 min at 25 V in
1X NuPage transfer buffer (Thermo Fisher Scientific,
Waltham, MA, USA). The membrane was blocked with
dry skim milk diluted to 5% in Wash buffer (1X TBS
with 0.1% Tween-20) for 1 h at room temperature. The
membrane was washed with Wash buffer 5 times for 3
min and incubated overnight at 4 °C with primary anti-
body diluted in 2.5% skim milk in Wash buffer. The
membrane was then washed 5 times for 3 min and incu-
bated with diluted secondary antibody for 1 h at room
temperature. Before visualization, the membrane was
washed 5 times for 3 min and then visualized by
incubating with the ECL solution SuperSignal West
Dura Extended Duration Substrate for 5 min (Thermo
Fisher Scientific, Waltham, MA, USA). Antibodies used:
CDX2 1:1000 (BioGenex, Freemont, CA, USA,
MU392A-UC); Vinculin 1:5000 (Abcam, Cambridge,
UK, ab129002); Goat anti-rabbit HRP 1:10,000 (Thermo
Fisher Scientific, Waltham, MA, USA, 32260); Goat
anti-mouse HRP 1:10,000 (Thermo Fisher Scientific,
Waltham, MA, USA, 32230).
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Statistical analysis
The paired Wilcoxon signed-rank test was used to deter-
mine statistical differences in the adhesion of cells with
pre- and postoperative serum and the level of statistical
significance was set at p-values < 0.01. The RTCA iCEL-
Ligence data analysis software 1.0 and Graphpad Prism
8 software were used for statistical analysis.
Results
In total, 38 patients were enrolled in the study. Seven
patients were excluded due to post-operative complica-
tions and one patient was excluded due to benign dis-
ease. A total of 30 patients, 19 male and 11 female, went
through laparoscopic colon cancer surgery within an
ERAS setting and were included in the study (see Table 1
for patient demographics). According to UICC staging
[32], patients were diagnosed with stage I-III cancer.
The patients had an ASA score [33] ranging from I to
III and had between 0 and 2 in WHO Performance Sta-
tus [34]. None of the patients had visible metastasis pre-
operatively. Serum from blood samples drawn on the
day prior to surgery and the day after surgery was used
for the analysis of adhesion.
Culturing five different colon cancer cell lines,
LS174T, Caco-2, DLD-1, SW480, and LoVo, in media
supplemented with perioperative serum from a single
patient, showed increased adhesion abilities in cells
seeded in postoperative serum compared to preoperative
serum for all cell lines (Fig. 1a). The difference in Cell
Index in percentage at 60 min varied from 3.5% in the
LS174T cell line to 8.0% in the LoVo cell line (Fig. 1b).
While all the cell lines showed varied extent of increase
in adhesion in postoperative serum, we chose the
LS174T cell line for testing our entire patient cohort
consisting of 30 patients. This cell line was chosen as a
genetically modified clone has been produced, which
contains inducible elements that control the expression
of CDX2 [31]. As a result, the cells do not express
CDX2 without being induced. To our knowledge, this is
the only colon cancer cell line still viable with complete
depletion of CDX2 expression. In other CDX2 positive
colon cancer cell lines, CDX2 acts as a linage survival
gene that cannot be inactivated [35].
When investigating our cohort of 30 patients a signifi-
cant difference in cell adhesion, with increased adhesion
in wild type LS174T cells seeded in postoperative serum
compared to preoperative serum was observed. A differ-
ence between the pre- and postoperative samples could
be observed 20min after seeding, and at 60 min the cells
had adhered to the surface and no further increase in
adhesion could be observed. The Cell Indexes at 60 min
were for 26 out of 30 patients higher in the postopera-
tive sample compared to the preoperative sample (p <
0.0001) (Fig. 2a). Cell Indexes were slightly lower for
three patients in the postoperative serum (Fig. 2b). The
sera from one patient gave the same Cell Index before
and after surgery.
To investigate the role of CDX2 in cell adhesion, the
colon cancer cell line LS174T with inducible CDX2 was
used. This cell line has previously been used to study the
effect of CDX2 on intestinal transcriptional regulation
[36–38]. Western blotting analysis of the LS174T wild
type and LS174T with inducible CDX2 cells was per-
formed to detect CDX2 levels. Results show no CDX2
expression in the LS174T with inducible CDX2 when
not treated with doxycycline (Fig. 3a). When treated
Table 1 Demographics for patients undergoing laparoscopic
colonic resection for colon cancer
Age, mean (SD) 67,6 (8,8)
Gender n (%) Male 19 (63,3)
Female 11 (36,7)
ASA-score n (%) 1 3 (10,0)
2 24 (80,0)
3 3 (10,0)
BMI n (%) < 18,5 1 (3,3)
18.5–24.9 12 (40,0)
25–29.9 8 (26,7)
> 30 9 (30,0)
Smoking n (%) Current smoker 5 (16,7)
Former smoker 13 (43,3)
Never smoker 12 (40,0)
Alcohol (drinks/week) n (%) 0–14/21 25 (83,3)
> 14/21 5 (16,7)




WHO Performance status n (%) 0 25 (83,3)
1 3 (10,0)
2 2 (6,7)
UICC n (%) 1 10 (33,3)
2 12 (40,0)
3 8 (26,7)
Anesthesia n (%) Intravenous 20 (66,7)
Inhalation 10 (33,3)
Laparoscopic procedure n (%) Right hemicolectomy 9 (30,0)
Transverse colectomy 1 (3,3)
Left hemicolectomy 1 (3,3)
Sigmoidectomy 18 (60,0)
Complete colectomy 1 (3,3)
ASA American Society of Anesthesiologist Score, BMI Body Mass Index, UICC
Union for International Cancer Control
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with doxycycline, expression of CDX2 was re-
established. Vinculin was used as a control to measure
total protein loaded. When seeding CDX2 negative
LS174T cells in pre- and postoperative patient serum
no difference in adhesion between the two groups was
seen (p = 0.21) (Fig. 3b). Out of the 30 patient samples,
only 11 had increased adhesion for cells seeded in
postoperative serum compared to preoperative serum
(Fig. 3c). However, when the cells had induced CDX2
at wild type levels, the results resembled those seen in
the wild type LS174T cells, with significantly increased
adhesion in postoperative serum compared to pre-
operative serum (p < 0.0001) (Fig. 3d). Twenty-six pa-
tients out of 30 showed increased adhesion for cells
seeded in postoperative serum compared to preopera-
tive serum (Fig. 3e).
Fig. 1 Adhesion measurements of five different colon cancer cell lines in pre- or postoperative patient serum a. Cell adhesion of LS174T, Caco-2,
DLD-1, SW480, and LoVo cells seeded in media with pre- or postoperative serum from one patient was measured. Mean Cell Index at 60 min is
shown, n = 4. b. The difference in percentage between adhesion ability of cells seeded in postoperative serum compared to preoperative serum
at 60min was calculated for each cell line. The positive bars (grey) indicate higher adhesion in cells in postoperative serum compared to cells in
preoperative serum
Fig. 2 Adhesion measurements in wild type LS174T cells a. The Cell Index for wild type LS174T cells seeded in pre- and postoperative serum was
measured for each patient. Mean results at 60 min for pre- and postoperative cell adhesion for each patient is shown. ****p < 0.0001. b. The
difference in percentage in adhesion at 60 min was calculated for each patient. The positive bars (black) indicate patients with higher adhesion in
cells in postoperative compared to preoperative serum, while the negative bars (grey) indicate patients with higher adhesion in cells in
preoperative compared to postoperative serum
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When comparing cell adhesion in cells treated with
preoperative serum samples, there was a significant in-
crease in adhesion in the CDX2 negative cells compared
to the CDX2 positive cells (p < 0.001) (Fig. 4a). For the
cells treated with postoperative serum, the CDX2 posi-
tive cells had significantly increased adhesion compared
to the CDX2 negative cells (p < 0.001) (Fig. 4b).
Discussion
In this study, we established an in vitro method for
measuring the effect of perioperative factors on the
adhesion ability of the LS174T colon cancer cell line
using serum from patients undergoing colon cancer sur-
gery. Commonly used methods for cell adhesion assays
typically include staining attached cells and using fluor-
escence for endpoint measurements [39–41], but by
using the method developed in this paper, it is possible
to monitor real-time cell adhesion for the entire adhe-
sion period. While this method does not allow us to dis-
tinguish between initial sedimentation, cell attachment,
cell spreading and stable cell adhesion, the mentioned
are all part of the passive cell adhesion process [42].
Fig. 3 Adhesion measurements in CDX2 inducible LS174T cells a. CDX2 protein expression was compared using western blotting. Cell lysate
from LS174T wild type cells and LS174T cells with inducible CDX2 with or without doxycycline treatment was used in the analysis. Vinculin was
used as a control. Bands are from the same gel b. The Cell Index for CDX2 negative LS174T cells seeded in pre- and postoperative serum was
measured. Mean results at 60 min for pre- and postoperative cell adhesion for each patient is shown. n.s. = not significant. c. The difference in
percentage in adhesion at 60 min was calculated for each patient. The positive bars (black) indicate patients with higher adhesion in
postoperative compared to preoperative serum, while the negative bars (grey) indicate patients with higher adhesion in preoperative compared
to postoperative serum. d. The Cell Index for CDX2 positive LS174T cells seeded in pre- and postoperative serum was measured. Mean results at
60 min for pre- and postoperative cell adhesion for each patient is shown. ****p < 0.0001. e. The difference in percentage in adhesion at 60min
was calculated for each patient. The positive bars (black) indicate patients with higher adhesion in postoperative compared to preoperative
serum, while the negative bars (grey) indicate patients with higher adhesion in preoperative compared to postoperative serum
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Investigating the adhesion abilities of the cells on a sur-
face that more resembles the in vivo biological surface
cancer cells interact with during metastasis may provide
further insight to the adhesion process examined in this
study.
Our study identified significantly increased cell adhe-
sion abilities in five different colon cancer cell lines in
postoperative serum, and further investigation using
genetically modified LS174T cells showed this increase
in adhesion to be eliminated by lack of CDX2 expres-
sion. This indicates that the absence of CDX2 expression
results in reduced cancer cell adherence, and that fluctu-
ation of CDX2 levels in cancer cells could be important
in the metastatic process of colon cancer cells.
CDX2 has been shown to regulate the expression of a
number of claudins [43, 44], a critical component of the
tight junctions in epithelial cells. Aberrant expression of
claudins has been seen in a variety of cancers, and it has
been hypothesized that reduced claudin expression pro-
motes tumorigenesis and metastasis by increasing the
motility and invasion of cancer cells [9]. Studies have
shown that reduced expression of claudin-1 is a pre-
dictor of poor prognosis and reduced disease-free sur-
vival [45–47], and that knockdown of claudin-1
expression in colon cancer cell lines significantly in-
crease cell invasiveness [45]. Reduced expression of
claudin-7 has been shown to be an early event in colo-
rectal carcinogenesis [48], and downregulation of
claudin-7 promotes EMT [49, 50]. Expression of
claudin-23 has been shown to be downregulated in
tumour tissue and downregulation is associated with
shorter overall survival in patients with colorectal tu-
mours [51]. Furthermore, CDX2 has been shown to me-
diate E-selectin ligand expression in colon cancer cells
[52], a crucial component in the attachment of cancer
cells to distant tissues during metastasis [10].
Exogenous CDX2 expression has been shown to be as-
sociated with reduced cell invasion in Lovo cells trans-
fected with CDX2 overexpression plasmid [53], indicating
that CDX2 may play a role in other metastatic processes
besides adhesion. Other components have also been
shown to influence the metastatic processes of adhesion,
invasion and migration, such as the G-protein coupled re-
ceptor 55 [54], and the C-type lectin DC-SIGNR [55].
The observed difference in adhesion property between
cells in pre- versus postoperative serum is most likely
due to factors released into the bloodstream in patients
during or after surgery. Previous studies have shown that
pro-inflammatory cytokines mediate the adhesion of
cancer cells to mesothelial and endothelial monolayers
in vitro [13, 14]. Changes in expression of cell adhesion
molecules in colon cancer cells have been associated
with progression of cancer. This alteration in adhesion
molecules could potentially facilitate the adhesion enab-
ling intravasation as well as extravasation and may be
part of organ selectivity in metastatic processes [15].
Furthermore, changes in expression of adhesion mole-
cules could also affect postoperative cancer cell survival,
as circulating tumour cells are vulnerable and depend on
fast attachment in order to survive [2].
Fig. 4 Adhesion measurement of CDX2 inducible LS174T cells in pre- and postoperative serum a. The Cell Index for CDX2 negative and CDX2
positive inducible LS174T cells seeded in preoperative serum was measured. Mean results at 60 min for each patient is shown. ***p < 0.001. b.
The Cell Index for CDX2 negative and CDX2 positive inducible LS174T cells seeded in postoperative serum was measured. Mean results at 60 min
for each patient is shown. **p < 0.01
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The underlying mechanisms of the interaction be-
tween the cellular adhesion molecules and factors in the
patient serum has not yet been determined. However,
when seeding the cells in patient serum, we can already
measure altered adhesion abilities between cells in pre-
vs postoperative serum 20min after seeding. This rapid
response indicates that factors in the patient serum dir-
ectly affects the adhesion molecules already expressed
on the surface of the cells or in the cytoplasm. Previ-
ously, RNA sequencing of the CDX2 inducible LS174T
cell line used in our study showed altered RNA levels of
several integrins, including integrin α3, α6, β4,and β6, in
cells without CDX2 expression compared to wild-type
LS174T cells [31]. Given the importance of the postop-
erative elevated adhesion and its possible correlation
with recurrence, an identification of the precise mecha-
nisms behind the interaction may provide valuable
knowledge in reducing disease recurrence.
Conclusions
CDX2 expression is low in invasive colorectal cancer
cells but is restored in metastases to a level correspond-
ing to that of the primary tumour [26]. Our results show
that CDX2 expression influences the adhesion ability of
cultured colon cancer cells, and indicates that adjust-
ments in CDX2 expression levels in cancer cells during
EMT and MET is vital in the metastatic process of colon
cancer. In conclusion, we demonstrate an in vitro
method for measuring the effect of perioperative factors
on the adhesion ability of the LS174T colon cancer cell
line using serum form patients undergoing colon cancer
surgery, and we demonstrate a differential effect on ad-
hesion depending on CDX2 expression. If results from
the method developed in this study can be shown to cor-
relate with clinical oncological outcomes, the method
may be applied in studies examining perioperative inter-
ventions in respect to their effect on short and long-
term oncological outcomes after surgery.
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The CDX2 transcription factor is regarded to be the master regulator of intestinal identity 
of the colon and plays a vital part in maintaining intestinal homeostasis. It is responsible 
for the transcriptional regulation of many genes involved in normal colon function, 
including several genes involved in the Wnt signaling pathway, and dysregulation of 
CDX2 expression has been implicated in the development and progression of colon 
cancer. This thesis has investigated the role of CDX2 in intestinal homeostasis as well 
as its role in development and progression of colon cancer.  
The development of a colon cancer cell line with inducible CDX2 expression described 
in paper I provides a model that can be used to investigate possible CDX2 target genes. 
Here we show that CDX2 regulates transcription of several novel genes, including genes 
involved in normal function of the colon, thereby expanding the role of CDX2 in colon 
homeostasis. A number of these new CDX2 targets are genes that have been associated 
with colon cancer, including the mucin encoded by the MUC5AC. The expression of 
MUC5AC in seen to be upregulated in early stage colon cancer, but decreases as the 
degree of dysplasia increases and patients with tumors that lack MUC5AC expression 
have worse prognosis (Imai et al., 2013; Wang et al., 2017). As MUC5AC is a CDX2 
target gene, the dysregulation of CDX2 in colon cancer may be involved in both the 
upregulation of the MUC5CA mucin in the development of colon cancer, but also with 
the subsequent downregulation leading to a worse prognosis.   
While other colon cancer cell lines are dependent on CDX2 expression (Natoli et al., 
2013; Salari et al., 2012), the LS174T cell line with inducible CDX2 are seen to be viable 
despite complete lack of CDX2 expression. This indicates that CDX2 does not play as 
vital a part in this particular cell line as it does in others investigated. The mechanisms 
behind the viability of the cell line despite CDX2 knockout are unknown but the absence 
of CDX2 may lead to fundamental alternations in the signaling networks of the cells. 
Thus, this should be taken into consideration when interpreting results obtained using 




In paper II, the VTI1A-TCF7L2 fusion protein was discovered to have dominant 
negative properties in Wnt signaling. This is not surprising, as other truncated members 
of the TCF/LEF family of transcription factors are seen to act as dominant negative 
regulators (Van de Wetering et al., 1996). However, we also uncover that the promoter 
of the fusion protein is transcriptionally regulated by CDX2, resulting in not only a 
protein with altered functional characteristics but also altered expression pattern. Other 
fusion proteins that play vital roles in cancer development have been identified, but only 
the functional characteristics of these proteins have been investigated (Soda et al., 2007; 
Tomlins et al., 2005; Yu et al., 2010). While altered protein function may be critical in 
oncogenesis, alternative promoter regions and thereby altered expression patterns may 
be an equally critical component in the effect of fusion proteins. As cancer cells are 
genetically instable, multiple fusion proteins have been observed that can potentially 
drive cancer development (Gao et al., 2018). When assessing the possible oncogenic 
effects of fusion proteins, not only the functional properties of the resulting fusion 
proteins should be investigated, but also the possible altered transcriptional regulation.  
The functional characteristics of the VTI1A-TCF7L2 fusion protein was only 
investigated in relation to its effect on the Wnt signaling pathway. The effects of the 
truncated v-SNARE protein, encoded by VTI1A, were not investigated in paper II. The 
v-SNARE protein facilitates vesicle transport by fusion of intracellular vesicles from the 
late endosome to the trans-Golgi complex (Bass et al., 2011). Several genome-wide 
association studies have shown association between known variants of the VTI1A gene 
and colorectal cancer (Wang et al., 2014; Zeng et al., 2016), lung cancer (Su et al., 2015), 
and glioma (Kinnersley et al., 2015; Melin et al., 2017), and a fusion involving the VTI1A 
gene has also been discovered in hepatocellular carcinoma (Tsuge et al., 2019). 
Therefore, the truncated VTI1A protein in the VTI1A-TCF7L2 fusion protein may also 
play a role in colon cancer tumorigenesis and the effect of the altered v-SNARE should 
be further investigated.  
In paper III we use a real-time, cell-based assay to show, for the first time, that 




demonstrate that the adhesion abilities of cancer cells are increased in postoperative 
serum compared to preoperative serum, and that this effect on adhesion seems to be 
dependent on CDX2 expression. While the molecular mechanisms behind the role of 
CDX2 in adhesion are yet to be determined, CDX2 is known to regulate transcription of 
a number of molecules important in cell adhesion, including cadherins (Hinoi et al., 
2002), claudins (Bhat et al., 2012; Sakaguchi et al., 2002; Satake et al., 2008), and 
matripase (Danielsen et al., 2018). Through RNA sequencing in paper I we have also 
discovered that the RNA levels of several integrins are altered in the inducible cells 
lacking CDX2 expression compared to wild-type cells, further implicating CDX2 in the 
cellular adhesion process.  
The method used in paper III utilizes the ability of colon cancer cell lines to adhere to 
a tissue-culture treated plastic surface. While the results clearly show alternations in the 
cells ability to adhere, it would be beneficial to examine cell adhesion on a more 
biological surface. This may also further aid in determining the molecular mechanisms 
behind the role of CDX2 in cell adhesion.  
The impact of the level of CDX2 on cellular adhesion reveals a possible mechanism by 
which CDX2 can be responsible for the progression of colon cancer. While the 
applicability of CDX2 as a prognostic marker is still debatable, the majority of studies 
find loss of CDX2 expression in cancer cells to be associated with worse overall survival 
(Bae et al., 2015; Bruun et al., 2018; Neumann et al., 2018). In tumor budding cells the 
level of CDX2 is often observed to be decreased (Coskun et al., 2014; Graule et al., 
2018; Hansen et al., 2018), and when taking the results from paper III, showing that 
CDX2 affects adhesion abilities of colon cancer cells, into account, the downregulation 
of CDX2 may be necessary for the cancer cells to disengage from the tumor. It has 
previously been suggested that downregulation of CDX2 acts as a precursor to EMT, 
and as circulating cancer cells reach a metastatic site, the level of CDX2 expression 
increases and the cancer cells undergo MET (Brabletz et al., 2004; Zhang et al., 2015). 
Fluctuation in the level of CDX2 during the metastatic process may therefore be an 




CDX2 is broadly known as a tumor suppressor in colon cancer and loss of CDX2 
expression in regarded to result in worse prognosis in colon cancer patients (Dalerba et 
al., 2016; Mallo et al., 1997). However, evidence also suggests that CDX2 is essential in 
cancer cell survival and proliferation (Natoli et al., 2013; Yu et al., 2019), thereby 
indicating that it may also have oncogenic properties. In other gastrointestinal cancers, 
as well as leukemia, CDX2 is regarded as an oncogene (Barros et al., 2012; Rawat et al., 
2012; Tamagawa et al., 2012). This debate of CDX2 as either a tumor suppressor or an 
oncogene indicates that both downregulation of expression as well as overexpression 
may play a role in cancer development.    
The results presented in this thesis have shown the substantial effect CDX2 has on the 
transcriptional activity of numerous genes in colon cancer cells. Further, it has 
demonstrated the influence of the expression of CDX2 on cell morphology in a 
perioperative setting, exploring its role in the metastatic progression of cancer.  
Despite the many advances into uncovering the impact of CDX2 dysregulation in colon 
cancer development, its role is not yet fully understood. Neither is the effect of CDX2 
expression on disease progression and metastasis, although studies suggest a possible 
prognostic ability. Thus, further investigations into the molecular mechanisms behind 
the role of CDX2 in the development and progression of colon cancer are important in 












6. Concluding remarks 
 
This thesis has investigated the effect of CDX2 expression on the transcriptional activity 
of genes involved in colon homeostasis and explored its role in the development and 
progression of colon cancer.  
A number of novel CDX2 target genes important in the homeostasis of the colon were 
discovered in paper I, where a method to integrate inducible transcriptional elements 
into cultured cells was developed. This model allowed tight control of CDX2 expression, 
in turn enabling investigation into downstream effector genes under varying 
concentrations of CDX2.  
The promoter of the recurrent colon cancer fusion protein VTI1A-TCF7L2 was 
identified in paper II as being transcriptionally activated by CDX2 in colon cancer cell 
lines. The fusion protein itself was shown to have dominant negative properties, resulting 
in a protein with not only altered functional characteristics but also altered expression 
pattern in the colon epithelium. 
The effect of surgical stress and CDX2 expression on adhesion abilities of colon cancer 
cell lines was demonstrated using a real-time, cell-based method in paper III. Colon 
cancer cells showed increased adhesion abilities in postoperative serum compared to 
preoperative serum in patients undergoing colon cancer surgery. It was further shown 
that the increased adhesion in the postoperative serum was dependent on CDX2 
expression.  
In summary, the results of this thesis provide information into the role of CDX2 in colon 
homeostasis, as well as its implication in colon cancer development and progression. 
Several new target genes of CDX2 are uncovered, including the colon cancer fusion 
protein VTI1A-TCF7L2 that could play a role in cancer development. The adhesion 
abilities of cultured cancer cells are seen to be affected by CDX2 expression, associating 




7. Future perspectives 
 
While the results from the papers presented in the thesis show the possible implication 
of CDX2 in colon cancer progression, the molecular mechanism behind the effect of 
CDX2 in the metastatic process remains to be determined. The regulation of several cell-
cell adhesion and tight junction molecules, including cadherins, claudins, and integrins, 
are seen to be regulated my CDX2 and modulation though the expression of these 
molecules may be the source of the effect on metastatic processes. Other cellular 
abilities, such as migration, invasion, and proliferation, are also considered important in 
the metastatic process, however the possible role of CDX2 in these are still unknown.      
The studies presented in the three papers of this thesis all rely on colon cancer cell lines, 
in particular the LS174T cell line. This cell line, as well as the other cell lines used in 
the studies, are all well-established cell lines that have been utilized for many years to 
investigate different aspects of colon regulation and cancer development. However, the 
selection of cells capable of surviving in vitro has introduced genetic alterations and 
these alternations may make them fundamentally different from cancer cells in the 
human body. This may result in altered signaling pathways that can affect the results 
gained from using this type of model. Another type of cell-based model that can be used 
are three-dimensional in vitro colon organoids. They contain the different types of cells 
found in the colon and thereby represent a more physiological model of the colon. They 
can be isolated and grown from both healthy and tumor tissue samples, and allows for a 
more detailed overview of colon function. Despite the advantages, the organoids are 
technically more difficult to handle and the standardized assays used in 2D cell lines 
must be customized the growing conditions of organoids. However, with the 
development of new handling techniques and validation of assays to be used in organoid 
culture they may become the standard cell-based system in the future. Investigating the 







Aamodt, R., Bondi, J., Andersen, S.N., Bakka, A., Bukholm, G., Bukholm, I.R.K., 2010. 
The Prognostic Impact of Protein Expression of E-Cadherin-Catenin Complexes 
Differs between Rectal and Colon Carcinoma. Gastroenterol. Res. Pract. 2010, 1–
7. 
Ackerman, M.E., Chalouni, C., Schmidt, M.M., Raman, V. V., Ritter, G., Old, L.J., 
Mellman, I., Wittrup, K.D., 2008. A33 antigen displays persistent surface 
expression. Cancer Immunol. Immunother. 57, 1017–1027. 
Angell, H.K., Bruni, D., Carl Barrett, J., Herbst, R., Galon, J., 2020. The immunoscore: 
Colon cancer and beyond. Clin. Cancer Res. 26, 332–339. 
Angus-Hill, M.L., Elbert, K.M., Hidalgo, J., Capecchi, M.R., 2011. T-cell factor 4 
functions as a tumor suppressor whose disruption modulates colon cell 
proliferation and tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 108, 4914–4919. 
Asgari-Karchekani, S., Karimian, M., Mazoochi, T., Taheri, M.A., Khamehchian, T., 
2019. CDX2 Protein Expression in Colorectal Cancer and ItsCorrelation with 
Clinical and Pathological Characteristics, Prognosis, and Survival Rate of Patients. 
J. Gastrointest. Cancer. 
Baba, Y., Nosho, K., Shima, K., Freed, E., Irahara, N., Philips, J., Meyerhardt, J.A., 
Hornick, J.L., Shivdasani, R.A., Fuchs, C.S., Ogino, S., 2009. Relationship of 
CDX2 Loss with Molecular Features and Prognosis in Colorectal Cancer: 
Implications for Clinical and Pathology Practice. Clin Cancer Res. Clin Cancer 
Res. July 15, 4665–4673. 
Bae, J.M., Lee, T.H., Cho, N.Y., Kim, T.Y., Kang, G.H., 2015. Loss of CDX2 expression 
is associated with poor prognosis in colorectal cancer patients. World J. 
Gastroenterol. 21, 1457–1467. 
Balbinot, C., Armant, O., Elarouci, N., Marisa, L., Martin, E., de Clara, E., Onea, A., 
Deschamps, J., Beck, F., Freund, J.N., Duluc, I., 2018. The Cdx2 homeobox gene 
suppresses intestinal tumorigenesis through non-cell-autonomous mechanisms. J. 
Exp. Med. 215, 911–926. 
Barros, R., Da Costa, L.T., Pinto-de-Sousa, J., Duluc, I., Freund, J.N., David, L., 
Almeida, R., 2011. CDX2 autoregulation in human intestinal metaplasia of the 
stomach: Impact on the stability of the phenotype. Gut 60, 290–298. 
Barros, R., Freund, J.N., David, L., Almeida, R., 2012. Gastric intestinal metaplasia 
revisited: Function and regulation of CDX2. Trends Mol. Med. 18, 555–563. 
Bass, A.J., Lawrence, M.S., Brace, L.E., Ramos, A.H., Drier, Y., Cibulskis, K., Sougnez, 
C., Voet, D., Saksena, G., Sivachenko, A., Jing, R., Parkin, M., Pugh, T., Verhaak, 
R.G., Stransky, N., Boutin, A.T., Barretina, J., Solit, D.B., Vakiani, E., Shao, W., 
Mishina, Y., Warmuth, M., Jimenez, J., Chiang, D.Y., Signoretti, S., Kaelin, W.G., 
Spardy, N., Hahn, W.C., Hoshida, Y., Ogino, S., DePinho, R.A., Chin, L., 
Garraway, L.A., Fuchs, C.S., Baselga, J., Tabernero, J., Gabriel, S., Lander, E.S., 




identifies a recurrent VTI1A-TCF7L2 fusion. Nat. Genet. 43, 964–968. 
Benahmed, F., Gross, I., Gaunt, S.J., Beck, F., Jehan, F., Domon-Dell, C., Martin, E., 
Kedinger, M., Freund, J.N., Duluc, I., 2008. Multiple Regulatory Regions Control 
the Complex Expression Pattern of the Mouse Cdx2 Homeobox Gene. 
Gastroenterology 135, 1238–1247. 
Bhat, A.A., Sharma, A., Pope, J., Krishnan, M., Washington, M.K., Singh, A.B., 
Dhawan, P., 2012. Caudal homeobox protein Cdx-2 cooperates with Wnt pathway 
to regulate claudin-1 expression in colon cancer cells. PLoS One 7. 
Boman, B.M., Fields, J.Z., 2013. An APC:WNT Counter-Current-Like Mechanism 
Regulates Cell Division Along the Human Colonic Crypt Axis: A Mechanism That 
Explains How APC Mutations Induce Proliferative Abnormalities That Drive 
Colon Cancer Development. Front. Oncol. 3, 1–15. 
Bonetti, L.R., Lionti, S., Vitarelli, E., Barresi, V., 2017. Prognostic significance of 
CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma. 
Virchows Arch. 471, 731–741. 
Boulanger, J., Vézina, A., Mongrain, S., Boudreau, F., Perreault, N., Auclair, B.A., 
Lainé, J., Asselin, C., Rivard, N., 2005. Cdk2-dependent phosphorylation of 
homeobox transcription factor CDX2 regulates its nuclear translocation and 
proteasome-mediated degradation in human intestinal epithelial cells. J. Biol. 
Chem. 280, 18095–18107. 
Boyd, M., Bressendorff, S., Møller, J., Olsen, J., Troelsen, J.T., 2009. Mapping of 
HNF4alpha target genes in intestinal epithelial cells. BMC Gastroenterol. 9, 1–16. 
Boyd, M., Hansen, M., Jensen, T.G.K., Perearnau, A., Olsen, A.K., Bram, L.L., Bak, M., 
Tommerup, N., Olsen, J., Troelsen, J.T., 2010. Genome-wide analysis of CDX2 
binding in intestinal epithelial cells (Caco-2). J. Biol. Chem. 285, 25115–25125. 
Brabletz, T., Spaderna, S., Kolb, J., Hlubek, F., Faller, G., Bruns, C.J., Jung, A., 
Nentwich, J., Duluc, I., Domon-Dell, C., Kirchner, T., Freund, J.-N., 2004. Down-
Regulation of the Homeodomain Factor Cdx2 in Colorectal Cancer by Collagen 
Type I. Cancer Res. 64, 6973–6977. 
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global 
cancer statistics 2018: GLOBOCAN estimates of incidence and mortality 
worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68, 394–424. 
Brenner, H., Kloor, M., Pox, C.P., 2014. Colorectal cancer. Lancet 383, 1490–1502. 
Bruun, J., Sveen, A., Barros, R., Eide, P.W., Eilertsen, I., Kolberg, M., Pellinen, T., 
David, L., Svindland, A., Kallioniemi, O., Guren, M.G., Nesbakken, A., Almeida, 
R., Lothe, R.A., 2018. Prognostic, predictive, and pharmacogenomic assessments 
of CDX2 refine stratification of colorectal cancer. Mol. Oncol. 12, 1639–1655. 
Buzza, M.S., Netzel-Arnett, S., Shea-Donohue, T., Zhao, A., Lin, C.Y., List, K., Szabo, 
R., Fasano, A., Bugge, T.H., Antalis, T.M., 2010. Membrane-anchored serine 
protease matriptase regulates epithelial barrier formation and permeability in the 
intestine. Proc. Natl. Acad. Sci. U. S. A. 107, 4200–4205. 
Cai, L., Bennedsen, A.L.B., Qvortrup, C., Gögenur, I., 2019. Increasing incidence of 




Cattin, A., Le Beyec, J., Barreau, F., Saint-Just, S., Houllier, A., Gonzalez, F.J., Robine, 
S., Pinçon-Raymond, M., Cardot, P., Lacasa, M., Ribeiro, A., 2009. Hepatocyte 
nuclear factor 4alpha, a key factor for homeostasis, cell architecture, and barrier 
function of the adult intestinal epithelium. Mol. Cell. Biol. 29, 6294–6308. 
Cecchini, M.J., Walsh, J.C., Parfitt, J., Chakrabarti, S., Correa, R.J., MacKenzie, M.J., 
Driman, D.K., 2019. CDX2 and Muc2 immunohistochemistry as prognostic 
markers in stage II colon cancer. Hum. Pathol. 90, 70–79. 
Cernat, L., Blaj, C., Jackstadt, R., Brandl, L., Engel, J., Hermeking, H., Jung, A., 
Kirchner, T., Horst, D., 2014. Colorectal cancers mimic structural organization of 
normal colonic crypts. PLoS One 9, 4–11. 
Chan, D.S.M., Lau, R., Aune, D., Vieira, R., Greenwood, D.C., Kampman, E., Norat, T., 
2011. Red and processed meat and colorectal cancer incidence: Meta-analysis of 
prospective studies. PLoS One 6. 
Chawengsaksophak, K., James, R., Hammond, V.E., Köntgen, F., Beck, F., 1997. 
Homeosis and intestinal tumours in Cdx2 mutant mice. Nature 386, 84–87. 
Coskun, M., Boyd, M., Olsen, J., Troelsen, J.T., 2010. Control of intestinal promoter 
activity of the cellular migratory regulator gene ELMO3 by CDX2 and SP1. J. Cell. 
Biochem. 109, 1118–1128. 
Coskun, M., Olsen, A.K., Bzorek, M., Holck, S., Engel, U.H., Nielsen, O.H., Troelsen, 
J.T., 2014. Involvement of CDX2 in the cross talk between TNF-α and Wnt 
signaling pathway in the colon cancer cell line Caco-2. Carcinogenesis 35, 1185–
1192. 
Coskun, M., Olsen, A.K., Holm, T.L., Kvist, P.H., Nielsen, O.H., Riis, L.B., Olsen, J., 
Troelsen, J.T., 2012. TNF-α-induced down-regulation of CDX2 suppresses 
MEP1A expression in colitis. Mol. Basis Dis. 1822, 843–851. 
Coskun, M., Soendergaard, C., Joergensen, S., Dahlgaard, K., Riis, L.B., Nielsen, O.H., 
Sandelin, A., Troelsen, J.T., 2017. Regulation of Laminin γ2 Expression by CDX2 
in Colonic Epithelial Cells Is Impaired During Active Inflammation. J. Cell. 
Biochem. 118, 298–307. 
Dalerba, P., Sahoo, D., Paik, S., Guo, X., Yothers, G., Song, N., Wilcox-Fogel, N., 
Forgó, E., Rajendran, P.S., Miranda, S.P., Hisamori, S., Hutchison, J., Kalisky, T., 
Qian, D., Wolmark, N., Fisher, G.A., van de Rijn, M., Clarke, M.F., 2016. CDX2 
as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N. Engl. J. Med. 
374, 211–222. 
Danielsen, E.T., Olsen, A.K., Coskun, M., Nonboe, A.W., Larsen, S., Dahlgaard, K., 
Bennett, E.P., Mitchelmore, C., Vogel, L.K., Troelsen, J.T., 2018. Intestinal 
regulation of suppression of tumorigenicity 14 (ST14) and serine peptidase 
inhibitor, Kunitz type -1 (SPINT1) by transcription factor CDX2. Sci. Rep. 8, 1–
14. 
Davidsen, J., Jessen, S.B., Watt, S.K., Larsen, S., Dahlgaard, K., Kirkegaard, T., 
Gögenur, I., Troelsen, J.T., 2020. CDX2 expression and perioperative patient 





Davidsen, J., Larsen, S., Coskun, M., Gögenur, I., Dahlgaard, K., Bennett, E.P., 
Troelsen, J.T., 2018. The VTI1A-TCF4 colon cancer fusion protein is a dominant 
negative regulator of Wnt signaling and is transcriptionally regulated by intestinal 
homeodomain factor CDX2. PLoS One 13. 
Dawson, H., Galván, J.A., Helbling, M., Muller, D.E., Karamitopoulou, E., Koelzer, 
V.H., Economou, M., Hammer, C., Lugli, A., Zlobec, I., 2014. Possible role of 
Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF 
mutation, high-level CpG Island methylator phenotype and mismatch repair-
deficiency. Int. J. Cancer 134, 2342–2351. 
Dekker, E., Tanis, P.J., Vleugels, J.L.A., Kasi, P.M., Wallace, M.B., 2019. Colorectal 
cancer. Lancet 394, 1467–1480. 
Dhawan, P., Singh, A.B., Deane, N.G., No, Y.R., Shiou, S.R., Schmidt, C., Neff, J., 
Washington, M.K., Beauchamp, R.D., 2005. Claudin-1 regulates cellular 
transformation and metastatic behavior in colon cancer. J. Clin. Invest. 115, 1765–
1776. 
Drummond, F., Putt, W., Fox, M., Edwards, Y.H., 1997. Cloning and chromosome 
assignment of the human CDX2 gene. Ann. Hum. Genet. 61, 393–400. 
Fearon, E.R., 2011. Molecular Genetics of Colorectal Cancer. Annu. Rev. Pathol. Mech. 
Dis. 6, 479–507. 
Fedirko, V., Tramacere, I., Bagnardi, V., Rota, M., Scotti, L., Islami, F., Negri, E., Straif, 
K., Romieu, I., La Vecchia, C., Boffetta, P., Jenab, M., 2011. Alcohol drinking and 
colorectal cancer risk: An overall and dose-Response meta-analysis of published 
studies. Ann. Oncol. 22, 1958–1972. 
Fevr, T., Robine, S., Louvard, D., Huelsken, J., 2007. Wnt/beta-catenin is essential for 
intestinal homeostasis and maintenance of intestinal stem cells. Mol. Cell. Biol. 27, 
7551–7559. 
Gallicchio, M., Rosa, A.C., Dianzani, C., Brucato, L., Benetti, E., Collino, M., Fantozzi, 
R., 2008. Celecoxib decreases expression of the adhesion molecules ICAM-1 and 
VCAM-1 in a colon cancer cell line (HT29). Br. J. Pharmacol. 153, 870–878. 
Gao, N., White, P., Kaestner, K.H., 2009. Establishment of Intestinal Identity and 
Epithelial-Mesenchymal Signaling by Cdx2. Dev. Cell 16, 588–599. 
Gao, Q., Liang, W.W., Foltz, S.M., Mutharasu, G., Jayasinghe, R.G., Cao, S., Liao, 
W.W., Reynolds, S.M., Wyczalkowski, M.A., Yao, L., et al., 2018. Driver Fusions 
and Their Implications in the Development and Treatment of Human Cancers. Cell 
Rep. 23, 227-238.e3. 
Garrison, W.D., Battle, M.A., Yang, C., Kaestner, K.H., Sladek, F.M., Duncan, S.A., 
2006. Hepatocyte nuclear factor 4a is essential for embryonic development of the 
mouse colon. Gastroenterology 130, 1207–1220. 
Gehart, H., Clevers, H., 2019. Tales from the crypt: new insights into intestinal stem 
cells. Nat. Rev. Gastroenterol. Hepatol. 16, 19–34. 
Grady, W.M., Markowitz, S.D., 2016. The molecular pathogenesis of colorectal cancer 





Graule, J., Uth, K., Fischer, E., Centeno, I., Galván, J.A., Eichmann, M., Rau, T.T., 
Langer, R., Dawson, H., Nitsche, U., Traeger, P., Berger, M.D., Schnüriger, B., 
Hädrich, M., Studer, P., Inderbitzin, D., Lugli, A., Tschan, M.P., Zlobec, I., 2018. 
CDX2 in colorectal cancer is an independent prognostic factor and regulated by 
promoter methylation and histone deacetylation in tumors of the serrated pathway. 
Clin. Epigenetics 10, 120. 
Gross, I., Duluc, I., Benameur, T., Calon, A., Martin, E., Brabletz, T., Kedinger, M., 
Domon-Dell, C., Freund, J.N., 2008. The intestine-specific homeobox gene Cdx2 
decreases mobility and antagonizes dissemination of colon cancer cells. Oncogene 
27, 107–115. 
Gross, I., Lhermitte, B., Domon-Dell, C., Duluc, I., Martin, E., Gaiddon, C., Kedinger, 
M., Freund, J.N., 2005. Phosphorylation of the homeotic tumor suppressor Cdx2 
mediates its ubiquitin-dependent proteasome degradation. Oncogene 24, 7955–
7963. 
Guo, R.J., Funakoshi, S., Lee, H.H., Kong, J., Lynch, J.P., 2010. The intestine-specific 
transcription factor Cdx2 inhibits b-catenin/TCF transcriptional activity by 
disrupting the b-catenin-TCF protein complex. Carcinogenesis 31, 159–166. 
Hanahan, D., Weinberg, R.A., 2011. Hallmarks of cancer: The next generation. Cell 144, 
646–674. 
Hansen, T.F., Kjær-Frifeldt, S., Eriksen, A.C., Lindebjerg, J., Jensen, L.H., Sørensen, 
F.B., Jakobsen, A., 2018. Prognostic impact of CDX2 in stage II colon cancer: 
results from two nationwide cohorts. Br. J. Cancer 119, 1367–1373. 
Hao, H.X., Xie, Y., Zhang, Y., Zhang, O., Oster, E., Avello, M., Lei, H., Mickanin, C., 
Liu, D., Ruffner, H., Mao, X., Ma, Q., Zamponi, R., Bouwmeester, T., Finan, P.M., 
Kirschner, M.W., Porter, J.A., Serluca, F.C., Cong, F., 2012. ZNRF3 promotes Wnt 
receptor turnover in an R-spondin-sensitive manner. Nature 485, 195–202. 
Heaney, A., Buggy, D.J., 2012. Can anaesthetic and analgesic techniques affect cancer 
recurrence or metastasis? Br. J. Anaesth. 109, i17–i28. 
Herr, R., Köhler, M., Andrlová, H., Weinberg, F., Möller, Y., Halbach, S., Lutz, L., 
Mastroianni, J., Klose, M., Bittermann, N., Kowar, S., Zeiser, R., Olayioye, M.A., 
Lassmann, S., Busch, H., Boerries, M., Brummer, T., 2015. B-Raf inhibitors induce 
epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Res. 75, 
216–229. 
Hinkel, I., Duluc, I., Martin, E., Guenot, D., Freund, J., Gross, I., 2012. Cdx2 controls 
expression of the protocadherin Mucdhl, an inhibitor of growth and B-catenin 
activity in colon cancer cells. Gastroenterology 142, 875-885.e3. 
Hinoi, T., Gesina, G., Akyol, A., Kuick, R., Hanash, S., Giordano, T.J., Gruber, S.B., 
Fearon, E.R., 2005. CDX2-regulated expression of iron transport protein 
hephaestin in intestinal and colonic epithelium. Gastroenterology 128, 946–961. 
Hinoi, T., Lucas, P.C., Kuick, R., Hanash, S., Cho, K.R., Fearon, E.R., 2002. CDX2 
regulates liver intestine-cadherin expression in normal and malignant colon 
epithelium and intestinal metaplasia. Gastroenterology 123, 1565–1577. 




H.., Cho, K.R., Fearon, E.R., 2001. Loss of CDX2 expression and microsatellite 
instability are prominent features of large cell minimally differentiated carcinomas 
of the colon. Am. J. Pathol. 159, 2239–2248. 
Hoppler, S., Kavanagh, C.L., 2007. Wnt signalling: variety at the core. J. Cell Sci. 120, 
385–393. 
Houde, M., Laprise, P., Jean, D., Blais, M., Asselin, C., Rivard, N., 2001. Intestinal 
Epithelial Cell Differentiation Involves Activation of p38 Mitogen-activated 
Protein Kinase that Regulates the Homeobox Transcription Factor CDX2. J. Biol. 
Chem. 276, 21885–21894. 
Hryniuk, A., Grainger, S., Savory, J.G.A., Lohnes, D., 2012. Cdx function is required 
for maintenance of intestinal identity in the adult. Dev. Biol. 363, 426–437. 
Hryniuk, A., Grainger, S., Savory, J.G.A., Lohnes, D., 2014. Cdx1 and Cdx2 Function 
as Tumor Suppressors. J. Biol. Chem. 289, 33343–33354. 
Imai, Y., Yamagishi, H., Fukuda, K., Ono, Y., Inoue, T., Ueda, Y., 2013. Differential 
mucin phenotypes and their significance in a variation of colorectal carcinoma. 
World J. Gastroenterol. 19, 3958–3968. 
Jess, T., Rungoe, C., Peyrin-Biroulet, L., 2012. Risk of Colorectal Cancer in Patients 
With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies. 
Clin. Gastroenterol. Hepatol. 10, 639–645. 
Jiang, Y., Ben, Q., Shen, H., Lu, W., Zhang, Y., Zhu, J., 2011. Diabetes mellitus and 
incidence and mortality of colorectal cancer: A systematic review and meta-
analysis of cohort studies. Eur. J. Epidemiol. 26, 863–876. 
Johnstone, C.N., Tebbutt, N.C., Abud, H.E., White, S.J., Stenvers, K.L., Hall, N.E., 
Whitehead, R.H., Cody, S.H., Catimel, B., Nice, E.C., Burgess, A.W., Heath, J.K., 
2000. Characterization of mouse A33 antigen, a definitive marker for basolateral 
surfaces of intestinal epithelial cells. Am. J. Physiol. - Gastrointest. Liver Physiol. 
279, 500–510. 
Kannarkatt, J., Joseph, J., Kurniali, P.C., Al-Janadi, A., Hrinczenko, B., 2017. Adjuvant 
Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma. J. Oncol. Pract. 13, 
233–241. 
Keller, M.S., Ezaki, T., Guo, R., Lynch, J.P., 2004. Cdx1 or Cdx2 expression activates 
E-cadherin-mediated cell-cell adhesion and compaction in human COLO 205 cells. 
Am. J. Physiol. Gastrointest. Liver Physiol. 287, G104–G114. 
Kim, S., Domon-Dell, C., Wang, Q., Chung, D.H., Di Cristofano, A., Pandolfi, P.P., 
Freund, J.N., Evers, B.M., 2002. PTEN and TNF-α regulation of the intestinal-
specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-κB-dependent 
pathway. Gastroenterology 123, 1163–1178. 
Kinnersley, B., Labussière, M., Holroyd, A., Di Stefano, A.L., Broderick, P., 
Vijayakrishnan, J., Mokhtari, K., Delattre, J.Y., Gousias, K., Schramm, J., 
Schoemaker, M.J., Fleming, S.J., Herms, S., Heilmann, S., Schreiber, S., 
Wichmann, H.E., Nöthen, M.M., Swerdlow, A., Lathrop, M., Simon, M., Bondy, 
M., Sanson, M., Houlston, R.S., 2015. Genome-wide association study identifies 




Kinugasa, T., Akagi, Y., Yoshida, T., Ryu, Y., Shiratuchi, I., Ishibashi, N., Shirouzu, K., 
2010. Increased claudin-1 protein expression contributes to tumorigenesis in 
ulcerative colitis-associated colorectal cancer. Anticancer Res. 30, 3181–3186. 
Korinek, V., Barker, N., Moerer, P., van Donselaar, E., Huls, G., Peters, P.J., Clevers, 
H., 1998. Depletion of epithelial stem-cell compartments in the small intestine of 
mice lacking Tcf-4. Nat. Genet. 19, 379–383. 
Kriegl, L., Horst, D., Reiche, J.A., Engel, J., Kirchner, T., Jung, A., 2010. LEF-1 and 
TCF4 expression correlate inversely with survival in colorectal cancer. J. Transl. 
Med. 8, 1–8. 
Krishn, S.R., Kaur, S., Smith, L.M., Johansson, S.L., Jain, M., Patel, A., Gautam, S.K., 
Hollingsworth, M.A., Mandel, U., Clausen, H., Lo, W.C., Fan, W.T.L., Manne, U., 
Batra, S.K., 2016. Mucins and associated glycan signatures in colon adenoma-
carcinoma sequence: Prospective pathological implication(s) for early diagnosis of 
colon cancer. Cancer Lett. 374, 304–314. 
Kuhnert, F., Davis, C.R., Wang, H., Chu, P., Lee, M., Yuan, J., Nusse, R., Kuo, C.J., 
2004. Essential requirement for Wnt signaling in proliferation of adult small 
intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc. Natl. 
Acad. Sci. U. S. A. 101, 266–271. 
Landau, M.S., Kuan, S.F., Chiosea, S., Pai, R.K., 2014. BRAF-mutated microsatellite 
stable colorectal carcinoma: An aggressive adenocarcinoma with reduced CDX2 
and increased cytokeratin 7 immunohistochemical expression. Hum. Pathol. 45, 
1704–1712. 
Larsen, S., Davidsen, J., Dahlgaard, K., Pedersen, O.B., Troelsen, J.T., 2019. HNF4α 
and CDX2 Regulate Intestinal YAP1 Promoter Activity. Int. J. Mol. Sci. 20. 
Läubli, H., Borsig, L., 2019. Altered Cell Adhesion and Glycosylation Promote Cancer 
Immune Suppression and Metastasis. Front. Immunol. 10, 1–9. 
Leedham, S.J., 2014. Measuring stem cell dynamics in the human colon--where there’s 
a wiggle, there’s a way. J. Pathol. 234, 292–295. 
Li, Chao, Zuo, D., Liu, T., Yin, L., Li, Chenyao, Wang, L., 2019. Prognostic and 
Clinicopathological Significance of MUC Family Members in Colorectal Cancer: 
A Systematic Review and Meta-Analysis. Gastroenterol. Res. Pract. 2019. 
Liang, K., Zhou, G., Zhang, Q., Li, J., Zhang, C., 2014. Expression of hippo pathway in 
colorectal cancer. Saudi J. Gastroenterol. 20, 188–194. 
Liang, P.S., Chen, T.Y., Giovannucci, E., 2009. Cigarette smoking and colorectal cancer 
incidence and mortality: Systematic review and meta-analysis. Int. J. Cancer 124, 
2406–2415. 
Loomans-Kropp, H.A., Umar, A., 2019. Increasing Incidence of Colorectal Cancer in 
Young Adults. J. Cancer Epidemiol. 2019, 9841295. 
Ma, C., Olevian, D., Miller, C., Herbst, C., Jayachandran, P., Kozak, M.M., Chang, D.T., 
Pai, R.K., 2019. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch 
repair protein deficient colon cancer. Mod. Pathol. 32, 1217–1231. 
Ma, Y., Yang, Y., Wang, F., Zhang, P., Shi, C., Zou, Y., Qin, H., 2013. Obesity and Risk 




Mallo, G.V., Rechreche, H., Frigerio, J.M., Rocha, D., Zweibaum, A., Lacasa, M., 
Jordan, B.R., Dusetti, N.J., Dagorn, J.C., Iovanna, J.L., 1997. Molecular cloning, 
sequencing and expression of the mRNA encoding human Cdx1 and Cdx2 
homeobox. Down-regulation of Cdx1 and Cdx2 mRNA expression during 
colorectal carcinogenesis. Int. J. cancer 74, 35–44. 
Mariadason, J.M., Bordonaro, M., Aslam, F., Shi, L., Kuraguchi, M., Velcich, A., 
Augenlicht, L.H., 2001. Down-regulation of beta-catenin TCF signaling is linked 
to colonic epithelial cell differentiation. Cancer Res. 61, 3465–3471. 
Mattiuzzi, C., Sanchis-Gomar, F., Lippi, G., 2019. Concise update on colorectal cancer 
epidemiology. Ann. Transl. Med. 7, 609–613. 
Melin, B.S., Barnholtz-Sloan, J.S., Wrensch, M.R., Johansen, C., Il’yasova, D., 
Kinnersley, B., Ostrom, Q.T., Labreche, K., Chen, Y., Armstrong, G., et al., 2017. 
Genome-wide association study of glioma subtypes identifies specific differences 
in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat. Genet. 
49, 789–794. 
Melo, F.D.S.E., Wang, X., Jansen, M., Fessler, E., Trinh, A., De Rooij, L.P.M.H., De 
Jong, J.H., De Boer, O.J., Van Leersum, R., Bijlsma, M.F., Rodermond, H., Van 
Der Heijden, M., Van Noesel, C.J.M., Tuynman, J.B., Dekker, E., Markowetz, F., 
Medema, J.P., Vermeulen, L., 2013. Poor-prognosis colon cancer is defined by a 
molecularly distinct subtype and develops from serrated precursor lesions. Nat. 
Med. 19, 614–618. 
Merlos-Suárez, A., Barriga, F.M., Jung, P., Iglesias, M., Céspedes, M.V., Rossell, D., 
Sevillano, M., Hernando-Momblona, X., Da Silva-Diz, V., Muñoz, P., Clevers, H., 
Sancho, E., Mangues, R., Batlle, E., 2011. The intestinal stem cell signature 
identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 
8, 511–524. 
Natoli, M., Christensen, J., El-Gebali, S., Felsani, A., Anderle, P., 2013. The role of 
CDX2 in Caco-2 cell differentiation. Eur. J. Pharm. Biopharm. 85, 20–25. 
Neeman, E., Ben-Eliyahu, S., 2013. Surgery and stress promote cancer metastasis: New 
outlooks on perioperative mediating mechanisms and immune involvement. Brain. 
Behav. Immun. 
Neumann, J., Heinemann, V., Engel, J., Kirchner, T., Stintzing, S., 2018. The prognostic 
impact of CDX2 correlates with the underlying mismatch repair status and BRAF 
mutational status but not with distant metastasis in colorectal cancer. Virchows 
Arch. 473, 199–207. 
Nishiuchi, A., Hisamori, S., Sakaguchi, M., Fukuyama, K., Hoshino, N., Itatani, Y., 
Honma, S., Maekawa, H., Nishigori, T., Tsunoda, S., Obama, K., Miyoshi, H., 
Shimono, Y., Mark Taketo, M., Sakai, Y., 2019. Microrna-9-5p-CDX2 axis: A 
useful prognostic biomarker for patients with stage II/III colorectal cancer. Cancers 
(Basel). 11. 
Olsen, A.K., Coskun, M., Bzorek, M., Kristensen, M.H., Danielsen, E.T., Jørgensen, S., 
Olsen, J., Engel, U., Holck, S., Troelsen, J.T., 2013. Regulation of APC and AXIN2 




Carcinogenesis 34, 1361–1369. 
Olsen, J., Eiholm, S., Kirkeby, L.T., Espersen, M.L.M., Jess, P., Gögenür, I., Olsen, J., 
Troelsen, J.T., 2016. CDX2 downregulation is associated with poor differentiation 
and MMR deficiency in colon cancer. Exp. Mol. Pathol. 100, 59–66. 
Olsen, J., Espersen, M.L.M., Jess, P., Kirkeby, L., Troelsen, J.T., 2014. The clinical 
perspectives of CDX2 expression in colorectal cancer: A qualitative systematic 
review. Surg. Oncol. 23, 167–176. 
Ong, B.A., Vega, K.J., Houchen, C.W., 2014. Intestinal stem cells and the colorectal 
cancer microenvironment. World J. Gastroenterol. 20, 1898–1909. 
Parker, B.C., Zhang, W., 2013. Fusion genes in solid tumors: An emerging target for 
cancer diagnosis and treatment. Chin. J. Cancer 32, 594–603. 
Parr, C., Sanders, A., Jiang, W., 2012. Hepatocyte Growth Factor Activation Inhibitors 
- Therapeutic Potential in Cancer. Anticancer. Agents Med. Chem. 10, 47–57. 
Pilati, C., Taieb, J., Balogoun, R., Marisa, L., Reynie, A. De, 2017. CDX2 prognostic 
value in stage II / III resected colon cancer is related to CMS classification Original 
article. Ann. Oncol. 1032–1035. 
Piñeros, M., Parkin, D.M., Ward, K., Chokunonga, E., Ervik, M., Farrugia, H., 
Gospodarowicz, M., O’Sullivan, B., Soerjomataram, I., Swaminathan, R., Znaor, 
A., Bray, F., Brierley, J., 2019. Essential TNM: a registry tool to reduce gaps in 
cancer staging information. Lancet Oncol. 20, 103–111. 
Pino, M.S., Chung, D.C., 2010. The chromosomal instability pathway in colon cancer. 
Gastroenterology 138, 2059–2072. 
Pinto, D., Gregorieff, A., Begthel, H., Clevers, H., 2003. Canonical Wnt signals are 
essential for homeostasis of the intestinal epithelium. Genes Dev. 17, 1709–1713. 
Pinto, R., Hansen, L., Hintze, J., Almeida, R., Larsen, S., Coskun, M., Davidsen, J., 
Mitchelmore, C., David, L., Troelsen, J.T., Bennett, E.P., 2017. Precise integration 
of inducible transcriptional elements (PrIITE) enables absolute control of gene 
expression. Nucleic Acids Res. 45. 
Pope, J.L., Ahmad, R., Bhat, A.A., Washington, M.K., Singh, A.B., Dhawan, P., 2014. 
Claudin-1 overexpression in intestinal epithelial cells enhances susceptibility to 
adenamatous polyposis coli-mediated colon tumorigenesis. Mol. Cancer 13, 1–13. 
Rawat, V.P.S., Humphries, R.K., Buske, C., 2012. Beyond Hox: The role of ParaHox 
genes in normal and malignant hematopoiesis. Blood 120, 519–527. 
Rings, E.H.H.M., Boudreau, F., Taylor, J.K., Moffett, J., Suh, E.R., Traber, P.G., 2001. 
Phosphorylation of the serine 60 residue within the Cdx2 activation domain 
mediates its transactivation capacity. Gastroenterology 121, 1437–1450. 
Robertson, J.H., Yang, S.Y., Winslet, M.C., Seifalian, A.M., 2009. Functional blocking 
of specific integrins inhibit colonic cancer migration. Clin. Exp. Metastasis 26, 
769–780. 
Ryan, É.J., Creavin, B., Khaw, Y.L., Kelly, M.E., Mohan, H.M., Geraghty, R., Ryan, 
E.J., Kennelly, R., Hanly, A., Martin, S.T., Fennelly, D., McDermott, R., Gibbons, 
D., O’Connell, P.R., Sheahan, K., Winter, D.C., 2018. Effects of CDX2 on 




colorectal cancer. BJS Open 2, 456–463. 
Sadanandam, A., Lyssiotis, C.A., Homicsko, K., Collisson, E.A., Gibb, W.J., 
Wullschleger, S., Ostos, L.C.G., Lannon, W.A., Grotzinger, C., Del Rio, M., 
Lhermitte, B., Olshen, A.B., Wiedenmann, B., Cantley, L.C., Gray, J.W., Hanahan, 
D., 2013. A colorectal cancer classification system that associates cellular 
phenotype and responses to therapy. Nat. Med. 19, 619–625. 
Sailaja, B.S., He, X.C., Li, L., 2016. The regulatory niche of intestinal stem cells. J. 
Physiol. 594, 4827–4836. 
Sakaguchi, T., Gu, X., Golden, H.M., Suh, E., Rhoads, D.B., Reinecker, H.C., 2002. 
Cloning of the human claudin-2 5′-flanking region revealed a TATA-less promoter 
with conserved binding sites in mouse and human for caudal-related homeodomain 
proteins and hepatocyte nuclear factor-1α. J. Biol. Chem. 277, 21361–21370. 
Sakamoto, N., Feng, Y., Stolfi, C., Kurosu, Y., Green, M., Lin, J., Green, M.E., Sentani, 
K., Yasui, W., McMahon, M., Hardiman, K.M., Spence, J.R., Horita, N., Greenson, 
J.K., Kuick, R., Cho, K.R., Fearon, E.R., 2017. BRAFV600E cooperates with 
CDX2 inactivation to promote serrated colorectal tumorigenesis. Elife 6, 1–25. 
Sakuma, K., Aoki, M., Kannagi, R., 2012. Transcription factors c-Myc and CDX2 
mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-
induced epithelial-mesenchymal transition. Proc. Natl. Acad. Sci. 109, 7776–7781. 
Salari, K., Spulak, M.E., Cuff, J., Forster, A.D., Giacomini, C.P., Huang, S., 2012. CDX2 
is an amplified lineage-survival oncogene in colorectal cancer. PNAS Plus 109, 
3196–3205. 
San Roman, A.K., Aronson, B.E., Krasinski, S.D., Shivdasani, R.A., Verzi, M.P., 2015. 
Transcription factors GATA4 and HNF4A control distinct aspects of intestinal 
homeostasis in conjunction with transcription factor CDX2. J. Biol. Chem. 290, 
1850–1860. 
Satake, S., Semba, S., Matsuda, Y., Usami, Y., Chiba, H., Sawada, N., Kasuga, M., 
Yokozaki, H., 2008. Cdx2 transcription factor regulates claudin-3 and claudin-4 
expression during intestinal differentiation of gastric carcinoma. Pathol. Int. 58, 
156–163. 
Shigematsu, Y., Inamura, K., Mise, Y., Saiura, A., Rehnberg, E., Yamamoto, N., 
Ishikawa, Y., Takahashi, S., Kanda, H., 2018. CDX2 expression is concordant 
between primary colorectal cancer lesions and corresponding liver metastases 
independent of chemotherapy: A single-center retrospective study in Japan. 
Oncotarget 9, 17056–17065. 
Simmini, S., Bialecka, M., Huch, M., Kester, L., Van De Wetering, M., Sato, T., Beck, 
F., Van Oudenaarden, A., Clevers, H., Deschamps, J., 2014. Transformation of 
intestinal stem cells into gastric stem cells on loss of transcription factor Cdx2. Nat. 
Commun. 5, 1–10. 
Slik, K., Turkki, R., Carpén, O., Kurki, S., Korkeila, E., Sundström, J., Pellinen, T., 
2019. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical 
Outcome in Stage II Colorectal Cancer. Am J Surg Pathol 43, 1473–1482. 




S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., 
Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., Mano, H., 2007. Identification 
of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 
448, 561–566. 
Spit, M., Koo, B.K., Maurice, M.M., 2018. Tales from the crypt: Intestinal niche signals 
in tissue renewal, plasticity and cancer. Open Biol. 8. 
Steinhardt, A.A., Gayyed, M.F., Klein, A.P., Dong, J., Maitra, A., Pan, D., Montgomery, 
E.A., Anders, R.A., 2008. Expression of Yes-associated Protein, YAP, in Common 
Solid Tumors. Hum. Pathol. 39, 1582–1589. 
Su, W.M., Chen, Z.H., Zhang, X.C., Su, J., Xie, Z., Yan, H.H., Yang, J.J., Chen, H.J., 
Zhou, Q., Zhong, W.Z., Guo, W.B., Chen, S.L., Wu, Y.L., 2015. Single nucleotide 
polymorphisms in VTI1A gene contribute to the susceptibility of Chinese 
population to non-small cell lung cancer. Int. J. Biol. Markers 30, 286–293. 
Subtil, C., Guérin, E., Schneider, A., Chenard, M.P., Martin, E., Domon-Dell, C., Duluc, 
I., Brabletz, T., Kedinger, M., Duclos, B., Gaub, M.P., Freund, J.N., 2007. Frequent 
rearrangements and amplification of the CDX2 homeobox gene in human sporadic 
colorectal cancers with chromosomal instability. Cancer Lett. 247, 197–203. 
Tabariès, S., Siegel, P.M., 2017. The role of claudins in cancer metastasis. Oncogene 36, 
1176–1190. 
Tamagawa, Y., Ishimura, N., Uno, G., Yuki, T., Kazumori, H., Ishihara, S., Amano, Y., 
Kinoshita, Y., 2012. Notch signaling pathway and Cdx2 expression in the 
development of Barrett’s esophagus. Lab. Investig. 92, 896–909. 
Tanabe, L.M., List, K., 2017. The role of type II transmembrane serine protease-
mediated signaling in cancer. FEBS J. 284, 1421–1436. 
Taylor, D.P., Burt, R.W., Williams, M.S., Haug, P.J., Cannon-Albright, L.A., 2010. 
Population-based family-history-specific risks for colorectal cancer : a 
Constellation Approach. Gastroenterology 138, 877–885. 
Tomlins, S.A., Rhodes, D.R., Perner, S., Dhanasekaran, S.M., Mehra, R., Sun, X., 
Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J.E., Shah, R.B., 
Pienta, K.J., Rubin, M.A., Chinnaiyan, A.M., 2005. Recurrent fusion of TMPRSS2 
and ETS transcription factor genes in prostate cancer. Science (80-. ). 310, 644–
648. 
Tong, K., Pellón-Cárdenas, O., Sirihorachai, V.R., Warder, B.N., Kothari, O.A., 
Perekatt, A.O., Fokas, E.E., Fullem, R.L., Zhou, A., Thackray, J.K., Tran, H., 
Zhang, L., Xing, J., Verzi, M.P., 2017. Degree of Tissue Differentiation Dictates 
Susceptibility to BRAF-Driven Colorectal Cancer. Cell Rep. 21, 3833–3845. 
Tóth, C., Sükösd, F., Valicsek, E., Herpel, E., Schirmacher, P., Tiszlavicz, L., 2018. Loss 
of CDX2 gene expression is associated with DNA repair proteins and is a crucial 
member of the Wnt signaling pathway in liver metastasis of colorectal cancer. 
Oncol. Lett. 15, 3586–3593. 
Tremblay, P.L., Huot, J., Auger, F.A., 2008. Mechanisms by which E-selectin regulates 
diapedesis of colon cancer cells under flow conditions. Cancer Res. 68, 5167–5176. 




1997. Regulation of lactase-phlorizin hydrolase gene expression by the caudal-
related homoeodomain protein Cdx-2. Biochem J. 322, 833–838. 
Tschaharganeh, D.F., Chen, X., Latzko, P., Malz, M., Gaida, M.M., Felix, K., Ladu, S., 
Singer, S., Pinna, F., Gretz, N., Sticht, C., Tomasi, M.L., Delogu, S., Evert, M., 
Fan, B., Ribback, S., Jiang, L., Brozzetti, S., Bergmann, F., Dombrowski, F., 
Schirmacher, P., Calvisi, D.F., Breuhahn, K., 2013. Yes-associated protein up-
regulates jagged-1 and activates the NOTCH pathway in human hepatocellular 
carcinoma. Gastroenterology 144, 1530-1542.e12. 
Tsuge, S., Saberi, B., Cheng, Y., Wang, Z., Kim, A., Luu, H., Abraham, J.M., Ybanez, 
M.D., Hamilton, J.P., Selaru, F.M., Villacorta-Martin, C., Schlesinger, F., 
Philosophe, B., Cameron, A.M., Zhu, Q., Anders, R., Gurakar, A., Meltzer, S.J., 
2019. Detection of Novel Fusion Transcript VTI1A-CFAP46 in Hepatocellular 
Carcinoma. Gastrointest. Tumors 6, 11–27. 
Van de Wetering, M., Castrop, J., Korinek, V., Clevers, H., 1996. Extensive alternative 
splicing and dual promoter usage generate Tcf-1 protein isoforms with differential 
transcription control properties. Mol. Cell. Biol. 16, 745–752. 
van der Bij, G.J., Oosterling, S.J., Beelen, R.H.J., Meijer, S., Coffey, J.C., van Egmond, 
M., 2009. The perioperative period is an underutilized window of therapeutic 
opportunity in patients with colorectal cancer. Ann. Surg. 249, 727–34. 
van Es, J.H., Haegebarth, A., Kujala, P., Itzkovitz, S., Koo, B.-K., Boj, S.F., Korving, J., 
van den Born, M., van Oudenaarden, A., Robine, S., Clevers, H., 2012. A Critical 
Role for the Wnt Effector Tcf4 in Adult Intestinal Homeostatic Self-Renewal. Mol. 
Cell. Biol. 32, 1918–1927. 
Veeman, M.T., Slusarski, D.C., Kaykas, A., Louie, S.H., Moon, R.T., 2003. Zebrafish 
Prickle, a Modulator of Noncanonical Wnt/Fz Signaling, Regulates Gastulation 
Movements. Curr. Biol. 13, 680–685. 
Verzi, M.., Hatzis, P., Sulahian, R., Philips, J., Schuijers, J., Shin, H., Freed, E., Lynch, 
J.P., Dang, D.T., Brown, M., Clevers, H., Liu, X.S., Shivdasani, R.A., 2010. TCF4 
and CDX2, major transcription factors for intestinal function, converge on the same 
cis-regulatory regions. Proc. Natl. Acad. Sci. U. S. A. 107, 15157–15162. 
Verzi, M.P., Shin, H., San Roman, A.K., Liu, X.S., Shivdasani, R.A., 2013. Intestinal 
Master Transcription Factor CDX2 Controls Chromatin Access for Partner 
Transcription Factor Binding. Mol. Cell. Biol. 33, 281–292. 
Vogel, L.K., Sæbø, M., Skjelbred, C.F., Abell, K., Pedersen, E.D.K., Vogel, U., Kure, 
E.H., 2006. The ratio of matriptase/HAI-1 mRNA is higher in colorectal cancer 
adenomas and carcinomas than corresponding tissue from control individuals. 
BMC Cancer 6, 1–8. 
Wang, H., Burnett, T., Kono, S., Haiman, C.A., Iwasaki, M., Wilkens, L.R., Loo, 
L.W.M., Van Den Berg, D., Kolonel, L.N., Henderson, B.E., Keku, T.O., Sandler, 
R.S., Signorello, L.B., Blot, W.J., Newcomb, P.A., Pande, M., Amos, C.I., West, 
D.W., Bézieau, S., Berndt, S.I., Zanke, B.W., Hsu, L., Lindor, N.M., Haile, R.W., 
Hopper, J.L., Jenkins, M.A., Gallinger, S., Casey, G., Stenzel, S.L., Schumacher, 




Trans-ethnic genome-wide association study of colorectal cancer identifies a new 
susceptibility locus in VTI1A. Nat. Commun. 5, 1–7. 
Wang, H., Jin, S., Lu, H., Mi, S., Shao, W., Zuo, X., Yin, H., Zeng, S., Shimamoto, F., 
Qi, G., 2017. Expression of survivin, MUC2 and MUC5 in colorectal cancer and 
their association with clinicopathological characteristics. Oncol. Lett. 14, 1011–
1016. 
Williams, B.B., Tebbutt, N.C., Buchert, M., Putoczki, T.L., Doggett, K., Bao, S., 
Johnstone, C.N., Masson, F., Hollande, F., Burgess, A.W., Scott, A.M., Ernst, M., 
Heath, J.K., 2015. Glycoprotein A33 deficiency: A new mouse model of impaired 
intestinal epithelial barrier function and inflammatory disease. DMM Dis. Model. 
Mech. 8, 805–815. 
Xia, J., Zeng, M., Zhu, H., Chen, X., Weng, Z., Li, S., 2018. Emerging role of Hippo 
signalling pathway in bladder cancer. J. Cell. Mol. Med. 22, 4–15. 
Xia, X., Xu, E., Quan, S., Huang, Q., Lai, M., 2009. No association between the 
polymorphisms in CDX2 coding regions and colorectal cancer in Chinese. Mol. 
Cell. Biochem. 331, 27–30. 
Xu, W., Zhu, Y., Shen, W., Ding, W., Wu, T., Guo, Y., Chen, X., Zhou, M., Chen, Y., 
Cui, L., Du, P., 2019. Combination of CDX2 expression and T stage improves 
prognostic prediction of colorectal cancer. J. Int. Med. Res. 47, 1829–1842. 
Yan, K.S., Janda, C.Y., Chang, J., Zheng, G.X.Y., Larkin, K.A., Luca, V.C., Chia, L.A., 
Mah, A.T., Han, A., Terry, J.M., Ootani, A., Roelf, K., Lee, M., Yuan, J., Li, X., 
Bolen, C.R., Wilhelmy, J., Davies, P.S., Ueno, H., Von Furstenberg, R.J., 
Belgrader, P., Ziraldo, S.B., Ordonez, H., Henning, S.J., Wong, M.H., Snyder, 
M.P., Weissman, I.L., Hsueh, A.J., Mikkelsen, T.S., Garcia, K.C., Kuo, C.J., 2017. 
Non-equivalence of Wnt and R-spondin ligands during Lgr5 + intestinal stem-cell 
self-renewal. Nature 545, 238–242. 
Yoshida, T., Kinugasa, T., Akagi, Y., Kawahara, A., Romeo, K., Shiratsuchi, I., Ryu, 
Y., Gotanda, Y., Shirouzu, K., 2011. Decreased expression of claudin-1 in rectal 
cancer: a factor for recurrence and poor prognosis. Anticancer Res. 31, 2517–25. 
Yu, J., Liu, D., Sun, X., Yang, K., Yao, J., Cheng, C., Wang, C., Zheng, J., 2019. CDX2 
inhibits the proliferation and tumor formation of colon cancer cells by suppressing 
Wnt/β-catenin signaling via transactivation of GSK-3β and Axin2 expression. Cell 
Death Dis. 10. 
Yu, J., Yu, J., Mani, R., Cao, Q., Brenner, C.J., Cao, X., Wang, G.X., Wu, L., Li, J., Hu, 
M., Cheng, H., Laxman, B., Vellaichamy, A., Li, Y., Dhanasekaran, S.M., Morey, 
R., Lonigro, R.J., Tomlins, S.A., Varambally, S., Qin, Z.S., Chinnaiyan, A.M., 
2010. An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-
ERG Gene Fusions in Prostate Cancer Progression. Cancer Cell 17, 443–454. 
Zeng, C., Matsuda, K., Jia, W.-H., Chang, J., Kweon, S.-S., Xiang, Y.-B., Shin, A., Jee, 
S.H., Kim, D.-H., Zhang, B., Cai, Q., et al., 2016. Identification of Susceptibility 
Loci and Genes for Colorectal Cancer Risk. Gastroenterology 150, 1633–1645. 
Zhang, B.Y., Jones, J.C., Briggler, A.M., Hubbard, J.M., Kipp, B.R., Sargent, D.J., 




Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. 
Clin. Colorectal Cancer 16, 124–128. 
Zhang, J.F., Qu, L.S., Qian, X.F., Xia, B.L., Mao, Z.B., Chen, W.C., 2015. Nuclear 
transcription factor CDX2 inhibits gastric cancer-cell growth and reverses 
epithelial-to-mesenchymal transition in vitro and in vivo. Mol. Med. Rep. 12, 
5231–5238. 
Zheng, J.B., Sun, X.J., Qi, J., Li, S.S., Wang, W., Ren, H.L., Tian, Y., Lu, S.Y., Du, J.K., 
2011. Effects of homeodomain protein CDX2 expression on the proliferation and 
migration of Lovo colon cancer cells. Pathol. Oncol. Res. 17, 743–751. 
Zygulska, A.L., Krzemieniecki, K., Pierzchalski, P., 2017. Hippo pathway - brief 
overview of its relevance in cancer. J. Physiol. Pharmacol. 68, 311–335. 
 
